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AIM AND OUTLINE OF THIS THESIS 
 
The first observation of vesicular structures outside of the cell dates back to the 1960s. 
Initially, these vesicles were believed to be mainly involved in extracellular processes 
like blood clotting and in maintaining the cellular homeostasis by acting as waste 
removal entities. However, during the last decade these extracellular vesicles (EVs) are 
increasingly regarded as important mediators of intercellular communication. It was this 
novel insight that sparked the mounting interest in these nanosized vesicles from both 
the therapeutic and diagnostic field, which is accompanied by numerous new 
applications exploiting EVs in different pharmaceutical domains. 
Because of their natural function as transporters of macromolecular components, it is 
hypothesized that EVs are endowed with unique features that rationalize their 
exploitation as a drug carrier system. Macromolecular therapeutics with an intracellular 
target, including nucleic acids and pharmaceutical proteins, require formulation into 
nanoparticles (i.e. so-called nanomedicines) to guide them across the many extra- and 
intracellular barriers. Unfortunately, many synthetic nanomedicines fail to merge drug 
delivery efficiency with acceptable biocompatibility. In light of these shortcomings, the 
first aim of this thesis is to explore EVs as bio-inspired carriers for small interfering RNA 
(siRNA) delivery. Indeed, the field of RNA interference (RNAi) is still struggling to 
translate its wide potential into a clinical applicable technology due to a lack of targeted 
and functional delivery. 
Chapter 1 provides a general introduction to EVs with a focus on their therapeutic and 
diagnostic applications. An overview of the main historical findings that shaped the 
further development of the field is followed by a more in depth discussion of the 
different EV types and their respective biogenesis pathways. Next, different methods to 
purify EVs are listed and discussed for their potential in a clinical setting. Finally, a 
comprehensive overview of the different fields of application for which EVs have been 
explored is given. Here, the main emphasis is put on exploiting EVs as a drug delivery 
vehicle with an outline of the most important strategic choices to be considered. In 
parallel, we aimed to pinpoint some of the major hurdles that need to be overcome to 
accelerate the development of this application. 
One of the first critical steps in harnessing EVs as a therapeutic carrier is developing 
robust methods to load these nanosized membranous vesicles with the therapeutic 
cargo of interest. In chapter 2 we thoroughly investigated the value of electroporation 
to load isolated EVs with siRNA and provide details on the emergence of electroporation 
artifacts that substantially overestimate the EV loading efficiency. 
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Furthermore, it is important to bear in mind that EVs are typically present in complex 
media (i.e. cell medium, serum, etc.). The strategies to isolate EVs are continuously 
evolving, though the field has not yet reached consensus on a gold standard protocol. In 
chapter 3 we provide a comparative analysis of different EV purification strategies, 
discuss the purity of the final isolate, both for endogenous as well as exogenous 
contaminants, and indicate some misinterpretations that impurities can entail in 
downstream experimental readouts. 
In light of the results obtained in the previous chapters, a new strategy to associate 
small RNAs to EVs is described in chapter 4. Here, cholesterol-conjugated siRNA (chol-
siRNA) was used to anchor the siRNA duplex in the EV membrane. This feat allowed us 
to provide a direct comparison between purified EVs and a lipid-based synthetic carrier 
for their ability to functionally deliver siRNA over the cellular barriers. In addition, in this 
chapter we evaluated the functional delivery of endogenous miRNA by EVs. 
Besides drug delivery, there is increasing interest in exploiting EVs for diagnostic 
applications. As EVs can be regarded as miniature windows on the composition and 
status of the parent cell, they are considered as an interesting biomarker source in liquid 
biopsies to detect and monitor a plethora of diseases. However, techniques that 
combine a broad molecular fingerprint with single vesicle sensitivity and high speed are 
currently lacking. Hence, a second aim in this thesis is to advance the field of EV 
characterization for diagnostics. In chapter 5 we describe a new nanotechnology 
platform based on surface enhanced Raman spectroscopy (SERS), which allows us to 
characterize and discriminate between EVs from different cellular origin in a mixture. 
Finally, in chapter 6 we aim to put both fields of application for EVs, as described in 
this thesis, in a broader perspective. Our own findings are positioned within these two 
frameworks by discussing the contributions of our studies to the respective fields. 
Furthermore, we pinpoint the predominant hurdles and suggest new approaches to 
accelerate future progress of both applications. Finally, the current status and future 
perspectives of all EV application fields are discussed in a pharmaceutical context.  
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Abstract 
During the past two decades, extracellular vesicles (EVs) have been identified as 
important mediators of intercellular communication, enabling the functional transfer of 
bioactive molecules from one cell to another. Consequently, it is becoming increasingly 
clear that these vesicles are involved in many (patho)physiological processes, providing 
opportunities for therapeutic application. Moreover, it is known that the molecular 
composition of EVs reflects the physiological status of the producing cell and tissue, 
rationalizing their exploitation as biomarker for various diseases. In this chapter the 
composition, biogenesis and diversity of EVs is discussed in a therapeutic and diagnostic 
context. We describe emerging therapeutic applications, including the use of EVs as 
drug delivery vehicles and as cell-free vaccines, and reflect on future challenges for 
clinical translation. Finally, we discuss the use of EVs as a biomarker source and 
highlight recent studies and clinical successes. 
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1. A general introduction to EVs 
1.1. A brief historical overview  
Cells release, in addition to single molecules (i.e. small molecules, peptides and 
proteins), macromolecular complexes (e.g. Argonaute2 (AGO2)-RNA complex) and 
lipoproteins, also membrane-enclosed vesicles in the extracellular medium. The first 
reports on such extracellular vesicles (EVs) date back to the late 1960s when it was 
observed that platelet free plasma contains vesicular material that could be pelleted 
down by ultracentrifugation (UC). These vesicles were mainly composed of 
phospholipids and appeared to promote blood clothing [1] and cartilage calcification [2]. 
In the years that followed, using electron microscopy imaging, vesicular structures could 
be visualized in duodenal fluid [3] and the first observations were made on tumor cell-
derived membrane vesicles [4, 5]. Initially it was assumed that the observed vesicles 
were solely released by outward budding of the cell membrane. Several years later, 
Johnstone and colleagues reported on the formation of intraluminal vesicles (ILVs) in 
late endosomes by inward budding of the endosomal limiting membrane. Following the 
fusion of these so-called multivesicular bodies (MVBs) with the cell’s plasma membrane, 
the ILVs are released in the surrounding medium [6, 7]. This discovery was made based 
on the observation that reticulocytes release their transferrin receptor, as part of the 
maturation into erythrocytes, associated to vesicles. As this mechanism was also 
observed in other species and appeared to be selective for certain membrane-associated 
proteins [8], these EVs were initially presented as a conserved and regulated waste 
removal pathway [9]. A seminal paper by Raposo et al. in 1996, reporting on the 
immune-modulating activity of B cell-derived EVs, inspired many others to evaluate the 
biological implications of these vesicles [10]. Two years later, Zitvogel et al. used EVs 
derived from tumor peptide-pulsed dendritic cells (DCs) as a cell-free anti-cancer 
vaccine providing the first therapeutic application of EVs [11]. Among others, these 
reports introduced the notion that EVs cannot solely be considered as a waste disposal 
mechanism but also as important mediators of intercellular communication. Owing to 
the work of many, it was becoming increasingly clear that EVs likely play a fundamental 
role in many (patho)physiological processes. Besides deciphering the biological function 
of EVs, their potential as biomarker source [12, 13] was recognized and the first clinical 
trials using EVs as an anti-cancer vaccine were initiated [14]. In addition, around a 
decade ago different groups identified the presence of miRNA, mRNA and proteins in 
EVs and, more importantly, the ability to functionally shuttle their cargo into recipient 
cells, reinforcing the belief that EVs facilitate communication between cells [15, 16] and 
fuelling the idea of exploiting these vesicles for drug delivery applications. 
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1.2. Biogenesis, cargo loading and composition  
EVs are generally categorized in three subtypes (i.e. exosomes, ectosomes and 
apoptotic bodies), based on distinct biogenesis pathways [17]. Apoptotic bodies are 
formed when a cell is dying via apoptosis, leading to blebbing and finally disintegration 
of the cellular plasma membrane with partitioning of the cellular content in different 
membrane-enclosed vesicles. Apoptotic bodies typically are larger particles (~0.5 - 4 
µm) containing cytoplasmic organelles and fragmented nuclei [18]. Although some 
studies have reported a communication and biological function for these vesicles [19, 
20], in this thesis we will focus on the smaller sized exosomes and ectosomes. Hence, 
apoptotic bodies are not considered when referring to EVs throughout this dissertation. 
Exosomes (50 – 150 nm) and ectosomes (50 – 1000 nm) do not only show a partly 
overlapping size distribution but also their biogenesis pathways are very similar (figure 
1A). In both cases their formation is preceded by the assembly of membrane micro-
domains composed of specific lipids (with an important role for ceramide) [21] and 
proteins, followed by budding and subsequent fission or pinching off. The main 
difference between both formation pathways is the location of the initial budding 
process. Indeed, ectosomes (also termed shedding vesicles or microvesicles) are 
released directly from the cell’s plasma membrane. Exosomes on the other hand, 
originate from the inward budding of early and late endosomes forming MVBs containing 
ILVs [22, 23]. Subsequently, the MVBs are transported to and fuse with the plasma 
membrane, requiring a dynamic interplay between members of the Rab and SNARE 
protein family, concurrently releasing the ILVs in the extracellular space [24-28]. Partly 
because both biogenesis pathways are analogous, to date there is no defined panel of 
markers to distinguish between both vesicle subtypes in a vesicular isolate. 
Nevertheless, a panel of generic markers (e.g. CD9, CD81, CD63, TSG101, etc.) was 
defined by the International Society of Extracellular Vesicles (ISEV) to indicate the 
presence of EVs in a sample [29].  
Numerous papers report that the relative molecular composition of EVs differs from the 
producer cell. Lipidomic analysis showed an accumulation of cholesterol, sphingomyelin, 
glycerophospholipids and phosphatidylserine (PS) in EVs [30]. Certain membrane-
associated proteins, for example many tetraspanins (e.g. CD9, CD81), appear enriched 
on the EV surface [31]. Finally, an array of reports show that specific mRNAs, miRNAs 
and other non-coding RNAs (e.g. t-RNA, Y-RNA, vault RNA, etc.) are enriched or 
underrepresented in EVs compared to their respective parent cells [32-37]. Based on 
these observations it is generally accepted that the composition of EVs is, at least 
partially, actively regulated by the parent cell [38], albeit that the mechanisms and 
associated key players regulating this cargo sorting remain largely elusive to date [34, 
39-42].  
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Figure 1. Schematic representation of the EV biogenesis and architecture. [A] The biogenesis 
pathways of exosomes and ectosomes (or shedding vesicles). Exosomes are formed by inward budding 
of the limiting membrane of early or late endosomes (LE) forming multivesicular bodies (MVBs) 
containing so-called intra-luminal vesicles (ILVs). Upon fusion of the MVBs with the cell membrane, the 
ILVs are released as exosomes in the extracellular medium. In contrast, ectosomes are released by 
direct budding from the plasma membrane. [B] The molecular architecture of extracellular vesicles with 
some key general and cell-type specific molecular components. General: Tetraspanins (e.g. CD63, 
CD81), Alix, Heat shock proteins (e.g. Hsp70), major histocompatibility complex (MHC)-I, structural 
proteins (e.g. actin), nucleic acids (e.g. miRNA, mRNA), integrins (type of integrin can be cell-type 
specific), lysobisphosphatidic acid (LBPA), cholesterol, ganglioside GM3 [43, 44]. Specific: MHC-II, 
CD80, CD86 and complement shielding proteins CD55/59 (in DC) [45], tumor-associated antigens 
(TAA; e.g. GP100 in melanoma cells) [46], perforin (in natural killer T cells) [47]. 
 
The overall EV configuration (i.e. a lipoprotein shell encapsulating an aqueous core 
containing soluble proteins and nucleic acids) and part of the molecular composition (i.e. 
proteins and lipids required in the EV biogenesis) are common among EVs isolated from 
different cells [43]. However, some EV-associated molecules are unique for the 
producing cell type (figure 1B). For example, MHC II is found on EVs secreted by 
antigen presenting cells (APC) [31, 48]. As another example, CD2, CD8 and CD56 were 
found in EVs derived from natural killer (NK) T cells and not in EVs derived from 
platelets, where the opposite holds true for CD41b, CD42a and CD61 [49].  
Furthermore, it appears that the culture conditions not only influence the cellular 
phenotype but also the number and/or composition of the secreted EVs. For instance, 
hypoxia triggers cancer cells to release more CD63-positive vesicles [50] with a 
modified molecular composition and distinct effect on recipient cells [51]. Comparable 
observations were made for an altered extracellular pH [52] and the presence of stress-
inducing molecules (e.g. lipopolysaccharide, H2O2, etc.) in general [53]. Besides the 
cellular microenvironment also the status of the cell influences the EV composition and 
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downstream activity. Where mature DCs release pro-inflammatory EVs enriched in MHC 
II and ICAM-1 [54], EVs derived from DCs cultured in the presence of IL10, an anti-
inflammatory cytokine, suppress the onset of inflammation in a mouse arthritis model 
[55]. The fact that phenotypic alterations in the parent cells are mirrored by the 
composition of the secreted EVs, can be exploited for diagnostic purposes (section 
3.2). 
The influence of the surrounding medium on the EV composition may have relevant 
clinical implications. For instance, Li et al. compared EVs derived from N2A 
neuroblastoma cells cultured both in serum containing cell medium or under starvation 
conditions, showing marked alterations in the protein composition [56]. Besides the 
changes in the composition of the EV itself, the presence or absence of serum proteins 
will likely also influence the protein corona surrounding the EVs [57]. It is well 
documented that this corona strongly influences the extra- and intracellular 
(transfection) behavior of synthetic nanoparticles, including liposomes [58, 59]. Given 
the analogy between EVs and liposomes [60], it is conceivable that a protein corona will 
also impact the EV interactome and thus biological function. However, to date the 
influence of these parameters on the EV functionality has not been thoroughly 
investigated. 
1.3. EV heterogeneity 
Evidence is mounting that within the exosome and ectosome population more distinct 
vesicle subtypes exist. When a specific exosome release pathway (i.e. via Rab27a 
inhibition) was silenced, the secretion of only a specific set of exosome-related 
molecules (i.e. CD63, Tsg101, Alix and Hsc70) decreased, whereas others (CD9 and 
Mfge8) were not affected [61]. This could indicate that different exosome subtypes exist 
of which the release is regulated by slightly different pathways. Additionally, Van Niel et 
al. showed a clear discrepancy in protein profile between EVs released from the apical or 
basolateral side of polarized epithelial cells [62]. Another report showed that vesicles 
isolated from conditioned cell medium and plasma by UC could be divided in two distinct 
populations by bottom-up density gradient UC. Both populations showed a different 
protein and nucleic acid composition, which correlated with a distinct biological effect on 
recipient cells [63]. To address this heterogeneity in more detail, more sensitive 
techniques have to be developed allowing single vesicle analysis. In this respect, a 
recent study by Smith and coworkers used Raman microspectroscopy to obtain a Raman 
spectrum, which can be regarded as a molecular fingerprint, on the single vesicle level. 
Following principal component analysis of the obtained spectra, these authors concluded 
that at least four types of vesicles with a clearly distinct molecular composition are 
released by a single cell type [64]. Conceivably, this is still an underestimation of the 
factual heterogeneity among EVs. Yet to date, it is impossible to physically separate 
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these specific EV subtypes, as reliable markers are lacking. This implies that the 
composition and functions, currently attributed to EVs, are likely the combined effect of 
multiple subtypes of vesicles. This notion further complicates the adoption of EVs in a 
pharmaceutical context as it is well possible that only a specific sub-fraction of vesicles 
induces a desired effect while others might entail off-target or even opposing effects. 
1.4.  EV purification protocols 
EVs represent only a fraction of the cell’s secretome. Parallel to the growing research 
interest in EVs, different methods to isolate and purify EVs from conditioned cell medium 
or biological fluids have been developed. The most common approaches are listed in 
table 1 and discussed further with a focus on their applicability in a pharmaceutical 
context. The predominant technique in the literature relies on differential centrifugation 
followed by UC, which is based on a difference in size and density between EVs and 
other components present in the respective medium [65]. It is important to note that 
many potential contaminants are co-purified using UC (e.g. lipoprotein particles, 
protein(-RNA) aggregates, etc.) [66] and that the yield is relatively low (i.e. 10 – 20 %) 
and dependent on the medium viscosity [67, 68]. Additionally, the impact of the high 
shear forces on the vesicle integrity are under debate. While some studies indicate no 
changes in the integrity of the EVs after UC [69, 70], others show subtle EV aggregation 
influencing the EV biodistribution [71, 72]. 
To safeguard EV stability and increase both the vesicle yield as well as purity of the 
isolate,  density gradient UC (iodixanol or sucrose) can be used [66, 73]. To underscore 
the superior separation resolution, it was shown that viral particles could be physically 
separated from EVs by using an iodixanol-based density gradient [74]. The major 
disadvantage of this technique is the long processing time.  
Another method, which was originally developed to concentrate viral particles [75], 
employs hydrophilic polymers (e.g. poly(ethylene glycol); PEG) and (high) salt 
concentrations to precipitate EVs. Although this method provides a high yield, which 
makes it interesting for small amounts of starting material or as a preparative 
concentrating step, it lacks specificity as many contaminants (e.g. protein aggregates) 
are co-isolated [66]. Hence, interpreting downstream analysis of precipitated EV 
isolates, should be done with caution. Additionally, the PEG polymer is also present in 
the final isolate, potentially shielding the EV surface and interfering with their 
functionality or downstream analysis [76].  
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Table 1. EV purification strategies. 
Method Principle of 
separation 
Purity Integrity Disadvantages Advantages 
Ultracentrifugation  
(UC) 
Size and density  Medium 
 
High shear forces 
might affect the EV 
integrity/functionality  
Relatively long procedure (~4 - 5 hours) 
The yield is drastically reduced when the 
viscosity of the samples is high (plasma 
> serum > cell medium > PBS) [68] 
Most used technique throughout the literature  
 
 
Density gradient 
UC / sucrose 
cushion UC 
Buoyant density High Mild forces Long procedure (~18 hours) 
 
Previously used in clinical settings [14, 77-79] 
Precipitation Salting out EVs 
using a PEG/salt 
solution 
Low Mild forces 
 
Low purity 
The PEG chain might envelope the EVs, 
possibly interfering with their 
functionality 
Applicable for large volumes 
Experience from the viral field 
Previously used in a clinical setting (as an EV 
concentration step prior to UC) [80] 
Affinity capture Binding of EV 
surface 
components  
High Mild forces  
 
Expensive (if antibody based) 
EV elution might damage surface 
proteins and functionality 
This method has the highest potential to 
physically separate different EV 
(sub)populations. However, due to the lack of 
specific markers for EV subtypes to date, this 
method is most frequently applied in the 
diagnostic field 
Size exclusion 
chromatography 
(SEC) 
Size Medium 
to high 
Mild forces The final EV isolate is diluted Increasingly used and promoted by the ISEV 
community 
Chromatographic methods (e.g. SEC and IEC) 
are often used in clinical settings (e.g. to 
purify monoclonal antibodies) 
Sequential 
filtration 
Size Unknown Risk of modifying the 
original EV 
architecture due to 
extrusion 
 
Sticking of EVs to the filter membrane 
lowers the yield 
Useful as a pre-process concentration step. 
Previously used for this purpose in clinical 
settings [14, 79] 
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Affinity-based capture of EVs has the potential to yield subpopulations with high purity. 
The best-known affinity-based approach exploits EV-surface protein recognition via 
antibodies (e.g. associated to beads, a polymer surface in a chip or a chromatography 
column) [81, 82].  Of note, this method requires knowledge of specific EV markers, 
which are however difficult to identify. To circumvent the lack of specific markers, a 
more general approach was recently presented in which antibodies are substituted by 
heparin as it appears to have a general affinity for EVs. However, the cross-reactivity 
with other components present in the respective media is a possible concern [83]. 
Overall, affinity-based capture of EVs might be very useful in an on-chip diagnostic set-
up using small sample sizes [84, 85]. Yet from a pharmaceutical point of view, when 
contemplating to use EVs as medicinal products, larger volumes will have to be 
processed, thus augmenting manufacturing costs. 
Finally, several separation methods are being developed for EVs that exploit differences 
in size, including size-exclusion chromatography (SEC) and filtration [86]. SEC enables 
fast sample processing. However, sample dilution is inherent to the technique as well as 
co-purification of large protein aggregates and larger lipoproteins. The main advantage 
of SEC is the mild conditions in combination with acceptable purity [71, 86, 87]. 
Alternatively, sequential filtration steps can first eliminate larger contaminants and 
subsequently concentrate EVs and eliminate smaller contaminants. Yet a major 
disadvantage compared to SEC are the often high forces used (via air pressure or 
centrifugal forces) possibly compromising the EV integrity. Moreover, sticking of EVs to 
the membrane filters might limit the yield [87]. In most cases filtration is used as a 
preparative step prior to one of the techniques mentioned above. 
Combining different purification methods based on complementary principles will be 
imperative to process very complex samples (e.g. plasma). The sequential combination 
of techniques is already commercially available, e.g. with the exo-spinTM system (CELL 
guidance systems). This approach merges an initial concentrating step using the 
precipitation method with subsequent SEC to enhance the sample purity. It is of note 
that the diversity of purification techniques used throughout the literature hampers 
unambiguous comparison of different studies. Until now, the importance of EV purity is 
most emphasized in the field of biomarker discovery as it is clearly shown that different 
isolation methods might greatly alter the obtained RNA/protein profiles [66]. In chapter 
3 of this thesis we will experimentally compare different purification strategies and 
discuss the importance of EV purity outside the field of biomarker discovery. 
 
 
 
 Chapter 1│ 25 
 
2. Therapeutic applications of EVs 
2.1.  Harnessing the intrinsic biological effect of EVs 
As discussed above, EVs are composed of numerous potentially bioactive molecules (i.e. 
lipids, proteins, nucleic acids and carbohydrates) of which the relative composition is 
regulated by the producer cell. In this respect, it is no surprise that EVs have an intrinsic 
biological effect that modulates the recipient cell’s phenotype [88], which can be 
exploited in a therapeutic context. These phenotypical alterations can be elicited by a 
receptor-ligand interaction at the cellular surface [89, 90] or at the luminal side of the 
(late) endosomes, thus triggering a downstream signaling pathway [91, 92]. 
Alternatively, it is believed that EVs can fuse with cellular membranes (plasma 
membrane and/or endosomal membrane) and release their content in the cytoplasm 
[93] (figure 2). 
As mentioned earlier, Raposo et al. showed that EVs derived from activated APCs could 
stimulate the immune system by presenting functional antigen-MHC complexes to T 
cells [10]. This observation was followed by many pre-clinical and clinical studies using 
antigen pulsed, DC-derived EVs as a cell-free alternative for cancer vaccination [94]. 
This application will be further discussed in section 2.3. 
 
 
Figure 2. Mechanisms behind EV-mediated phenotypical changes in recipient cells. (a) The EV 
surface proteins/lipids can interact with receptors on the recipient cell’s surface, eliciting an intracellular 
signaling pathway or triggering receptor mediated endocytosis. Alternatively, (b) the EV cargo (e.g. 
proteins and nucleic acids) can be released in the cell’s cytoplasm via membrane fusion with the limiting 
cell membrane or (c) with the endosomal membrane after initial internalization via 
phagocytosis/endocytosis. Finally, it is also possible that (d) EVs release their content (after partial 
degradation) in the endolysosomes where it can trigger endosomal receptors (e.g. toll-like receptors). 
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Another example of the use of EVs as a cell surrogate therapy are mesenchymal stem 
cell (MSC)-derived vesicles. MSC are stromal cells with multipotent differentiation 
capacity and have been intensively investigated for their potential regenerative and 
immunosuppressive effects in many animal models and clinical trials. Although originally 
believed to be the result of MSC homing to and engraftment at injured tissues, it is now 
becoming increasingly clear that the biological effect of these cells is mainly to be 
attributed to their secretome, including EVs [95, 96]. In this respect, MSC-derived EVs 
have been studied in dedicated mouse models for their tissue-protective effects 
following acute kidney failure [95], myocardial infarct [97], liver injury [98] and neural 
injury after middle cerebrate artery occlusion [99]. Considering their 
immunosuppressive nature, MSC EVs are also under investigation for a multitude of 
inflammatory conditions. For instance, in the field of auto-immune diseases, EVs shed 
by MSC have shown to limit the pro-inflammatory response and induce a shift towards a 
beneficial regulatory T cell profile in type I diabetes [100], which is currently being 
investigated in a clinical setting (NCT02138331). As another example, MSC EVs are also 
successfully investigated in refractory graft-versus-host disease [80]. The exact 
mechanism behind the therapeutic effect of MSC-derived EVs remains largely obscure 
and is a topic of intensive investigation [101]. It is however known that stem cell EVs 
are enriched in signaling proteins, including cytokines, chemokines, interleukins and 
growth factors [102]. The use of EVs as a surrogate for cell based therapies is 
intensively studied as it might entail some benefits. EVs are more resistant to freeze-
thaw processes, are genetically stable making them a safer alternative to whole cells 
and they are likely less immunogenic allowing allogeneic therapy. Multiple 
comprehensive reviews have been published giving a more detailed overview of 
published data on this topic [103, 104].  
Next to their exploitation as surrogates for cell therapy, EVs from specific cell types 
have shown interesting features that can be exploited in a therapeutic context. For 
example, NK-cell derived EVs were shown to contain killer proteins (e.g. perforins) 
which are taken up by tumor cells and induce tumor cell death [47]. Adipose-derived 
stem cells (ADSC) release EVs containing Neprilysin (i.e. an A-degrading enzyme), 
which lowered the A-level secreted by N2A cells and thus might be a valuable therapy 
to investigate further in Alzheimer’s disease [105].  
It is of note that these reports have to be interpreted with careful consideration of the 
used EV purification protocol. Dependent on the selected method, non-EV contaminants 
can be co-isolated, possibly leading to observations being incorrectly attributed to EVs 
[29]. Moreover, many reports focus on a specific component of EVs, e.g. small non-
coding RNA such as miRNAs, often neglecting the true complexity of the EV composition 
in which lipids and proteins likely also play a key role [106]. As a result of this 
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complexity, EVs can simultaneously interfere with different signaling pathways, leading 
to pleiotropic effects. For example, it was observed that EVs derived from immortalized 
cardiomyocytes (HL-1 cells) significantly altered the expression of 161 genes in 
fibroblasts (NIH/3T3 cells) after co-culture [107]. This complexity implies that the 
observed effects are likely very difficult to mimic by synthetic, single-API (active 
pharmaceutical ingredient) drug therapies. On the other hand, care should be taken that 
this intrinsic complexity does not impede the translatability of EVs into a viable 
pharmaceutical product [108]. 
2.2.  Harnessing EVs as a drug delivery vehicle 
2.2.1. Beneficial features of EVs as nanocarriers 
As outlined above, EVs are involved in the communication between cells due to their 
ability to deliver biomolecules from one cell type to another, thereby crossing both 
extra- and intracellular barriers. Based on this particular feature, EVs are also 
envisioned as biological nanocarriers for the delivery of exogenous therapeutic 
(macro)molecules. The encapsulation of drugs in nanoparticles (creating so-called 
nanomedicines) is a well-established approach to (1) modify the pharmacokinetics (PK) 
and biodistribution of the therapeutic cargo, (2) solubilize hydrophobic drugs, (3) 
protect the drug from the extracellular environment and (4) guide the therapeutic cargo 
across existing extra- and intracellular barriers. Both low molecular weight 
chemotherapeutics, but especially membrane-impermeable macromolecular drugs (e.g. 
nucleic acids and proteins) require nanocarriers to enhance their delivery across 
biological membranes. Unfortunately, many synthetic nanoparticles, including lipid and 
polymer-based nanoparticles, demonstrate insufficient in vivo targeting to extrahepatic 
tissues and fail to merge (intracellular) drug delivery efficacy with biocompatibility 
[109]. Since the identification of EVs as nature’s own intercellular communication tools, 
it is hypothesized that their Darwinian optimization could outperform conventional 
synthetic nanomedicines [110]. Indeed, EVs are believed to encompass many 
interesting features for drug delivery: (1) a proteo-lipid architecture that protects the 
encapsulated cargo, (2) their specific composition minimizes recognition by the 
mononuclear phagocyte system (MPS) [111], (3) their possibility to be patient self-
derived nature mitigates activation of the adaptive immune system, (4) they contain 
specific lipids that help stabilize the vesicles in the blood circulation (e.g. GM3, 
sphingomyelin and cholesterol) and stimulate membrane fusion [52, 112] as well as 
surface proteins that have likewise been linked to membrane fusion in cell-cell and 
virus-cell interactions (e.g. CD9, CD81) [113, 114] and finally (5) EVs seem to possess 
intrinsic cell and tissue targeting properties [115]. 
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2.2.2. Extracellular behavior of EVs 
One of the main motivations to incorporate drugs into nanocarriers is to modulate their 
biodistribution and tissue targeting. Free drugs are often rapidly cleared from the body 
and show poor tissue selectivity, which can in part be remedied by their formulation into 
nanomedicines. Unfortunately, without appropriate surface modification (e.g. 
PEGylation), they are easily recognized by the MPS and rapidly cleared from the blood 
circulation, leading to predominant sequestration by liver and spleen and limiting 
extravasation in other tissues of interest. As EVs are abundantly present and stable in 
the blood circulation, it was speculated that EVs could have longer circulation times and 
mediate drug targeting to extrahepatic and non-lymphoid tissues. However, reports 
studying the PK of IV injected EVs observed short half-lives  (~2 minutes [116, 117] 
and ~20 minutes [118]) with predominant uptake by liver, lung, kidney and spleen, 
thus closely resembling the biodistribution of synthetic liposomes [71, 119, 120]. The 
elimination after IV injection occurs via hepatic and renal routes [118] in which MPS-
associated macrophages seem to play a key role [119]. It is conceivable that this 
recognition is in part mediated by the exposure of PS at the external side of EV 
(subtypes) [121, 122]. It is of note that in these studies tumor- or HEK 293T-derived 
EVs have been used. For immature DC-derived EVs it was reported that they carry 
surface proteins (i.e. CD55 and CD59) that inhibit complement-mediated clearance 
[123]. On the other hand, Whitehead et al. showed that EVs derived from malignant 
cells were far more prone to complement activation compared to non-malignant cells, 
which might help to explain some of the reported PK data [124]. Furthermore, also the 
selected purification protocol or the transfer of allogeneic EVs can potentially influence 
the EV’s PK profile [71]. 
Despite the intrinsic targeting to APC and limited circulation time often reported for EVs, 
it appears that a certain fraction is still able to home to alternative organs and tissues. 
For instance, it was shown by Hoshino et al. that the integrins present on the surface of 
tumor-derived EVs determined the organs/cell types that are preferentially targeted 
[115]. Such observations rationalize the engineering of EVs with specific targeting 
moieties to enhance tissue or cell specific homing. One of the first engineered EVs was 
reported by Alvarez-Erviti et al. who equipped EVs from immature DCs with a Lamp2b-
RVG targeting peptide, via genetic engineering of the producer cell with the respective 
plasmid construct, to enable delivery of siRNA across the blood brain barrier (BBB) 
[125]. The same targeting ligand was also used to shuttle liposomes over the BBB for 
the delivery of siRNA [126]. The BBB targeting enhancement was later quantified by 
Wiklander et al. to be around two-fold [120]. Nonetheless, the majority of the vesicles is 
still present in MPS-associated tissues (i.e. liver, spleen and lung) [120]. The fact that 
targeting ligands are providing modest benefits is likely the result of the short circulation 
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time. On the other hand, the partial degradation of the RVG targeting peptide during EV 
formation might also contribute to this observation. Indeed, Hung et al. showed that 
when fusing a targeting peptide to the Lamp2b protein (a protein inherently present on 
the EV surface), it should be equipped with glycosylation sites to protect it against 
protease degradation by the producing cell. The unprotected Lamp2b-RVG targeting 
construct showed only marginally improved internalization by N2A cells bearing the 
nicotinic acetylcholine receptor (i.e. the RVG target) compared to non-targeted EVs due 
to peptide degradation [127]. In analogy with reports on synthetic liposomes, efforts to 
simultaneously enhance the circulation time and confer specific targeting properties 
have also been explored for EVs. For instance, hydrophilic PEG-chains were inserted in 
the EV lipid bilayer carrying targeting nanobodies® at their distal end to both shield the 
EV surface from off-target interactions (leading to a prolonged circulation time) yet 
allow specific interactions with a targeted receptor [128, 129]. However, such 
approaches greatly alter the composition and behavior of EVs, both in the extracellular 
environment as well as following intracellular uptake, and the question is raised to what 
extent these approaches are advantageous over synthetic drug-loaded nanocarriers.  
The ability to cross the BBB is an interesting and often referred to feature attributed to 
EVs. Although the RVG-targeting ligand associated to the EV surface in the previously 
mentioned studies likely plays a potentiating role [125], EVs derived for unmodified 
hematopoietic cells were also shown to cross the BBB. This event was reported to be 
rare, yet vastly increased under peripheral inflammatory conditions [130]. The 
mechanism behind this process remains to be elucidated. One hypothesis is based on 
transcytosis in which EVs are internalized by (apical) endocytosis of endothelial cells and 
are again released intact by exocytosis at the basolateral side [131]. A recent study 
compared four types of EVs derived from different brain cells (i.e. brain endothelial cells 
(bEND.3), glioblastoma A-172 cells, neural glyoblastoma U87 cells and neuroectodermal 
tumor PFSK-1 cells) for their ability to deliver cytotoxic drugs over the BBB in an 
embryo zebrafish model. Only the bEND.3 derived EVs were able to transfer their cargo 
into the brain, underscoring the existence of EV specificity [132]. 
Besides transferring cargo over the BBB, tumor targeting is another therapeutic 
application for which nanomedicines can provide a clear benefit. For this purpose, 
nanomedicines typically rely on the enhanced permeation and retention (EPR) effect to 
extravasate and accumulate in the tumor mass. Based on their small size, it is 
conceivable that EVs can also exploit this effect for anti-cancer treatment. However, 
such passive targeting of EVs to tumors gave rise to contradictory results. Smyth et al. 
IV injected EVs (60 µg) derived from the tumor itself but found very little amount in the 
tumor tissue (4T1 breast cancer and PC3 prostate cancer cells) compared to liver and 
spleen [119]. In contrast, Lai et al. found a marked signal of HEK293-derived EVs (100 
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µg) in the tumor (Gli36 glioblastoma) alongside with the liver and spleen [118]. An 
example of successful active tumor targeting by modified EVs was reported by Ohno et 
al. who observed a three-fold enhancement in the tumor tissue (HCC70 hepatocellular 
carcinoma) using EGFR-targeted (via the GE11 peptide) EVs [133]. Comparable results 
were obtained with iRGD equipped EVs that bind to v3 integrins in tumor tissue. 
Importantly, these vesicles, when loaded with doxorubicin, strongly reduced tumor 
growth in a MDA-MB-231 breast cancer cell model [134]. Inspiration for targeting 
ligands is often obtained from viruses. For instance, HEK293-derived EVs have been 
modified with gp350 (i.e. a ligand for CD21 expressed on B cells and a component of the 
Epstein-bar virus (EBV) envelope), conferring the viral tropism to EVs for normal and 
leukemic B cell targeting [135]. 
Finally, altering the PK of EVs can also be done by changing the route of administration. 
Indeed, Wiklander et al. compared IV, SC and IP injection of HEK293T EVs showing a 
clear difference in biodistribution [120]. After footpad injection accumulation of EVs in 
the lymph nodes was reported [136, 137] and intranasal application showed an 
accumulation in the brain [138, 139], in which the delivered anti-inflammatory cargo 
(i.e. curcumin) could still be detected up to 12 hours after administration [138]. 
2.2.3. Intracellular trafficking of EVs 
The ability of EVs to shuttle their cargo over the cellular barriers is of key importance. 
Especially when considering EVs for the delivery of macromolecular therapeutics, which 
require delivery into the cell’s cytoplasm (e.g. miRNA, mRNA) or even nucleus (e.g. 
pDNA). 
Nanoparticles can employ distinct endocytic uptake pathways to gain access to cells. 
Numerous studies have investigated the mechanism(s) by which EVs are associated to 
and subsequently internalized by cells. Many different types of surface molecules, both 
EV- and cell-associated, have been identified as being involved in EV-cell contact (i.e. 
tetraspanins, integrins, proteoglycans and lectins) as comprehensively reviewed by 
Mulcahy et al. [140]. These interactions, possible preceded by surfing onto filopodia 
[141], mostly lead to cell uptake via one of the common endocytosis pathways (i.e. 
clathrin- and caveolin-dependent endocytosis, lipid raft-mediated endocytosis, 
macropinocytosis or phagocytosis) [106, 140]. It is also interesting to note that 
inhibition of a given pathway is almost never able to completely abrogate the EV uptake, 
hinting toward the involvement of multiple uptake mechanisms and/or reflecting EV 
heterogeneity [140]. In this regard, it would be an interesting strategy to also link the 
effect of uptake inhibitors to the induced phenotypical changes in recipient cells as this 
would help to elucidate which specific uptake pathway(s) lead(s) to functional cellular 
release of the EV cargo. 
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As the interaction of EVs with cells likely involves multivalent ligand-receptor binding 
and subsequent endocytosis, it is reasonable to assume that they finally are trafficked to 
lysosomes for degradation [141, 142]. Hence, delivery of drugs into the cell cytoplasm 
will require a mechanism that allows the EV cargo to escape the endolysosomal 
compartment. Also for synthetic nanomedicines the endolysosomal entrapment is one of 
the major hurdles for efficient cellular delivery. The delivery efficiency of nanomedicines 
hinges on strategies to cross the endosomal barrier, such as the so-called proton sponge 
effect and/or lipid bilayer fusion [143]. As many of the effects mediated by EVs have 
been attributed to the functional delivery of miRNA and mRNA [88], this implies that 
(subtypes of) EVs contain built-in mechanisms to stimulate endosomal escape. The most 
plausible theory describes back-fusion of internalized EVs with the endosomal 
membrane, thus releasing their content in the cytoplasm (figure 2). However, few 
reports directly demonstrated EV fusion with plasma-and/or endosomal membranes. 
Some studies labeled EVs with a self-quenching dye after which they were incubated 
with cells. An enhancement of fluorescence was indicative of dye dequenching and 
hence fusion of (a fraction of) EVs with cellular membranes [52, 93]. Alternatively, 
luciferin containing EVs were able to evoke a luminescent signal after interaction with 
luciferase expressing cells, suggesting cytosolic delivery of the EV luminal cargo [93]. 
Whether this intracellular delivery process is linked to a particular receptor-ligand 
interaction or requires a specific proteolipid composition is currently unknown.  
Alternative to relying on the intrinsic EV properties to obtain functional delivery, EVs 
have been modified with delivery-enhancing peptides. Temchura et al. decorated 
antigen-loaded EVs with a vesicular stomatitis virus G (VSV-G) protein to stimulate the 
cross-presentation of these antigens in recipient DCs [144]. The VSV-G protein 
promotes the fusion of lipid membranes at lower pH (i.e. ~6) and can thus drive 
destabilization of the endosomal/phagosomal membrane following internalization [145]. 
These authors showed that the VSV-G protein stimulated MHC I mediated antigen 
presentation and elicited an antigen-specific CD8+ T cell response [144]. The previously 
mentioned RVG targeting ligand [120, 146, 147] and iRGD [134, 148] have also been 
reported to have membrane-destabilizing properties, possibly contributing to enhanced 
cytoplasmic delivery of the encapsulated cargo.  
It is of note that not for all phenotypical effects EV internalization is necessary. 
Physiological effects attributed to EVs can be based on proteins and lipids present on the 
surface of EVs interacting with ligands on the target cell’s surface, triggering 
intracellular signaling pathways (figure 2) [89, 149-151] or via enzymatic activity 
present inside or on the surface of EVs [152]. 
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2.2.4. Loading EVs with a therapeutic cargo 
The clinical implementation of EVs as a viable drug delivery platform will require 
optimized methods allowing efficient loading with the drug of choice. As already 
indicated above, EVs have been evaluated as a drug delivery vehicle for a vast diversity 
of therapeutic cargos, including both small molecules (e.g. doxorubicin, curcumin,…) 
and macromolecules (i.e. RNA, DNA and proteins). The strategies to incorporate these 
drugs into EVs can generally be divided in pre- and post-formation approaches (figure 
3) [153]. In the former case, the therapeutic cargo is first loaded into the respective 
producer cell followed by its packaging into EVs during their biogenesis. For the latter 
approach, EVs are first purified from the producer cell’s conditioned culture medium 
after which they are loaded with the therapeutic cargo via one of the methods 
represented in table 2. 
 
 
Figure 3. Schematic outline of strategies explored in the literature pertaining to the 
incorporation of therapeutic agents into EVs. Pre-formation strategies rely on the cell to 
incorporate the therapeutic cargo into EVs. This cargo can be directly transfected into the cellular 
cytoplasm or can be encoded for via the transfection of the respective pDNA, creating a more 
sustainable production source. Both for nucleic acids (e.g. mRNA and miRNA) and proteins, some 
sequences are known that can enhance the cargo’s incorporation into EVs. Post-formation loading 
strategies start from purified EVs. Hydrophobic cargoes can be loaded into the EV membrane by 
incubation at ambient or enhanced temperature. Hydrophilic cargoes (e.g. enzymes, nucleic acids) are 
loaded by inducing transient pores via electroporation, sonication, freeze-thaw cycles or saponins in the 
EV membrane enabling the cargo to passively migrate into the EV lumen. 
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Table 2. Post-formation loading strategies for EVs 
Method Cargo Efficiency Remarks Ref. 
EP:  
 M+ electrodes (400 V; 
125 μF) 
 Buffer: OptiprepTM; 
neutral pH 
siRNA 25 % of the total 
siRNA 
EVs are equipped with a 
RVG targeting peptide 
and show functional 
transfer of siRNA over 
the BBB  
[125] 
EP:  
 M+ electrodes (150 V; 
100 µF)  
 Buffer: Cytomix buffer 
siRNA 90 % of the total 
number of beads 
carrying EVs is 
positive for siRNA 
Delivery to monocytes 
and lymphocytes 
[154] 
EP: 
 N.R. 
miRNA No significant 
encapsulation 
reported 
Switched to pre-
formation loading (see 
table 3) 
[133] 
EP: 
 M+ electrodes (0.75 
kV/cm)  
 Buffer: Trehalose 
containing buffer  
5 nm 
superparamagnetic 
iron oxide 
nanoparticles 
0.40 - 0.45 µg iron/µg 
EV 
 [155] 
EP:  
 M+ electrodes  
 Buffer: PBS 
70 kDa Dextran 
/Saporin 
0.4 % and 0.5 % of 
the total dextran and 
saporin, respectively. 
Required Lipofectamine 
LTX and GALA fusogenic 
peptide for functional, 
in vitro delivery 
[156] 
EP: 
 M+ electrodes (350 V; 
150 μF) 
 Buffer: non-specified 
electroporation buffer 
Doxorubicin 20 % of the added 
doxorubicin 
EVs equipped with a 
targeting ligand (i.e. 
iRGD associated to 
LAMP2) – non targeted 
EVs were not functional  
[134] 
Co-incubation (T=37°C) miRNA (miR-150) N.R. Indirect proof of 
successful delivery is 
provided via restoration 
of the effect when using 
miR-150 knockout EVs 
[157] 
Co-incubation + 0.01 % 
saponins, *freeze/thaw, 
*sonication, *extrusion 
Catalase (240 
kDa) 
~15 – 25 % of the 
added catalase 
* indicated techniques 
show significant 
alteration of the EV 
structure 
[139] 
Co-incubation (+ 0.01 % 
saponins), hypotonic dialysis 
Porphyrins Up to ~2.5 x 1015 
molecules/EV 
Allowed to induce 
phototoxicity in tumor 
cells 
[158] 
Co-incubation (T=22°C – 5 
minutes) 
Curcumin 2.9 µg/µg EVs IP injection [159] 
Co-incubation (T=22°C – 5 
minutes) 
Cucumin / JSI-124 N.R. Intranasal 
administration 
[138] 
Co-incubation (T=37°C – 2 
h) 
Doxorubicin / 
paclitaxel 
132 ng/µg and 7.3 
ng/µg, respectively 
 [132] 
EV-liposome mixing followed 
by freeze-thaw cycles 
Lipids (-PEG) N.A. Alteration of the EV 
membrane composition 
[129] 
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Method Cargo Efficiency Remarks Ref. 
EV-micelle mixing followed 
by elevation of temperature 
(40°C) 
Lipids (-PEG) (-
nanobody®) 
N.A. Incorporation of 
targeting nanobodies + 
PEGylation for an 
enhanced circulation 
time in vivo 
[128] 
EP electroporation; M+ metal; PBS phosphate buffered saline; N.R. not reported; N.A. not 
applicable; GALA: a pH-sensitive fusogenic peptide; IP intraperitoneal; PEG poly(ethylene glycol). 
 
In a pre-formation loading approach the endogenous sorting machinery of the cell is 
used to load the cargo into the EVs (table 3). Loading of specific nucleic acids (siRNAs, 
miRNAs, mRNAs) into EVs can be accomplished by transfection of the producer cell with 
the respective cargo by lipofection [53]. A comparable approach, by incubating the 
producer cell (i.e. MSC) with free paclitaxel, has also been evaluated. The paclitaxel-
loaded EVs that were secreted by the MSCs, induced an anti-proliferative effect on in 
vitro cultured adenocarcinoma cells [160]. Alternatively, the RNA of interest can be 
expressed in the producer cell via a plasmid vector encoding for the respective 
therapeutic nucleic acid (e.g. miRNA [161], siRNA [162], mRNA [163]). Unfortunately, 
such pre-formation loading approaches typically show limited loading efficiency and 
should be optimized for each selected producer cell type and cargo. In addition, one 
needs to anticipate that the selected cargo can influence the producer cell’s functionality 
and viability, hence impairing the loading process. Although still largely elusive, the 
expanding knowledge on the endogenous cargo sorting machinery can be exploited to 
increase the drug loading efficiency by modifying the therapeutic cargo. In this respect, 
proteins can be equipped with a plasma membrane anchoring and oligomerization 
domain to stimulate EV loading [164]. Alternatively, proteins can also be sorted into EVs 
by creating a fusion construct, containing the protein of interest linked to a protein that 
is inherently associated to EVs as has been done for EV targeting purposes (section 
2.2.2) [146, 165] or to fluorescently label EVs (e.g. CD63-GFP) [166]. Likewise, also for 
nucleic acids, evidence is mounting that by altering the nucleotide sequence the sorting 
efficiency can be modulated. Bolukbasi et al. identified a specific sequence in the 3’-UTR 
region of mRNA strands that promotes its accumulation in glioblastoma-derived EVs. 
This ~25 nucleotide sequence contained a miR-1289 binding region and a CUGCC 
sequence. Incorporation of this so-called ‘zip-sequence’ in the 3’-UTR of a mRNA strand 
increased its packaging into EVs two-fold compared to the unmodified sequence. This 
enrichment could even be further enhanced when miR-1289 was overexpressed in the 
producing cell [35]. Regarding miRNA sorting, Koppers-lalic et al. discovered that 3’-
uridylated miRNAs are enriched in human B cell-derived EVs [41]. Villarroya-Beltri and 
colleagues showed that miRNAs containing a GGAG sequence were overrepresented in 
primary T lymphoblast EVs. They suggest that this sequence is selectively recognized by 
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the RNA binding protein heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNPA2B1) 
and subsequently drives incorporation into EVs [34]. However, these sequences could 
not be retrieved in miRNA accumulating in colorectal cancer-derived EVs, implying the 
existence of distinct sorting pathways, which possibly differ between cell types [167]. 
Although progress is being made, in general these sorting mechanisms remain vaguely 
defined. 
In addition to the above mentioned loading approaches for small molecules and 
macromolecules, viral capsids (i.e. adeno-associated virus; AAV) have been loaded in 
EVs thus creating so-called vexosomes. These hybrid vesicles are composed of viral 
particles coated with or associated to EVs. Vexosomes aim to merge the efficient 
transfection capabilities of the AAV and the immune-shielding properties of EVs to 
produce a potentially efficient and biocompatible delivery vehicle [168-170]. 
On the other hand, post-formation loading approaches attempt to load drugs in isolated 
and purified EVs. In this regard, the most frequently reported method, especially for 
hydrophilic membrane-impermeable components, is electroporation (EP). EP is 
traditionally used to introduce nucleic acids in cells, using high-voltage electric pulses to 
create transient pores in the plasma membrane [171]. The group of Matthew Wood 
reported the first successful EP of siRNA into DC-derived EVs, allowing functional 
delivery across the BBB in a mouse model of Alzheimer’s disease [146]. Following this 
pioneering report, other research groups have shown comparable results for loading 
siRNA and even DNA strands up to 1000 bp into EVs [154, 172-175]. Besides nucleic 
acids, 5 nm superparamagnetic iron oxide particles and large proteins have been loaded 
in purified EVs using EP (table 2). Despite the widespread use of this technique, no 
thorough investigation of the biophysical background is available. In this respect, 
chapter 2 is devoted to critically evaluate EP as a loading method for siRNA. Other 
post-formation strategies that are being explored for hydrophilic molecules are also 
based on transiently destabilizing the EV membrane, including repeated freeze-thaw 
cycles, sonication, extrusion or saponin treatment (table 2). These techniques have 
been evaluated for both small molecules (i.e. porphyrins) [158] as well as 
macromolecules (i.e. the 240 kDa catalase enzyme) [139]. It is important to note that 
for the former methods, the integrity of the EVs can be significantly compromised [139]. 
One report also suggests that antibody-coated EVs derived from B1a cells can interact 
with and take up miRNAs from the environment by simple co-incubation and 
subsequently shuttle it into cells. However, the mechanism behind this post-formation 
miRNA loading, as well as the generality of this loading approach, remain to be 
elucidated  [157]. 
For hydrophobic membrane-permeable molecules, simple co-incubation at ambient or 
elevated temperature are often sufficient to load EVs [132, 159]. Indeed, EVs derived 
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from EL4 cells incubated with curcumin at room temperature were, after intranasal 
delivery, able to significantly delay brain tumor growth in the GL26 mice tumor model 
[138]. Curcumin-loaded plant EVs for example, are currently under clinical evaluation in 
colon cancer (NCT01294072). An overview of other small molecules loaded via co-
incubation is given in table 2. However, leakage of these therapeutics out of the 
vesicles in biological fluids (e.g. plasma) can limit their practicality. 
As long as the fundaments of EV biogenesis and cargo sorting are not clear, pre-
formation methods will suffer from limited efficiency. Indeed, when comparing both 
loading strategies for paclitaxel, the post-formation method yields ~21 mg/g EV [176] 
and ~7.3 mg/g EV [132] compared to ~2 µg/g EV [160] for the pre-formation method. 
Overall, loading hydrophobic small molecules in EVs is more straightforward and 
efficient. For post-formation loading of hydrophilic compounds, especially 
macromolecules, important progress still has to be made before efficient clinical 
application of EVs as drug delivery vehicles can be envisioned.  
2.2.5. Producer cell source selection 
The choice of an adequate producing cell when aiming to exploit EVs as a drug delivery 
vehicle, is of pivotal importance as it will define the PK behavior (i.e. the stability in the 
blood circulation and organotropism; section 2.2.2) and the intrinsic biological effect 
(both physiological and pathological; section 2.1) of the EV carrier. It has been 
suggested that MSCs form a sustainable source of EVs. MSCs produce high quantities of 
EVs and neither the EV yield nor their composition is altered by immortalizing the 
producer cell. Moreover, MSCs are known for their low immunogenicity making 
allogeneic applications possible [80, 177] (NCT02138331). However, it is also shown 
that MSC-derived EVs stimulate tumor vascularization and tumor growth which might 
induce undesirable off-target effects [178]. Besides MSCs, immature DCs have also 
been proposed as an interesting EV source due to their low immunogenicity, 
immunosuppressive effects and the ease with which autologous sources can be obtained 
[110, 179].  
As the field is moving closer to clinical applications, the concept of high vesicle yield with 
minimal production costs is of increasing importance. In this respect, research groups 
have started to focus on alternative sources of EVs. Grapefruit- and milk-derived EVs 
have been investigated as drug delivery vehicles [180-182]. Additionally, the idea of 
creating EV mimicking vesicles is gaining interest (e.g. by means of sequential extrusion 
of cells through micro- and nanoporous filters [183, 184] or by mixing synthetic 
components attempting to reproduce the most important EV characteristics [185]). 
However, the latter approach is difficult to implement as long as the knowledge on 
which components are essential for EV functionality is lacking or incomplete.  
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Table 3. Pre-formation loading of EVs 
Cargo  Producer 
cell 
Method of producer 
cell transfection 
Efficiency Target cell/Functional 
delivery?  
Remarks ref 
Mir-143 and mir-143BP1 THP-1 Lipofection: LipoTrustTM 
EX Oligo + miRNA 
Estimation: 0.2 - 0.25 
% of the stabilized 
miRNA present in the 
cell 
No functional delivery 
reported 
Differentiation of THP-1 cells 
into macrophages further 
stimulated miRNA secretion in 
EVs / immune-EM confirmation 
of miRNA presence 
[186] 
mRNA HEK-293T Lipofection: 
Lipofectamine 2000 + 
plasmid (+ 3’ UTR 
zipcode sequence)  
No absolute values 
reported per EV (~2 
fold increase versus 
non-modified) 
No functional delivery 
reported 
 [35] 
mRNA (CD-UPRT 4 
mRNA) / respective 
protein 
HEK-293T Lipofection: 
Lipofectamine 2000 + 
plasmid (equipped with a 
strong promoter i.e. 
cytomegalovirus 
promotor) 
No absolute values HEI-193 cells Used as enzyme to functionalize 
a small molecule 
chemotherapeutic prodrug (5-
fluorocytosine) / sucrose 
gradient to confirm EV 
association 
[187] 
miRNA (let7a) HEK293 Lipofection: HiPerFect 
reagent  + plasmid (final 
concentration 50 nM) 
No absolute values Breast cancer cells 
(HCC70) 
GE11 peptide for EGFR 
targeting 
[133] 
miR-143, miR-146a, 
miR-155 
HEK293/ 
COS-7 
Lipofection: 
LipofectamineLTX + 
plasmid overexpressing 
the respective pri-miRNA  
2.57 %, 15.6 %, 1.38 
% (percentage 
extracellular versus 
intracellular) 
COS-7 EV association confirmed using 
RNAse treatment / using the 
neutral sphingomyelinase 
inhibitor GW4869 
[161] 
mRNA: Cre recombinase 
mRNA (+ protein?)2 
MDA-MB-
231 
mammary 
tumor cells 
Lipofection: 
lipofectamine 2000 + 
plasmid  
No absolute values MCF-7 and T47D 
mammary tumor cells 
Included delivery over long 
distance in vivo  
[163] 
(Cy3-tagged) miR-223 
 
Macrophage  
(IL-4 
activated) 
Lipofection: X-
tremeGENE siRNA 
Transfection Reagent + 
miRNA 
No absolute values Breast cancer cells 
(SKBR3) 
Delivery experiment via co-
culture system 
[188] 
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Cargo  Producer 
cell 
Method of producer 
cell transfection 
Efficiency Target cell/Functional 
delivery?  
Remarks ref 
(FITC-tagged) miR-150  THP-1 cells Lipofection:  
lipofectamine 2000 + 
pre-miRNA  (400 pmol 
per 60 mm dish) 
0.002 pmol miRNA per 
µg EV (protein 
concentration) 
HMEC-1 cells  Targeting of c-myb [53] 
siRNA L929 cells Lipofection: 
lipofectamine 2000 + 
siRNA duplex (60 pmol 
per 105 cells) 
0.001 pmol siRNA per 
µg EV (protein 
concentration) 
S180 cells 0.4 pmol siRNA per mouse (400 
µg EVs per mouse) 
[189] 
Paclitaxel MSCs 
(SR4987 
cells) 
Incubation of producer 
cell with 2000 ng/ml 
paclitaxel for 24 h 
2.03 ng paclitaxel/mg 
protein 
CFPAC-1 (i.e. a paclitaxel 
sensitive 
adenocarcinoma cell line) 
 
EVs loaded with paclitaxel show 
an anti-proliferative effect 
[160] 
Adeno-associated virus 
(AAV) 
HEK 293T 
cells 
Calcium phosphate 
transfection of plasmids 
coding for different AAV 
components 
0.01 % - 0.2 % of the 
produced AAV are 
associated to EVs 
(depending on the AAV 
subtype) 
U87 and 293T cells EVs protect AAVs from immune 
recognition 
[168] 
TyA-GFP as model 
protein 
Jurkat T-
cells 
Electroporation of the 
respective plasmid 
>10-fold increase 
compared to 
unanchored 
No functional delivery 
reported 
Targeting proteins to EVs via 
membrane anchors3 and the 
TyA-oligomerization domain 
[164] 
siRNA (via plasmid) HEK 293T  Lipofectamine 2000 + 
plasmid 
~0.15 pmol/µg EV Neuro2A RVG targeting (via fusion to the 
LAMP2 protein, which is 
inherently present on EVs) 
[162] 
Iron oxide nanoparticles THP-1 Incubation in serum free 
medium 
 
 SKOV-3 cells Magnetic targeting in vitro [190] 
1An aromatic benzene-pyridine analog was added to the 3′-overhang region of the RNA strand (higher nuclease resistance). 2Part of Cre-LoxP system to 
visualize functional protein/mRNA delivery to recipient cells. 3E.g. myristoylation tag or PIP2-binding domain. 4Cytosine deaminase-uracyl 
fosforibosyltransferase.
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2.3. EVs as vaccination platform 
The first therapeutic application of EVs was based on the use of DC-derived EVs as a 
surrogate for DC-based anticancer vaccination [11]. APC-derived EVs harbor both 
(antigen-loaded) MHC I and II as well as the necessary co-stimulatory factors to directly 
trigger (CD8+ and CD4+) T cell activation [10, 48]. However, in vivo, DC-derived EVs 
likely interact first with endogenous DCs (via cell surface adhesion or intracellular 
processing), transferring their antigens to endogenous APCs and so augmenting T cell 
activation [191, 192]. The use of DC-derived EVs for cancer immunotherapy has already 
been evaluated in phase I clinical trials for both melanoma [14] and non-small-cell lung 
carcinoma (NSCLC) [78]. Although DC-derived EVs exhibited an excellent safety profile, 
the therapeutic effects were limited with no substantial CD8+ T cell response. 
Nonetheless, pre-clinical studies have shown that co-delivery of adjuvants could vastly 
improve the evoked immune response. In this respect, Chaput et al. reported the 
combination of DC-derived EVs with CpG (a TLR3 agonist) [193], Guo and colleagues 
combined DC-derived EVs with another TLR3 agonist, i.e. polyinosinic-polycytidylic acid 
(poly(I:C)) and cyclophosphamide [194] and Gehrmann et al. associated -
galactosylceramide (an iNKT stimulatory factor) to antigen-loaded DC-derived EVs, 
which induced a potent NK, -T cell innate immune response and enabled proliferation 
of antigen-specific T and B cells [195]. Currently, a phase II clinical trial in NSCLC 
patients (NCT01159288) is evaluating the combination of cyclophosphamide with DC-
derived EVs (pulsed with a range of antigens and INF-) that showed an improved 
immune stimulatory capacity in pre-clinical studies [196]. 
As pointed out above (section 1.2), EVs derived from cancerous cells have shown to 
carry a panel of known (e.g. CEA, GP100, HER2, melan-A, PSMA) [46, 197] and likely to 
date unknown tumor antigens. This is not only of interest from a diagnostic point of view 
but also makes tumor-derived EVs, which have shown to outperform free antigens [195, 
198] and whole tumor lysate [199, 200], an attractive candidate to evaluate as a cell-
free vaccine. Building on these promising observations, a clinical trial has been 
conducted using EVs isolated from ascites fluid. Unfortunately, similar to the DC-derived 
EVs, the effect of unmodified EVs was unsatisfactory. However, when co-injecting GM-
CSF as adjuvant, a more pronounced anti-tumor cytotoxic T lymphocyte response was 
induced [77]. Just as for DC-derived EVs, tumor-derived EVs in preclinical reports 
benefit from the indirect antigen presentation by endogenous APCs. This can be 
stimulated by combining tumor-derived EVs with synthetic adjuvants [201] or using EVs 
derived from (genetically) modified tumor cells to enhance the presence of adjuvant-like 
components (e.g. heat treatment to enhance hsp70 in tumor-derived EVs [202] or 
genetically engineer tumor cells to release IL18 [203] or IL12 [204] in EVs). It appears 
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that for both strategies of EV-mediated anticancer vaccination, vesicles have to be 
modified to enhance their immune stimulatory effect.  
Despite the multitude of reports showing the potential of (adjuvant-modified) tumor-
derived EVs as antigen delivery vehicles, caution should be taken as there is mounting 
evidence that tumor-derived EVs exhibit immune suppressive characteristics. Indeed, 
besides antigens, the presence and functional transfer of fasL [205], TGF-[206] and 
NKG2D ligand [207] by tumor-derived EVs was also reported, all of which can blunt the 
activity of effector T cells. Moreover, some tumor-derived EVs are considered pro-
metastatic via niche formation [115, 208], angiogenesis stimulation and extracellular 
matrix degradation (e.g. via the presence of metalloproteinases) [209]. Additionally, 
providing a source for tumor-derived EVs in a clinical context is not evident. The most 
elegant, easy accessible source is ascites fluid. However, only few tumors entail the 
accumulation of EVs in this biofluid [46]. Alternatively, EV mimics can be produced from 
cancer cell biopsies via sonication. Whether these vesicles have the same ability as 
natural EVs to evoke an anti-tumor immune response is not known [210]. To make use 
of tumor-antigen bearing EVs without the negative characteristics of tumor-derived EVs, 
a DNA vaccine (delivered via an adenoviral vector or EP) was developed that encodes a 
fusion protein comprising (the extracellular part of) a known tumor-antigen and an EV-
associated protein (C1C2 domain of lactadherin or the gag protein). Expression of this 
fusion construct shuttles the associated antigens to the surface or lumen of secreted 
EVs, respectively [165, 211]. Nevertheless, this technology is limited to well-
characterized antigens and would likely benefit from an additional immune modulator. 
Excellent dedicated reviews on the interplay between EVs and the immune system can 
be found in the literature [212]. 
Next to eukaryotic cells, also prokaryotic cells release vesicles in the extracellular 
environment, which are termed outer membrane vesicles (OMVs). It is interesting to 
note that the use of OMVs as vaccination tool against infectious diseases is currently the 
most advanced therapeutic application of EVs with different ongoing and completed 
clinical trials (up to phase IIIb; e.g. NCT01423084, NCT01478347, NCT02446743, …) 
and a selection of OMVs that have already reached market approval (e.g. Bexsero® and 
MenBvac® for serogroup B meningococcal disease). For a comprehensive discussion on 
the use of OMVs as vaccination technology the reader is referred to Van Der Pol et al. 
[213]. 
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3. Diagnostic applications of EVs 
3.1. An introduction to biomarkers 
A biomarker can be defined as an objectively measured characteristic that indicates the 
medical state of the patient. Biomarkers can assist clinicians in making a reliable 
diagnosis and can be used as a clinical endpoint surrogate in clinical trials. For both 
applications it is critical that the correlation between disease and biomarker is well 
characterized and validated [214].  
A reliable biomarker has to fulfill a number of prerequisites. First, a biomarker needs to 
be specific, a feature with which many known biomarkers struggle (e.g. prostate specific 
antigen (PSA) often gives false positives for benign prostate hypertrophy) [215]. Also, it 
is of critical importance that a biomarker is robust and valid meaning that under all 
given conditions a correlation exists between the biomarker and the disease. In this 
respect it is important to have a clear understanding of the role of the biomarker in the 
pathophysiology of the disease. Ideally, biomarkers should be predictive, indicating that 
the quantity of the biomarker can be (positively or negatively) correlated with the 
severity of the disease. Furthermore, it is of interest that the biomarker is easy 
accessible, thereby minimizing the burden for the patient. Finally, the sensitivity of the 
biomarker (or diagnostic assay to quantify the biomarker) will determine the extent to 
which early diagnosis is feasible [214]. 
Parallel with the emergence of personalized medicine, the importance of adequate 
biomarkers is further increasing. Personalized medicine can provide a significant benefit 
for diseases exhibiting a strong inter-patient pheno- and/or genotype heterogeneity, as 
is the case for many tumors [216]. Therapies that are tailored towards a specific 
phenotype (e.g. Herceptin® for HER2 positive breast cancer patients) are often 
developed in parallel with a biomarker assay (i.e. a companion diagnostic), which 
enables the clinician to select patients who are eligible for the respective therapy [217]. 
3.2. EVs as biomarker 
EVs can be regarded as a stable and easy accessible fingerprint of the parent cell [218]. 
Indeed, the EV composition will depend on the type and even status of the producer cell 
[219, 220]. As EVs are avidly secreted by the large majority of cell types in the human 
body, they can be retrieved from all bodily fluid [221]. EVs have been isolated from e.g. 
urine [12], plasma [27], semen [26], nasal secretion [25], breast milk [222], the 
aqueous humor of eyes [223], cerebrospinal fluid [224], peritoneal fluid [225] and 
bronchoalveolar lavage (BALF) [226]. Depending on the disease for which the biomarker 
is being developed, an accessible biofluid should be considered in which the EVs of 
interest are likely the most concentrated and a liquid biopsy can be easily obtained. 
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Moreover, due to their liposome-like architecture, EVs protect their cargo against the 
harsh environment present in many of these media providing a more stable, hence 
reliable, biomarker source compared to naked RNA or proteins in e.g. blood. 
EVs have been linked to a plethora of (patho)physiological processes. They are involved 
in maintaining cellular homeostasis but have also been linked to, for example cancer 
progression. Glioblastoma-derived EVs have shown the ability to spread oncogenic 
transformation by transferring the oncogenic form of the epidermal growth factor 
receptor (EGFRvIII) to surrounding cells [227]. These EGFRvIII expressing vesicles were 
also detected in the serum of 7 out of 25 glioblastoma patients and have been proposed 
as biomarker source [13]. Additionally, tumor-derived EVs have shown the ability to 
promote cancer growth by inhibiting cancer-specific immune recognition (section 2.3) 
[89, 228]. Moreover, EVs are also involved in the metastasis of tumor cells as they are 
believed to prepare a pre-metastatic niche at a secondary tissue or organ (the seed-
and-soil hypothesis) [115, 136, 208]. The fact that EVs play such an important role in 
the process of tumor formation strengthens the validity and robustness of their use as 
biomarker in cancer detection. Besides cancer, EVs are also exploited by viral particles 
(e.g. HIV, EBV, hepatitis C) to mediate their spread, making EVs valuable tools to detect 
viral diseases as well [229]. Furthermore, EVs are associated with neurological, 
metabolic, cardiovascular and kidney conditions and are therefore also proposed as 
biomarkers for these diseases [230-232]. 
In the literature, many different clinical samples have been shown to contain EV-
associated biomarkers with diagnostic/prognostic value or disease monitoring potential. 
In this respect, the EV concentration present in serum of tumor-bearing patients was 
shown to be increased compared to healthy controls [218, 233-236]. The EV protein 
abundance also has prognostic value as it was observed that patients with stage III 
melanoma with a high EV-associated TYRP2 protein burden, showed increased risk of 
disease progression [208]. Moreover, following resection of the primary tumor, the EV 
concentration markedly decreased, indicating its correlation with the tumor presence 
[236]. However, relying solely on EV concentration lacks specificity as the same 
observation was made for distinct cancer types [218, 233-236] and, importantly, for 
non-disease stimuli (e.g. physical exercise [237]). Furthermore, early diagnosis of many 
cancers will not be possible. Therefore, it is of outstanding interest to look in more detail 
to the EV cargo (i.e. proteins, miRNA, mRNA,…) as they provide an easy accessible 
window to monitor the status of the respective producer cell (section 1.2). In this 
respect, the exploitation of comparative omic-studies is fundamental for the detection of 
new biomarkers. For instance, it was revealed that a panel of eight EV-associated 
proteins was upregulated in the urine of patients with bladder cancer compared to 
healthy subjects [238]. Likewise, miRNA profiling of plasma-derived EVs identified a 
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panel of four tumor-specific miRNAs of potential use in a screening test for lung 
carcinoma [239]. A comprehensive review on this topic was recently issued by An and 
colleagues [240]. 
Isolating EVs from a liquid biopsy prior to molecular analysis enhances the sensitivity 
(compared to whole blood/urine analysis) as highly abundant serum/plasma proteins 
(e.g. albumin) and urine proteins (e.g. Tamm–Horsfall glycoprotein) are removed [241]. 
It is estimated that less than 0.01 % of the proteins present in plasma are EV 
associated [242]. It is important to realize that in biological fluids, in general, the vast 
majority of EVs are derived from healthy cells. Hence, it is reasonable to speculate that 
the sensitivity and specificity can be further enhanced through isolation of cell- or 
tissue-specific EVs prior to a biomarker assay. Such an approach was explored by Taylor 
and Gercel-Taylor, who isolated EVs from plasma by antibody-based capturing (using an 
anti-EPCAM antibody) and subsequently analyzed the miRNA profile in this tumor EV 
enriched population. The combination of EPCAM-based EV capture and downstream 
miRNA quantification could be used to distinguish between healthy patients and patients 
at different stages of ovarian cancer [234]. Another example of the importance of an 
upstream EV selection was provided by Shi et al., who measured -synuclein levels in 
plasma of healthy individuals and patients suffering from Parkinson’s disease. When 
analyzing -synuclein levels in plasma using the total EV population, no significant 
difference could be observed between both groups. However, when the quantification 
was performed on plasma EVs positive for L1 cellular adhesion molecule (L1CAM), which 
is primarily expressed in the central nervous system, the -synuclein levels were 
significantly enhanced in Parkinson’s disease patients [243]. Yet, it is important to note 
that specific cancer markers are not always known or present on the EV surface. 
Furthermore, population assays neglect an additional level of complexity conferred by 
the specific composition of individual vesicles, which can provide relevant supplementary 
information. Therefore, techniques that allow analysis on the single vesicle level are of 
great interest [244]. For diagnostic purposes such an approach will require screening of 
large amounts of vesicles, as ‘diseased’ EVs are rare among the total isolated EV 
population. One promising approach relies on modifying flow cytometry 
equipment/protocols to detect single nanosized EVs [245-247]. However, to date flow 
cytometry is not able to detect the lower size range of EVs and requires antibodies (and 
hence also knowledge of a particular disease marker) to phenotype EVs. Unfortunately, 
antibody-independent techniques that combine single vesicle sensitivity and high 
acquisition speed are not yet available. In chapter 5 we aim to address this request by 
designing a new EV analysis platform based on Raman spectroscopy. 
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3.3. Perspectives  
The wide-spread interest from both academia and industry in exploiting EVs in a 
diagnostic context is evident from ongoing and completed clinical trials (NCT02702856, 
NCT01779583, NCT02147418, NCT01860118, NCT02439008, NCT02464930, 
NCT02662621) and extensive investments from the pharmaceutical industry (e.g. 
Exosomedx, Exosome sciences, Codiak Biosciences, Hansabiomed, etc.). These 
investments are accompanied by a multitude of filed patents claiming technical solutions 
for the purification and/or readout of this new type of biomarker source. A first 
diagnostic test (the ExoDx Lung (ALK) by Exosomedx), based on detecting a specific 
NSCLC-associated mutation present in exosomal RNA, became commercially available at 
the beginning of 2016 [248].  
Nonetheless, various issues still hamper the full exploitation of their biomarker potential. 
For instance, the lack of standardized purification protocols counteracts reproducibility 
and strongly influences biomarker identification. Due to this lack of consensus, to date 
there are no established specialized EV-biobanks, where a specific biofluid/biopsy 
sample can be correlated to the patient’s medical record [249]. Moreover, elaborate 
purification protocols precludes fast screenings and hence restrains investigation and 
validation in large patient cohorts. Besides the purification protocol, also other 
parameters (e.g. the sample collection procedure, specific reagents, sample storage 
conditions) can influence the outcome of biomarker identification studies [250]. In 
response to this unmet need, an ISEV position paper was issued, describing guidelines 
on how to handle different biological fluid samples and emphasizing the importance of a 
comprehensive experimental description to enhance reproducibility, yet a standardized 
purification protocol is currently unavailable [251]. 
 
4. General conclusions 
Inspired by their involvement in many (patho)physiological processes and their role as 
nature’s own intercellular transport vehicles for biomolecules, a multitude of therapeutic 
and diagnostic applications have been explored for EVs.  
To date, EVs have been explored as biological nanocarriers for synthetic drugs ranging 
from small molecule chemotherapeutics to macromolecular siRNA, proteins and mRNA in 
various preclinical studies. However, clinical translation will essentially depend on 
substantial improvements in cost-effective EV isolation methods, improved drug loading 
techniques and more detailed knowledge on EV composition, heterogeneity and inherent 
biological effects. Additionally, a knowledgeable assessment of the value of EVs as drug 
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delivery vehicles will require a direct comparison between EVs and current state-of-the-
art synthetic and viral delivery vehicles.  
The complex composition of EVs conceivably correlates with off-target effects. On the 
other hand this inherent complexity, conferred by the many bioactive components 
associated to EVs, enables them to induce potential beneficial effects likely challenging 
to mimic with therapeutic formulations containing a single active component. In this 
respect, MSC-derived EVs have been investigated in the field of regenerative medicine, 
auto-immune diseases and other inflammatory conditions as a safer alternative to whole 
cell therapeutics. EVs derived from both antigen-pulsed DC and tumor cells have been 
tested extensively for vaccination purposes. Despite the fact that the current clinical 
data show limited effect, pre-clinical reports indicate that modifications (e.g. co-delivery 
of an adjuvant) can further stimulate the evoked immune response. Nonetheless, it is 
important to note that safety concerns on the use of tumor-derived EVs are raised as 
many reports have linked EVs released by tumor cells to disease progression and 
metastasis. Also here, ample attention should be given to further optimize EV isolation 
and characterization protocols. 
Finally, EVs have great potential to be harnessed in a diagnostic, prognostic and 
treatment monitoring context. EVs form a reliable and easy accessible window on the 
physiological status of the parent cell. They contain a vast amount of molecular 
information, which can be extracted by downstream proteomic, transcriptomic, 
miRNomic and lipidomic analysis, the feasibility of which has recently been underpinned 
by the first EV-based diagnostic test acquiring FDA approval. To galvanize further 
development of EVs as biomarkers, again fast, efficient and standardized purification 
protocols in combination with sensitive quantification methods will be essential. 
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Abstract 
Extracellular vesicles (EVs) are specialized endogenous carriers of proteins and nucleic 
acids and are believed to be involved in intercellular communication. EVs are therefore 
proposed as candidate drug delivery systems for the delivery of nucleic acids and other 
macromolecules. However, the preparation of EV-based drug delivery systems is 
hampered by the lack of techniques to load the vesicles with nucleic acids. In this 
chapter we have characterized in detail the use of electroporation for this purpose. 
When EVs were electroporated with siRNA, the siRNA retention was comparable with 
previously published results (~20 – 25 %). Remarkably, when siRNA was electroporated 
in the absence of EVs, a similar or even greater siRNA retention was measured. 
Scattering-based single particle tracking and confocal microscopy showed extensive 
formation of insoluble siRNA aggregates after electroporation, which could be 
dramatically reduced by addition of ethylenediaminetetraacetic acid (EDTA). Other 
strategies to reduce aggregate formation, including the use of cuvettes with conductive 
polymer electrodes and the use of an acidic citrate buffer, resulted in a more efficient 
reduction of siRNA precipitation than EDTA. However, under these conditions, siRNA 
retention was below 0.05 % and no significant differences in siRNA retention could be 
measured between samples electroporated in the presence or absence of EVs. These 
results show that electroporation of EVs with siRNA is accompanied by extensive siRNA 
aggregate formation, which may cause overestimation of the amount of siRNA actually 
loaded into EVs. Overall, the data clearly illustrate that electroporation is far less 
efficient than previously described, and highlight the necessity for alternative methods 
to prepare siRNA-loaded EVs. 
 
Schematic representation of siRNA-EV mixtures after electroporation in metal 
electrode cuvettes. 
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1. Introduction 
As discussed in chapter 1, EVs are theoretically endowed with many interesting 
features which rationalizes the exploration of their potential as a drug delivery vehicle. 
Indeed, after secretion of the vesicles, the lipid bilayer protects the cargo against 
plasma and immune components, fixes the ratio between biological molecules and 
assists in functional delivery to target cells, where the vesicular content may provoke 
functional changes [1-3]. Interestingly, (sub)populations of vesicles may deliver their 
cargo by direct fusion with the plasma membrane of target cells, circumventing the 
endosomal-lysosomal pathway and resulting in efficient release of the cargo in the 
cytoplasm [3, 4]. These characteristics are very attractive for drug delivery purposes, 
especially in the case of nucleic acid-based drugs, given that endosomal escape is one of 
the major bottlenecks for the intracellular delivery of nucleic acids [5-7]. Hence, in 
recent years the exploitation of (endogenous) EVs as delivery vehicle for, amongst 
others, RNA interference (RNAi)-based therapeutics (i.e. miRNA and siRNA) has gained 
attention. 
RNAi is a highly conserved, natural mechanism used by eukaryotic cells to regulate the 
gene expression on a post-transcriptional level. The process is mediated by the cell‘s 
dedicated RNAi machinery that is activated by a small RNA duplex (i.e. siRNA or miRNA) 
recognizing a specific region in an mRNA strand [8] (figure 1). MiRNAs are the product 
of primary-miRNA (pri-miRNA), which are stem-and-loop RNA strands transcribed from 
regions in the genomic DNA by RNA polymerase II. These pri-miRNA are recognized and 
cleaved by Drosha (i.e. a RNase III-like enzyme) into shorter (~70 - 100 nucleotides 
(nt)) hairpin-like RNAs called precursor-miRNA (pre-miRNA) that are subsequently 
exported into the cytoplasm by the exportin-5/Ran-GTP heterodimer complex. There, 
the pre-miRNAs are further processed by Dicer (also a RNase III-like enzyme) into a 
mature miRNA duplex (~18 - 25 nt). The latter is incorporated in a protein complex 
termed the RNA-induced silencing complex (RISC) which retains one of the two strands 
(referred to as the guide or antisense strand). The now activated RISC (RISC*) will scan 
mRNA strands for regions complementary to the guide strand. Upon (partial) base 
pairing, the protein expression is inhibited via repression of the mRNA translation or via 
Argonaute 2 (AGO2; an endonuclease associated to RISC) mediated cleavage of the 
phosphodiester backbone of the mRNA strand. SiRNAs are the result of exogenous 
double stranded RNA (dsRNA) processed by Dicer in the cell’s cytoplasm. Similar to the 
miRNAs, siRNA is recognized by the RISC complex allowing AGO2-mediated cleavage of 
the respective mRNA strand. Indeed, siRNAs and miRNAs display many similarities. The 
major difference between both classes of RNAi effectors relates to specificity. SiRNAs are 
highly specific with only one theoretical mRNA target, whereas miRNAs generally have 
multiple targets (some miRNA have up to 100 mRNA targets) [9, 10]. 
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Figure 1. Schematic representation of the RNA interference (RNAi) pathway, activated 
by small interfering RNA (siRNA) or microRNA (miRNA). The RNAi pathway can be targeted 
for therapeutic purposes by introducing synthetic siRNA and synthetic miRNA into the cellular 
cytoplasm (indicated in red). This figure was adopted with permission from ref. [11]. 
 
The high specificity, yet broad applicability of the RNAi mechanism makes it a very 
interesting target for therapeutic intervention. By introducing synthetic siRNA or miRNA 
in the cytoplasm, the overexpression of specific deregulated genes in a diseased cell can 
be restored (figure 1). However, efficient clinical use of these small RNA duplexes is 
hampered by some of its inherent characteristics. Unmodified RNA is not stable in 
(nuclease rich) biological fluids leading to rapid clearance and loss of functionality. 
Moreover, it can trigger the innate immune system causing unwanted side effects. 
Additionally, siRNA and miRNA are relatively large (~14 kDa), negatively charged 
macromolecules that are not able to spontaneously migrate over the cellular membranes 
and enter the cytoplasm where the RNAi machinery is located. In this respect, many 
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solutions have been proposed to (partly) counter these adverse features. Careful 
placement of chemical modifications into the RNA backbone (e.g. substitution of the 
phosphodiester linkage with phosphorothioate or substitution of the ribose 2’-OH group 
by 2’-fluoro or 2’-O-methyl) protects RNA against enzymatic degradation and can 
mitigate interaction with toll-like receptors [12, 13]. Furthermore, much effort is 
invested in the development of nanosized delivery carriers which shield the RNA cargo 
from the harsh (extracellular) environment and shuttle the RNA over the different extra- 
and intracellular biological barriers, finally delivering the cargo to the cytoplasm of the 
target cell. Although the benefits of packaging siRNA into (nanosized) drug delivery 
vehicles are indisputable, to date none of the developed approaches address all the 
multifaceted requirements to efficiently overcome all barriers [7, 10]. 
In this context, EVs appear as an excellent drug delivery vehicle candidate. Yet, the 
exploration of their practical use has been limited by the lack of techniques to load them 
with the desired therapeutics. Several strategies have been proposed to encapsulate 
siRNA or miRNA into EVs, including transfection-based approaches and electroporation 
(chapter 1). Briefly, in the transfection-based approach, donor cells are transfected 
with a suitable expression vector, which induces overexpression of the desired small 
RNA. Subsequently, the RNA is incorporated into EVs and may be transferred to other 
cells. Using this technique, a number of reports have described the successful loading of 
a variety of siRNAs and miRNAs into EVs and showed their inhibitory effects in target 
cells [14-17]. Alternatively, donor cells can be directly transfected with the siRNA or 
miRNA of choice using conventional transfection reagents. This results in the secretion 
of EVs, functionally loaded with the selected small RNAs [18-23]. However, a 
disadvantage of this pre-formation loading technique is that remainders of transfection 
reagents may influence the encapsulation process and the behavior of the modified EVs. 
Furthermore, the levels of the desired small RNAs that are secreted into the vesicles are 
low and vary widely among sequences. Indeed, the biochemical pathways for cargo 
loading into EVs are still largely elusive and hence uncontrollable. In addition, the 
transfected miRNA/siRNA may alter target gene expression in the donor cell, which 
complicates the selection of feasible donor cells and target sequences. By loading small 
RNAs into purified EVs using electroporation, loading efficiency may be independent of 
the sequence of the small RNA that is incorporated into EVs. Different groups reported 
successful loading of EVs with exogenous siRNA by electroporation [24-27]. Wahlgren et 
al. demonstrated that the exogenous siRNA could be detected in up to 85.2 % of the 
electroporated EVs (however no encapsulation efficiency was reported) via bead-based 
flow cytometry analysis. Loaded EVs induced knockdown of the siRNA target genes 
when incubated with monocytes or lymphocytes [25]. Alvarez-Erviti et al. showed that 
approximately 25 % of the electroporated siRNA was loaded into EVs and that 
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retargeted EVs were functional in vivo, reducing expression of the BACE1 target gene in 
mouse brains by 60 % [24, 26]. 
Based on these reports it appears that electroporation is able to maintain EV integrity 
and functionality with concomitant encapsulation of high levels of small RNAs. The 
reported high encapsulation efficiency after electroporation is intriguing, given that the 
introduction of nucleic acids into preformed nanosized carrier systems is challenging and 
not commonly performed. Efficient loading of drug delivery systems with nucleic acids is 
generally only achieved during assembly of the carriers [28]. The electroporation 
technique therefore may offer an elegant solution for the loading of EVs with siRNA. 
However, the biophysical mechanism by which electroporation results in high 
encapsulation levels of siRNA into EVs remains unclear. In this chapter, we sought to 
further study and characterize the electroporation process for the loading of siRNA into 
EVs. 
 
2. Experimental section 
2.1. Materials 
OptiPrepTM was obtained from Sigma-Aldrich (Steinheim, Germany). Nucleic acids used 
in this chapter are listed in table 1 (siRNA) and table S1 (primers) (see supporting 
information at the end of this chapter). The Micro BCA Protein Assay Kit was from 
Thermo Scientific (Rockford, IL). Electroporation cuvettes with aluminum electrodes 
were from Bio-Rad Laboratories, Inc (Hercules, CA) or VWR (Leuven, Belgium) and 
cuvettes with conductive polymer electrodes (NucleocuvettesTM) and 4D-Nucleofector 
electroporation buffers were from Lonza (Basel, Schwitzerland). TRIzol Reagent, 
GlycoBlue, Taqman miRNA Reverse Transcription Kit, MicroAmp Optical 96-well plates 
and Lipofectamine 2000 were purchased from Life Technologies (Paisley, UK). FastStart 
SYBR Green Master was obtained from Roche (Penzberg, Germany) and Rox passive 
reference dye was from Bio-Rad Laboratories, Inc (Hercules, CA). pCMV-Luc vector was 
obtained from PlasmidFactory (Bielefeld, Germany) and pGL4.74[hRluc/TK] vector and 
Dual Luciferase Reporter Assay System kit were from Promega (Leiden, The 
Netherlands).  
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Table 1. Sequences and modifications of siRNAs used in this chapter. 
Target Abbreviation Modification Manufacturer Sequence a) 
    Sense strand (5’-3’) Antisense strand (5’-3’) 
Negative control Cy5-labeled siRNA Cy5 b)  Eurogentec UGCGCUACGAUCGACGAUGtt CAUCGUCGAUCGUAGCGCAtt 
Negative control Cy3-labeled siRNA Cy3 b) Integrated DNA Technologies CAGAAGACUGUGGAUGGCCtt GGCCAUCCACAGUCUUCUGgg 
Luciferase reporter gene siRNA LUC / Integrated DNA Technologies GAUUAUGUCCGGUUAUGUACG UACAUAACCGGACAUAAUCGG 
Negative control siRNA CTRL / Eurogentec UGCGCUACGAUCGACGAUGtt CAUCGUCGAUCGUAGCGCAtt 
eGFPc) reporter gene siRNA GFP / Eurogentec CAAGCUGACCCUGAAGUUCtt GAACUUCAGGGUCAGCUUGtt 
a)lower case bold letters represent deoxyribonucleotides, capital letters represent ribonucleotides; b)Cy5 or Cy3 fluorescent label is linked at the 5’ end of 
the sense strand; c)enhanced green fluorescent protein 
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2.2. Cell culture and isolation of extracellular vesicles 
Human embryonic kidney (HEK293T) and mouse neuroblastoma (Neuro2A) cell lines 
were maintained in Dulbecco’s modified eagle medium (DMEM; Invitrogen) 
supplemented with 10 % fetal bovine serum (FBS; HycloneTM), 100 U/ml penicillin and 
100 µg/ml streptomycin (Invitrogen). All cells were grown in a humidified atmosphere 
containing 5 % CO2 at 37°C.  
For EV production, cells were initially cultured in standard cell medium after which they 
were washed and incubated for 48 hours in EV-depleted medium prepared via overnight 
ultracentrifugation (UC) at 100 000 g. As culture medium is often supplemented with 
FBS to supply nutrients for cellular growth, it important to note that FBS houses a 
substantial amount of EVs from bovine origin, for which it has been shown that they can 
influence the recipient cell’s phenotype [29]. To circumvent the presence of these 
bovine vesicles in the final EV-isolates, different alteration on classic cell culture medium 
have been used throughout the literature. Researchers have used OptiMEM [30], 
overnight ultra-centrifuged cell medium (as used in this chapter) [29, 31], ultra-filtrated 
(UF) cell medium (as used in chapters 3 to 5) [32], commercial vesicle-depleted FBS 
[33] and cell medium without FBS [19]. This seemingly trivial choice has however 
shown to influence the protein composition of the produced EVs [34].  
Next, conditioned cell medium was harvested and EVs were isolated by a standard 
differential centrifugation/filtration protocol. Briefly, the medium was centrifuged for 10 
minutes at 300 g, followed by 10 minutes at 2 000 g to remove cells and cell debris. 
Subsequently, the medium was filtered through 0.22 µm syringe filters and EVs were 
pelleted by centrifugation for 70 minutes at 100 000 g. Pellets were washed with 
phosphate buffered saline (PBS) and pelleted again by centrifugation for 70 minutes at 
100 000 g. Resulting pellets were resuspended in the desired electroporation buffer and 
the yield was determined using a Micro BCA Protein Assay (Pierce) with bovine serum 
albumin (BSA) protein standards. 
2.3. Electroporation buffers 
Citric acid based buffer consisted of 18.6 mM citric acid and 29.4 mM disodium 
phosphate with a pH of 4.4. Phosphate-free buffer contained 125 mM sodium chloride, 5 
mM potassium chloride, 1.5 mM calcium chloride, 10 mM glucose, and 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) adjusted to pH 7.4. OptiPrep-
based buffer consisted of 21 % OptiPrepTM, 1.25 mM potassium phosphate and 25 mM 
potassium chloride adjusted to pH 7.2. Cytomix electroporation buffer consisted of 120 
mM potassium chloride, 0.15 mM calcium chloride, 10 mM potassium phosphate, 25 mM 
HEPES, 2 mM EGTA and 5 mM magnesium chloride, adjusted to pH 7.6 with potassium 
hydroxide. 
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2.4. Electroporation in metal electrode cuvettes 
Electroporations were performed in 0.4 cm cuvettes with aluminum electrodes using a 
Bio-Rad Gene Pulser II with capacitance extender set at 400 V and 125 µF. For every 
electroporation the sample volume was fixed at 200 µL, containing 3 µg EVs and 3 µg 
siRNA unless otherwise stated. After electroporation, all electroporation cuvettes were 
incubated on ice for at least 30 minutes before further processing. 
2.5. Scattering-based single particle tracking 
The size and concentration of particle aggregates was determined via scattering-based 
single particle tracking using a NanoSight LM10 instrument (Malvern). Prior to analysis, 
the samples were diluted in deionized water. For each condition three independent 
samples were prepared and analyzed. Per measurement a movie of 60 seconds was 
recorded. To evaluate particle aggregation in conductive polymer cuvettes, the samples 
were diluted with PBS and analyzed using a Nanosight LM10 instrument connected to a 
syringe pump device (Malvern) while the temperature was maintained at 22˚C. Flow 
was set at 20 and for each sample a 180 seconds movie was recorded. All data was 
analyzed with the NTA Analytical Software suite version 2.3.  
2.6. Confocal microscopy 
Confocal microscopy of aggregates containing Cy5-labeled siRNA was performed using a 
Nikon Cs1 confocal laser scanning module installed on a motorized Nikon TE2000-E 
inverted microscope (Nikon Benelux, Brussels, Belgium) equipped with an oil immersion 
objective lens (60x, NA 1.4, Nikon, Japan). Samples were transferred directly from the 
electroporation cuvettes into wells of a glass-bottomed 96-well plate (Greiner Bio-one, 
Frickenhausen, Germany) for analysis. When indicated, EVs present in electroporated 
samples were labeled using Annexin V – alexa fluor 488 (Molecular probes). To this end, 
89 µL of the electroporated sample was mixed with 10 µL of a 10x Annexin binding 
buffer (100 mM HEPES, 1.4 M NaCl, 25 mM CaCl2, pH 7.4) and 1 µL Annexin V – alexa 
fluor 488 stock. The mixture was allowed to incubate for 15 minutes at room 
temperature prior to imaging. 
2.7. Fluorescence Fluctuation Spectroscopy 
To assess the percentage of encapsulated Cy5-labelled siRNA into EVs by 
electroporation, fluorescence fluctuation spectroscopy (FFS) was used as previously 
described [35]. Prior to analysis, the electroporated samples were diluted 10-fold in the 
respective buffer and 60 µL was transferred to the wells of a glass-bottomed 96-well 
plate (Greiner Bio-one, Frickenhausen, Germany). The focal volume was positioned in 
the sample and FFS measurements were performed during a 30 seconds time-interval. A 
motorized Nikon TE2000-E inverted microscope, equipped with a water immersion 
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objective lens (60x, NA 1.2, Nikon) and a 637 nm laser line for the excitation of Cy5-
siRNA, was used. The fluorescence intensity fluctuations were recorded with the 
fluorescence correlation spectrometer MicroTime 200 (picoquant GmbH, Berlin, 
Germany), equipped with SymPhoTime software. For each condition, samples were 
prepared in triplicate. The fluorescence intensity of the baseline (i.e. the average 
fluorescence in the focal volume) in the fluctuation profiles was determined as 
previously described [35]. The siRNA complexation efficiency was subsequently 
calculated using equation 1. 
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






mediumationelectroporbefore
mediumationelectroporafter
efficiencyoncomplexatisiRNA 100100(%)               (eq.1)              
Where 
ationelectroporafter  is the average intensity of the baseline after electroporation, ationelectroporbefore  is 
the average intensity of the baseline before electroporation and  medium  is the average intensity of the 
baseline of the medium without fluorescently labeled siRNA. 
 
2.8. eGFP gene silencing assay 
eGFP reporter gene silencing experiments were performed using human non-small-cell 
lung carcinoma cells (H1299_eGFP), which stably express the enhanced green 
fluorescent protein (eGFP). Cells were grown in RPMI 1640 medium supplemented with 
10 % FBS, 2 mM glutamine and 100 U/ml penicillin/streptomycin at 37°C in a 
humidified atmosphere containing 5 % CO2. Cells were plated in a 24-well plate in a 
concentration of 1.36 x 104 cells per cm2. Twenty-four hours after seeding, samples 
were applied: 3 µg of siRNA targeted against eGFP (siRNA GFP) or siRNA CTRL was 
electroporated in the presence or absence of 3 µg HEK293T EVs in an OptiPrepTM-based 
electroporation buffer at 400 V and 125 µF in aluminum electroporation cuvettes (0,4 
cm, Bio-Rad), diluted with 4 mL PBS and centrifuged at 100 000 g for 70 minutes. 
Pellets were resuspended in 500 µl OptiMEM and co-incubated with the H1299_eGFP 
cells. As a positive control, lipofectamine RNAiMAX (Invitrogen) was used in combination 
with siRNA GFP and siRNA CTRL according to the manufacturer’s instructions. After 4h 
incubation, samples were removed and cells were washed with PBS and incubated in full 
cell medium for 48h after which eGFP expression was measured using a BD Biosciences 
FACSCalibur™ (BD Biosciences) flow cytometer. Data analysis was performed by using 
the BD CellQuest ProTM (BD Biosciences) analysis software and reported as the average 
eGFP expression (%) normalized to non-treated cells. 
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2.9. Statistical data analysis 
When applicable, statistical data analysis was done with GraphPad Prism 6 (GraphPad 
Software). Comparing multiple conditions was done using an ANOVA-test followed by a 
Tukey post hoc test. Direct comparison between two conditions was done using a 
student t-test. A p-value < 0.05 was considered as statistically significant. The degree of 
significance is indicated using ns (p ≥ 0.05), *(p < 0.05), **(p < 0.01), ***(p < 
0.001), ****(p < 0.0001). 
 
3. Results 
3.1. Quantification of siRNA loading into EVs by electroporation 
When aiming to use endogenous EVs as nanosized carriers for the delivery of siRNA, it is 
essential to have an efficient siRNA loading method available. A method proposed by 
Alvarez-Erviti et al. described that about 25 % of fluorescently labeled siRNA could be 
encapsulated in EVs by electroporation using optimized settings and reagents [24, 26]. 
We evaluated this loading approach under similar experimental conditions and 
quantified the amount of retained siRNA in EVs by FFS. Briefly, FFS is a microscopy 
based technique that monitors fluorescence intensity fluctuations in the excitation 
volume of a confocal microscope. The fluorescence fluctuations originate from the 
movement of fluorescently labeled molecules (in this case Cy5-siRNA) in and out of the 
fixed excitation volume. The average fluorescence signal is proportional to the 
concentration of freely diffusing fluorescently labeled siRNA in solution. Complexation of 
siRNA into (nano)particles results in a decrease of the average fluorescence signal. This 
can be used to quantify siRNA complexation (section 2.7) without the need for sample 
pre-treatment, which has previously been demonstrated for lipo-and polyplexes [35-
37]. When FFS was used to quantify Cy5-siRNA loading in EVs after electroporation 
under the previously reported conditions (3 µg labeled-siRNA and 3 µg EVs 
electroporated in an OptiPrepTM-based buffer), siRNA complexation appeared comparable 
(~18 %) to what was observed by Alvarez-Erviti and colleagues [26] (figure 2A). When 
no electric pulse was applied, no Cy5-siRNA complexation could be detected. However, 
when Cy5-siRNA was electroporated in the absence of EVs, an even higher siRNA 
complexation (~24 %) was measured indicating that other factors than encapsulation in 
EVs contribute to the observed siRNA complexation (figure 2A). To further confirm 
these observations, EVs were pelleted by ultracentrifugation after electroporation and 
the amount of siRNA fluorescence in the pellet was assessed by fluorescence 
spectroscopy (see supporting experimental section). Also in this assay, electroporation 
in the absence of EVs resulted in high amounts of siRNA retention (figure S1A). To 
verify that these results are not dependent on the fluorescent label associated to the 
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siRNA strands, the same experiment was repeated with unlabeled siRNA. In this 
approach the retained siRNA after ultracentrifugation was measured by RT-PCR (see 
supporting experimental section). It was quantified that 3.7 % of the siRNA was 
retained in the EV pellet after electroporation (figure S1B). Again, when electroporation 
was performed in the absence of EVs, a substantial portion of siRNA could be recovered 
from the pellet (2.3 %). This phenomenon appeared to be independent of the EV source 
as no difference in retained siRNA could be observed between HEK293T- and Neuro2A-
derived EVs (figure S1). Thus, although absolute values differed between methods, the 
percentage of retained siRNA following electroporation in the absence of EVs was similar 
to (or even greater than) the retention obtained in the presence of EVs. 
Taken together, these data suggest that electroporation causes siRNA to be retained in 
particles which could not be distinguished from EVs by FFS, and which co-sediment at 
centrifugal forces usually applied to pellet EVs. In order to better visualize this 
phenomenon, electroporated samples were analyzed by confocal microscopy. After 
electroporation of Cy5-siRNA in the absence of EVs, an excessive number of irregularly 
shaped insoluble fluorescent aggregates were detected (figure 2B). Hence, siRNA 
appears to strongly aggregate when subjected to electroporation. Moreover, 
electroporation in the presence of EVs led likewise to massive aggregation in which EVs 
and siRNA co-precipitate (figure 2C). 
This effect was not specific for the OptiPrepTM-based electroporation buffer, but was also 
observed for the previously described Cytomix electroporation buffer [25] by FFS and 
confocal microscopy (figure 2A and 2B), albeit the extent of aggregation was slightly 
lower compared to the OptiPrepTM-based buffer.  
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Figure 2. Precipitation of siRNA after electroporation in OptiPrepTM-based and Cytomix 
electroporation buffer in the presence (+) or absence (−) of EVs derived from HEK293T cells. 
[A] Complexation efficiency of Cy5-siRNA as measured by FFS in OptiPrepTM-based and Cytomix 
electroporation buffer. Experiments were performed in triplicate and data are presented as mean ± SD. 
[B] Representative confocal microscopy images of aggregate formation of Cy5-siRNA (red) of the 
indicated mixtures. [C] Representative confocal microscopy image of EVs (Annexin V – alexa fluor 488 
labeled; green) and Cy5-siRNA (red) after electroporation in OptiPrepTM-based electroporation buffer. 
The scale bar indicates 10 µm. 
 
3.2. Effect of EV concentration on siRNA precipitation 
Interestingly, when increasing concentrations of EVs were added to the electroporation 
mixture, fluorescence of the EV pellet after electroporation decreased (figure S1C). A 
similar effect was previously reported by Wahlgren et al. [25], who showed that the 
percentage of EVs containing fluorescently labeled siRNA after electroporation decreased 
from 85.2 % to 0.073 % when the EV concentration in the electroporation cuvettes was 
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increased from 0.25 µg/µL to 4 µg/µL. These data suggest that the presence of EVs may 
reduce, but not necessarily remove, the formation of siRNA aggregates after 
electroporation. To check the possibility that some siRNA aggregates might still be 
loaded into free EVs (i.e. EVs not incorporated in the large aggregates as depicted in 
figure 2C) or otherwise associated with free EVs, electroporated samples were floated 
on a sucrose gradient and the siRNA content of each fraction was analyzed by RT-PCR 
(figure S2A-C). Here it was clearly observed that free floating EVs (indicated with the 
marker CD9 by immunoblotting) did not contain siRNA. The fact that we could not 
retrieve CD9 expression in the high density fractions (what we would expect based on 
the observations in figure 2C) might be due to the fact that the procedure used to 
prepare samples for immunoblotting is not disruptive enough to break up the formed 
aggregates and thus prevents the EV associated proteins to migrate over the SDS-PAGE 
gel. 
These data illustrate that, when not taken into account, electroporation-induced siRNA 
aggregation causes a severe overestimation of the amount of siRNA actually loaded into 
EVs. This aggregation needs to be prevented in order to quantitatively analyze the 
siRNA encapsulation in EVs after electroporation. Furthermore, the formation of siRNA 
aggregates might inhibit the loading of siRNA into EVs. Therefore, we investigated the 
mechanism by which siRNA aggregation occurs during electroporation.  
3.3. Effect of EDTA on siRNA precipitation and loading efficiency 
It has previously been described that electric discharges in electroporation cuvettes 
containing metal electrodes can cause the release of metal cations (e.g. Al3+-cations, 
Fe3+-cations) from the electrodes. These multivalent cations can react with phosphate 
and hydroxide anions present in the electroporation buffer and possibly nucleic acids, 
causing the formation of insoluble aggregates trapping nucleic acids [38]. Given that in 
our experiments cuvettes with aluminum electrodes were applied, it was hypothesized 
that these components caused the siRNA precipitation described in figure 2.  
To test this hypothesis, the OptiPrepTM-based buffer was electroporated without siRNA or 
EVs and the concentration of formed aggregates was measured by scattering-based 
single particle tracking. It was confirmed that the buffer was particle-free before 
electroporation. Strikingly, after electroporation an average of 4 x 109 particles per mL 
(figure 3A) with a broad size distribution could be detected (figure S3A). To point out 
the influence of aluminum cations in the formation of these aggregates, the same buffer 
was electroporated in the presence of increasing concentrations of EDTA. EDTA acts as a 
chelator and forms soluble complexes with aluminum ions, which may prevent 
interactions of these ions with buffer components and macromolecules. Indeed, 
scattering-based single particle tracking revealed that addition of EDTA to the 
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electroporation buffer decreased particle formation during electroporation in a 
concentration-dependent manner (figure 3A). Furthermore, when EVs and siRNA were 
electroporated in the presence of EDTA, RT-PCR showed a similar concentration-
dependent inhibition of siRNA retention (figure S3B). EDTA at 1 mM concentration 
reduced particle formation and siRNA precipitation by 98 - 99 % in both experiments. 
Again similar results were found by FFS and fluorescence spectroscopy (figures 3B and 
figure S3C, respectively). These observations are supported by results obtained using 
the Cytomix electroporation buffer (containing the chelator EGTA), which showed less 
aggregation after electroporation than the OptiPrepTM-based buffer (figure 2A). Under 
the aggregate-reducing conditions depicted in figures 3B and figure S3 retention was 
again lower in the presence of EVs than in the absence of EVs (approximately 1 % 
versus 3 %, respectively), supporting the previous finding that increasing concentrations 
of EVs inhibit aggregate formation. Together, these results strongly suggest that 
aluminum-induced aggregation, and not encapsulation into EVs, is responsible for the 
observed complexation of siRNA as depicted in figure 2 and reported by others [25, 
26].  
 
Figure 3. Addition of EDTA to the OptiPrepTM-based electroporation buffer affects aggregate 
formation and retention of siRNA. [A] Concentration of particles formed in OptiPrepTM buffer after 
electroporation in the presence of increasing concentrations of EDTA as measured by scattering-based 
single particle tracking. [B] Complexation efficiency of Cy5-siRNA in HEK293T EVs after electroporation 
as measured by FFS. Experiments were performed in triplicate and data are presented as mean ± SD. 
[C] Representative confocal microscopy images of aggregate formation of Cy5-siRNA (red) in OptiPrepTM 
electroporation buffer in the absence or presence of 1 mM EDTA. The scale bar indicates 10 µm.  
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Of note, while 1 mM EDTA strongly inhibited aggregate formation and reduced the 
observed retention of siRNA after electroporation, a minor amount of aggregates was 
still formed (figure 3A), which could interfere with accurate determination of loading 
efficiency in the presence of EVs. These aggregates could be clearly distinguished from 
the background by confocal microscopy (figure 3C), and might account for the 1 % 
siRNA retention observed with FFS and fluorescence spectroscopy when EVs were 
electroporated in the presence of EDTA (figures 3B and figure S3C). Given that 
increasing EDTA concentrations above 1 mM could not completely inhibit this process 
(figure 3A), our results suggest that chelation of aluminum ions is insufficient to 
completely inhibit the formation of siRNA aggregates. Therefore alternative methods to 
reduce background aggregate formation were investigated. 
 
3.4. Effect of electroporation buffer on siRNA precipitation and loading 
efficiency 
As both phosphate and hydroxide anions in the OptiPrepTM-based buffer potentially 
contribute to aggregate formation, using a buffer devoid of these anions could possibly 
prevent siRNA precipitation. We first evaluated a phosphate-free electroporation buffer 
for the formation of aggregates. However, the amount of formed aggregates after 
electroporation in the presence of Cy5-siRNA was comparable to the amount in the 
OptiPrepTM-based buffer (figure 4A, left panel). In addition, similar amounts of particles 
were formed after electroporation in the absence of siRNA (figure 4B). This indicates 
that phosphate anions, in the concentration used in the OptiprepTM based buffer, likely 
play a minor role in the formation of aggregates. Dabbs et al. demonstrated that both 
acidic pH (implicating low hydroxide concentrations) and the presence of citric acid can 
prevent the formation of aluminum oxyhydroxide aggregates [39]. Therefore a citric 
acid based buffer (pH 4.4) was evaluated for aggregate formation after electroporation. 
Following electroporation of this buffer in the presence of Cy5-siRNA, no fluorescent 
aggregates could be detected and only minute amounts of particles could be measured 
via scattering-based single particle tracking (figure 4A, right panel and figure 4B). In 
agreement with this result, FFS measurements showed near undetectable siRNA 
complexation following electroporation of Cy5-siRNA without EVs (figure 4C). Hence, 
this buffer could potentially allow for precise measurements of encapsulation of siRNA in 
EVs. Unfortunately, after siRNA electroporation in the presence of EVs no encapsulation 
could be detected (figure 4C).  
However, it can not be excluded that the EV integrity might have been compromised in 
this acidic environment, possibly reducing siRNA encapsulation. In order to avoid the 
formation of aggregates while maintaining physiological pH, we next investigated an 
alternative electroporation strategy. 
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Figure 4. Effect of various electroporation buffers on the formation of aggregates after 
electroporation. [A] Representative confocal microscopy images of phosphate-free buffer (left) and 
citric acid buffer (right) after electroporation in the presence of Cy5-siRNA. Scale bars represent 10 μm. 
[B] Particle concentration after electroporation of OptiPrepTM, phosphate-free and citric acid buffers, as 
measured by scattering-based single particle tracking using electroporation cuvettes of two different 
manufacturers. [C] Complexation efficiency of Cy5-siRNA after electroporation in OptiPrepTM- or citric 
acid-based buffer in the presence or absence of HEK293T EVs, as measured by FFS. The data are 
presented as mean ± SD (n=3). 
 
3.5. Effect of electrode material on siRNA precipitation and loading efficiency 
Given that metal ions released from the electrodes play a crucial role in the formation of 
precipitates, it was anticipated that the use of cuvettes with conductive polymer 
electrodes instead of metal electrodes could prevent aggregate formation. Such polymer 
cuvettes are commonly used in the Lonza Nucleofector™ technology. Particle formation 
in the OptiPrepTM buffer after electroporation in these conductive polymer cuvettes was 
indeed dramatically reduced compared to conventional aluminum cuvettes (figure 
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S4A). This effect was independent of the used voltage and capacitance during 
electroporation. Polymer cuvettes could thus be valuable for aggregate-free 
electroporation of EVs.  
To optimize loading of siRNA into EVs using these cuvettes, EVs were electroporated 
with unlabeled siRNA at varying EV:siRNA ratios and siRNA retention was determined by 
RT-PCR (figure S4B). Unfortunately, only minor amounts of siRNA (maximally 0.09 % 
of total siRNA) could be detected in EV pellets. In addition to siRNA:EV ratios, also 
electroporation settings of the Lonza 4D-Nucleofector were optimized for the loading of 
siRNA in EVs. Again, using a variety of electroporation programs, no marked siRNA 
retention could be measured  (figure S4C). None of the programs resulted in more than 
0.04 % of total siRNA retention in the EV pellet. These findings were confirmed by 
sucrose gradient flotation of EVs electroporated in conductive polymer cuvettes (figure 
S2D). To determine whether the small amounts of siRNA detected in the EV pellets after 
electroporation in conductive polymer cuvettes could be attributed to actual siRNA 
loading into EVs, samples were subjected to either one or two wash steps after which 
the siRNA present in the pellet was quantified by RT-PCR (table S2). After two washes, 
no significant differences in siRNA retention could be measured between siRNA 
electroporated in the presence and absence of EVs, albeit siRNA was still detectable in 
both conditions (average Ct values of 21). Notably, after two washes the endogenous EV 
enclosed miRNAs (i.e. miR-143 and miR-146a) could still be detected in the washed 
samples (Ct values ranging from 31 to 34), indicating that EVs were not lost during the 
extensive wash procedure.  
Despite the here observed aggregation effect, previous papers still report functional 
delivery of the siRNA to recipient cells with associated target gene knockdown [25, 26]. 
To verify these observations, EVs electroporated in aluminum (figure 5) and conductive 
polymer (figure S5) cuvettes were evaluated in a reporter gene silencing assay (i.e. an 
eGFP and a luciferase assay, respectively) for their ability to functionally deliver siRNAs. 
As expected by the lack of loading of siRNA into EVs, no siRNA-mediated gene silencing 
effects was induced. It is interesting to note that in the case of metal electrodes, hence 
the presence of aluminum aggregates, the eGFP expression was lowered compared to 
the PBS control. This reduction in eGFP expression was however not siRNA-mediated as 
both the control sequence (siRNA CTRL) and the targeted sequence (siRNA GFP) showed 
the same effect. This trend was also observed in a luciferase gene reporter assay 
indicating that likely the aluminum aggregates influence the gene expression of the 
recipient cell. The mechanism behind this lowered protein expression is currently not 
known. Samples electroporated in conductive polymer cuvettes had no influence on the 
luciferase expression (figure S5).  
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Figure 5. Evaluation of the functionality of siRNA delivery by electroporated samples in metal 
electrode based cuvettes. Samples containing non-specific control siRNA (siRNA CTRL) or eGFP siRNA 
(siRNA GFP) were electroporated (using Bio-Rad aluminum electrode cuvettes – 400 V – 125 µF) in the 
presence or absence of HEK293T EVs in OptiPrepTM-based buffer. H1299_eGFP cells were incubated with 
the respective samples for 4h in OptiMEM medium. Controls included transfection of siRNA using 
Lipofectamine RNAiMax and free siRNA (not electroporated). After 48h, eGFP expression was analyzed 
by flow cytometry and normalized to eGFP expression in PBS treated cells (mean ± SD, n = 3).  
 
4. Discussion 
The obtained data provide conclusive evidence that electroporation can induce strong 
aggregation of siRNA, which might be mistakenly interpreted as encapsulation of siRNA 
into EVs if proper control experiments are omitted. Complex formation between metal 
ions from the electrodes and hydroxide ions from the electroporation buffer were shown 
to be the major cause of siRNA precipitation. While removal of one or both of these 
components (i.e. metal ions and/or hydroxide ions) almost completely inhibited this 
process, the loading efficiency of siRNA into EVs in these cases was found to be below 
0.05 %. Furthermore, similar siRNA retention was found when siRNA was electroporated 
in the absence of EVs. These data suggest that any siRNA measured after 
electroporation and washing of EVs can be attributed to traces of wash solution and not 
to actual loading of siRNA into EVs. This extremely inefficient encapsulation of siRNA 
could be expected when performing electroporations under these conditions. According 
to scattering-based single particle tracking measurements and corresponding to a 
previous report [40], an electroporation volume of 200 µL with 15 µg/mL EVs contains 
approximately 2.5 x 1010 vesicles. Based on the size distribution of the EVs, and 
assuming they exist as perfect spherical structures in the electroporation buffer, the 
total volume of EVs can be calculated. When this calculation was performed using the EV 
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size distributions commonly measured (median size of 110 nm), it was found that the 
total internal volume of EVs comprised 0.04 % of the total electroporation volume (200 
µL). Hence, assuming that loading of siRNA by electroporation occurs by passive 
diffusion of the macromolecules through pores in the EV membrane, no more than 0.04 
% of the siRNA molecules would be expected to enter the lumen of the EVs. In practice 
this is likely to be even lower, given that pores are only temporarily formed during 
electroporation and that the calculation is based on empty spherical structures, while 
EVs are dense vesicles already enriched in macromolecules. This theory is supported by 
the findings in this work, that show that when electroporation artefacts are effectively 
prevented, no encapsulation of siRNA into EVs could be detected. Although unlikely, it 
should be noted that loading efficiencies might differ depending of the source of the EVs. 
Despite our findings that loading efficiencies were similar among EVs derived from two 
different cell lines, EVs derived from primary cells may show different loading behavior 
during electroporation.  
In this work we show that extensive aggregate formation occurs during electroporation, 
resulting in precipitation of siRNA and EVs. This finding is consistent with a previous 
report, which showed that electric discharges through a solution cause DNA, RNA and 
some proteins to precipitate [38]. Furthermore, we showed that aggregate formation 
decreased with increasing concentrations of EVs. This effect may be due to the capturing 
of multivalent ions on the negatively charged EV membrane, or by changes in buffer 
conductivity upon addition of EVs. Furthermore, the formed siRNA-EV-aluminum 
complexes were not able to induce a RNAi-mediated gene knockdown under the tested 
conditions. Our findings demonstrate the importance of a variety of analysis techniques 
for the determination of loading efficiency. The main techniques used in this work (i.e. 
FFS, fluorescence spectroscopy and RT-PCR) revealed similar trends as a function of 
electroporation conditions, but absolute values for loading efficiency varied between 
fluorescence based measurements and RT-PCR. FFS and fluorescence spectroscopy 
generally showed over 5-fold higher siRNA retention or complexation than RT-PCR. The 
reason for this discrepancy is unclear. After electroporation siRNA could potentially be 
damaged or unavailable due to association with metal ions, resulting in less copies to be 
detected via RT-PCR. Indeed, aggregation of siRNA may cause the critical 3’ ends of 
siRNA to become unavailable for reverse transcription and subsequent PCR, resulting in 
an underestimation of the siRNA concentrations. Alternatively, fluorescently labeled 
siRNA might be more prone to aggregation than unlabeled siRNA. Nevertheless, these 
discrepancies warrant the use of multiple analysis techniques and controls to adequately 
measure loading of siRNA in EVs. 
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5. Conclusion 
In contrast to previous reports we show that electroporation of siRNA into EVs results in 
extensive precipitation of siRNA. Due to this process, encapsulation efficiency is easily 
overestimated when commonly used electroporation conditions and analysis techniques 
are employed. The presented data further show that electroporation is far less efficient 
than previously believed. This work highlights an important complication of the 
electroporation technique and demonstrates the necessity for alternative methods to 
load EVs with macromolecules such as siRNA, in order to maximize the therapeutic 
applicability of EVs as a drug delivery vehicle. 
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Supporting experimental section 
Electroporation in polymer cuvettes 
Electroporations were performed using a Bio-rad Gene Pulser I with capacitance 
extender set at 400 V and 125 µF. For every electroporation the sample volume was 
fixed at 100 µL, containing 1.5 µg EVs and 1.5 µg siRNA unless otherwise stated. A 
custom designed adapter was used to properly connect the electrodes to the 
electroporator. Electroporations of 16-well 20 µL Nucleocuvette™ strips were performed 
in a Lonza 4D-NucleofectorTM X unit. EVs where suspended in 4D-Nucleofector buffer P3 
with supplement 1 and electroporated in a total volume of 20 µL containing 0.6 µg EVs 
and 0.6 µg siRNA. After electroporation, all electroporation cuvettes were incubated on 
ice for at least 30 minutes before further processing. 
Fluorescence spectroscopy 
To evaluate the encapsulation of siRNA in EVs using fluorescence spectroscopy, 3 µg EVs 
were mixed with 3 µg Cy3-labelled siRNA in OptiPrepTM-based electroporation buffer and 
electroporated in 0.4 cm cuvettes with aluminium electrodes. Samples were diluted 10-
fold with PBS and centrifuged for 70 minutes at 100 000 g to remove unbound siRNA. 
Pellets were resuspended in PBS and siRNA fluorescence (excitation 560 nm; emission 
610 nm) was determined using a fluorescence plate reader. A calibration curve of free 
Cy3-siRNA was used to calculate the percentage of encapsulation. 
Quantitative reverse transcription polymerase chain reactions 
Encapsulation of non-fluorescent siRNA (siRNA LUC) in EVs was analysed by quantitative 
reverse transcription PCR (RT-PCR). After electroporation, samples were diluted 10x 
with PBS and centrifuged at 100 000 g for 70 minutes to remove unbound siRNA. RNA 
was isolated from pellets with TRIzol Reagent according to the manufacturer’s 
recommendations, with minor modifications. In brief, pellets were dissolved in TRIzol 
and solution was spiked with 10 fmol of internal control siRNA (siRNA GFP), followed by 
chloroform extraction. Isopropanol and 1 µL GlycoBlue were added to the aqueous 
phase and sample was stored overnight at -20˚C for maximal RNA recovery. RNA was 
pelleted by centrifugation at 12 000 g and 4˚C for 30 minutes, washed with 80 % 
ethanol and air dried. Dry RNA pellets were reconstituted in 20 µL nuclease-free water 
and stored at -20˚C until analysis. Standard solutions of siRNA LUC and siRNA GFP were 
prepared by serially diluting 10 µM stocks of both siRNAs in 10-fold dilution steps (range 
 Chapter 2│ 89 
 
10 µM – 100 pM). Standard solutions were also purified with TRIzol Reagent according 
to described protocol to ensure equal PCR efficiency among samples and standards. 
Reverse transcription of standards and samples was performed in a GeneAmp PCR 
System 9700 (Applied Biosystems, Foster City, CA) thermocycler using a Taqman 
MicroRNA Reverse Transcription Kit, according to manufacturer’s instructions. Each 7.5 
µL reverse transcription reaction contained 1 µL of RNA template, 1 mM dNTPs, 1.9 U 
RNAse Inhibitor, 50 nM reverse stemloop primer (custom designed as described by Chen 
et al. [41], see table S1) and 25 U MultiScribe Reverse Transcriptase in 1x Reverse 
Transcription buffer.  
Quantitative PCR was performed in 10 µL reactions containing 1 µL of reverse 
transcription product, 0.625 µM of sequence-specific forward primer, 0.625 µM of 
stemloop-specific reverse primer (table S1) and 0.013 µL of Rox passive reference dye 
in 1x FastStart SYBR Green master. Reactions were prepared in MicroAmp Optical 96-
well plates and were run on a Viia™ 7 Real Time PCR System (Applied Biosystems, 
Foster City, CA) using the following settings: 10 minutes at 95˚C; 40 cycles of 15 
seconds at 95˚C, 30 seconds at 60˚C and 20 seconds at 72˚C; melting curve analysis; 
store at 4˚C. Amplification curves were analysed with Viia 7 software version 1.2.1 and 
Ct values were determined for siRNA LUC and siRNA GFP. Each plate contained a set of 
siRNA LUC and siRNA GFP standard solutions which were used to construct calibration 
curves. Total copy number (Cn) of siRNA LUC and siRNA GFP in each sample was 
calculated and CnsiRNALUC was normalised for CnsiRNAGFP using eq. S1. From normalised 
CnsiGFPLUC the loading efficiency of siGFP LUC in each sample was calculated. All 
electroporation samples for RT-PCR were prepared in triplicate and each RNA isolate was 
analysed in duplicate. Using this method, traces of siRNA could still be accurately 
quantified. 
 
siRNAGFP
siRNAGFP
siRNALUCsiRNALUC
Cn
Cn
CnCnNormalised                                                    (eq. S1) 
where Cn siRNAGFP is the mean CnsiRNAGFP of all samples processed in the same experiment. 
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table S1. Primers for RT-PCR. 
Name Sequence (5’-3’) manufacturer 
Reverse_stemloop_ 
siRNA LUC 
GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCGATT Sigma-Aldrich 
Forward_siRNA 
LUC 
CCGCTAATACATAACCGGACAT Sigma-Aldrich 
Reverse_stemloop_ 
siRNA GFP 
GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAGCAC Sigma-Aldrich 
Forward_siRNA GFP CCGCTAAGGACTTGAAGAAGTC Sigma-Aldrich 
Reverse_miR-143 GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGAGCTA Sigma-Aldrich 
Forward_miR-143 CGCTAATGAGATGAAGCACTG Sigma-Aldrich 
Reverse_miR-146a GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAACCCA Sigma-Aldrich 
Forward_miR-146a CGCTAATGAGAACTGAATTCC Sigma-Aldrich 
Reverse_stemloop GTGCAGGGTCCGAGGT Sigma-Aldrich 
 
Fractionation using sucrose gradients 
EVs were electroporated in OptiPrep-based buffer as described before, using 15 µg/mL 
EVs and 15 µg/mL siGFP LUC in 200 µL total volume for cuvettes with aluminium 
electrodes, or 100 µL total volume for cuvettes with conductive polymer electrodes. 
After electroporation, duplicate samples were combined to 400 µL electroporation 
samples (corresponding to 6 µg EVs/siRNA LUC) and mixed with 1.5 mL of 2.5 M 
sucrose in PBS in SW40 tubes (Beckman Instruments). Samples were overlaid with a 
linear gradient of 0.4 - 2 M sucrose in PBS in SW40 tubes (Beckman Instruments) and 
centrifuged for 15 hours at 202 000 g. Gradient fractions of 1 mL were collected from 
the top of the gradients and sucrose densities measured by refractometry. Subsequent 
fractions were pooled in pairs of two and 60 µL aliquots were collected for RNA isolation. 
Each 60 µL aliquot was mixed with 300 µL Trizol, RNA was isolated, and RT-PCR was 
performed according to the method described before. The siRNA content of each fraction 
was expressed as a relative concentration compared to the fraction with the lowest 
sucrose density (top fraction), using eq. S2. Remainders of pooled sucrose fractions 
(1940 µL) were diluted to 4 mL with PBS and centrifuged at 100 000 g for 70 minutes. 
Pellets were dissolved in 25 µL sample buffer for immunoblot analysis.  
topfraction
Xfraction
Xfraction
Cn
Cn
ionconcentratsiRNArelative                                              (eq. S2) 
XfractionCn is the measured copy number of siRNA in the 60 µL sample of fraction X and topfractionCn is 
the measured copy number of siRNA in the 60 µL sample of the top fraction of the gradient. 
 
 Chapter 2│ 91 
 
Immunoblotting 
Stored samples were heated to 95˚C for 10 minutes, snap cooled on ice and subjected 
to 12 % SDS-PAGE. Proteins were electrotransferred to Immobilon-FL polyvinylidene 
difluoride (PVDF) membranes (Millipore). Blots were blocked with 50 % v/v Odyssey 
Blocking Buffer (LI-COR Biosciences) in Tris buffered saline (TBS). CD9 immunolabelling 
was performed with 50 % v/v Odyssey Blocking Buffer in TBS containing 0.1 % 
Tween20 and rabbit anti-CD9 antibody (Abcam, ab92726, 1:4000 dilution). Primary 
antibodies were probed with Alexa Fluor 680-conjugated anti-rabbit antibodies 
(Invitrogen, 1:7500 dilution) and bands were visualised using an Odyssey Infrared 
Imager (LI-COR Biosciences, Leusden, the Netherlands) at 700 nm. 
Dual luciferase reporter assay 
Neuro2A cells were transfected during 24 hours with a combination of pCMV-Luc and 
pGL4.74[hRluc/TK] (driving expression of Firefly luciferase and Renilla luciferase, 
respectively) using Lipofectamine 2000 according to manufacturer’s instructions. 
Subsequently cells were washed with PBS, trypsinised and seeded in a gelatin-coated 
96-well plate at a density of 3 x 104 cells per well. Cells were allowed to attach for 24 
hours, and medium was replaced with EV-depleted medium. 3 µg of siRNA against 
Firefly luciferase (siRNA LUC) or non-specific control (siRNA CTRL) siRNA was 
electroporated in the presence or absence of 3 µg Neuro2A EVs in OptiPrep-based 
electroporation buffer at 400 V and 125 µF, diluted with 4 mL PBS and centrifuged at 
100 000 g for 70 minutes. Pellets were resuspended in 50 µL PBS and added to the 
cells. As controls, 10 pmol of both siRNAs were complexed with Lipofectamine 2000 
according to manufacturer’s instructions and added to the cells in antibiotic-free 
medium. Cells were incubated for 48 hours and lysed with Passive Lysis Buffer 
(Promega). Lysates were mixed with substrates from the Dual Luciferase Reporter Assay 
System kit (Promega) according to manufacturer’s instructions and activities of both 
luciferases were sequentially measured at room temperature for 5 seconds using a 
SpectraMax L luminescence microplate reader (Molecular Devices). Firefly luciferase 
activity was normalised to Renilla luciferase activity and expressed as a percentage of 
normalised Firefly luciferase activity in untreated cells.  
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Supporting results 
 
 
Figure S1. Retained siRNA after electroporation in OptiPrepTM-based buffer in the presence 
(+) or absence (−) of EVs from HEK293T or Neuro2A cells. [A] Retained percentage of Cy3-siRNA 
in 100 000 g pellets before (−) or after (+) electroporation as measured by fluorescence spectroscopy. 
[B] Retained percentage of unlabeled siRNA in 100 000 g pellets as measured by RT-PCR. [C] Retained 
percentage of Cy3-siRNA in 100 000 g pellets in the presence of increasing amounts of EVs as 
measured by fluorescence spectroscopy. Experiments were all performed in triplicate and data are 
presented as mean ± SEM. 
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Figure S2. Fractionation of electroporation samples on sucrose gradients. Unlabeled siRNA was 
electroporated in OptiPrepTM buffer in the absence [A] or presence [B–D] of Neuro2A EVs in cuvettes 
with aluminum electrodes [A, C] or conductive polymer electrodes [D] at 400 V and 125 μF. 
Electroporation samples were floated on a sucrose gradient and RT-PCR was used to determine relative 
concentrations of siRNA in each sucrose fraction compared to siRNA concentrations in fractions with the 
lowest sucrose density (bar charts). Immunoblotting shows the presence of the EV marker CD9 in the 
100 000 g pellet of each fraction. Bars in the bar charts correspond to the lanes on the immunoblots 
below. Most representative data of three independent experiments is shown. 
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Figure S3. Electroporation in the absence or presence of a chelating agent. [A] Size distribution 
of aggregates in OptiPrepTM buffer after electroporation, as measured by scattering-based single particle 
tracking. The experiment was performed in triplicate and data are presented as mean ± SEM (grey 
area). [B] Percentage of retained unlabeled siRNA in 100 000 g pellet after electroporation of Neuro2A 
EVs in the presence of increasing concentrations of EDTA as measured by RT-PCR. [C] Percentage of 
retained Cy3-siRNA in the 100 000 g pellet after electroporation in the presence (+) or absence (−) of 
HEK293T EVs and 1 mM EDTA as measured by fluorescence spectroscopy. Experiments were performed 
in triplicate and the data are presented as mean ± SEM. 
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Figure S4. The influence of cuvettes with conductive polymer electrodes on the aggregate 
formation and siRNA retention in Neuro2A EVs. [A] Concentration of particles in OptiPrepTM 
electroporation buffer after electroporation in cuvettes with aluminum electrodes (at standard settings) 
or conductive polymer electrodes (at a range of voltages and capacitances), as measured by scattering-
based single particle tracking. [B] Percentage of retained unlabeled siRNA in 100 000 g pellet at various 
EVs:siRNA ratios after electroporation in a 4D-Nucleofector using the EH-100 program compared to 
electroporation in the Bio-Rad Gene Pulser, as measured by RT-PCR. [C] Percentage of retained 
unlabeled siRNA in 100 000 g pellet after electroporation of 0.6 μg EVs with 0.6 μg siRNA in the 4D-
Nucleofector using various programs. Data are presented as mean ± SEM (n = 3). 
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Table S2. Retained percentage of unlabeled siRNA in 100 000 g pellets after 
electroporation of siRNA in the presence or absence of Neuro2A EVs in cuvettes with conductive 
polymer electrodes, as measured by RT-PCR. After electroporation in OptiPrepTM electroporation 
buffer at 400 V and 125 µF, samples were centrifuged at 100 000 g (washed once), or 
subsequently resuspended in PBS and centrifuged again (washed twice).  
Sample                           Retained siRNA (%)a 
 Washed once Washed twice 
siRNA, electroporated 0.2411 ± 0.0394 0.0008 ± 0.0005b 
EVs + siRNA, not electroporated 0.0736 ± 0.0274  0.0001 ± 0.0001b 
EVs + siRNA, electroporated 0.0856 ± 0.0255 0.0014 ± 0.0009b 
aData are presented as mean percentage of total siRNA ± SD, n = 3. bRetained siRNA did not 
significantly differ among conditions when analyzed by an one-way ANOVA (p = 0.099).  
 
 
 
Figure S5.  Evaluation of the functionality of siRNA delivery by electroporated samples in 
metal and polymer cuvettes. Neuro2A cells expressing Firefly luciferase and Renilla luciferase were 
incubated with siRNA which was electroporated in the presence or absence of Neuro2A EVs in cuvettes 
with aluminum or conductive polymer electrodes at 400 V and 125 μF. Controls included transfection of 
siRNA using Lipofectamine 2000 and siRNA mixed with EVs (not electroporated). After 48h, activities of 
both luciferases were analyzed and Firefly luciferase activity was normalized to Renilla luciferase 
activity. Luciferase activities are expressed as the percentage of activity relative to the PBS control 
(mean ± SEM, n=3–6). 
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Abstract 
Despite the growing interest in the (patho)physiological function and potential 
pharmaceutical application of extracellular vesicles (EVs), there is no general consensus 
regarding the most optimal protocol to separate EVs from non-vesicular components. In 
this chapter we provide a comparative analysis of different EV isolation strategies, 
discussing the purity of the final isolate and highlighting the importance of purity on 
downstream experimental readouts. First we show that ultracentrifugation (UC), which 
is one of the most exploited strategies and has long been considered as the gold 
standard, co-purifies protein(complexes) with nuclease activity that should be taken into 
account when focusing on (EV-associated) nucleic acids. In a second part of this chapter 
three commonly used purification strategies (i.e. precipitation, UC and density gradient) 
were evaluated for their ability to remove non-incorporated fluorescent dye. For both 
types of impurities, endogenous and exogenous, density gradient purification 
outperforms the other evaluated strategies. Overall these results demonstrate that the 
implementation of stringent purification techniques and adequate control experiments is 
of pivotal importance to draw reliable conclusions from downstream experiments 
performed with EV isolates. 
 
Schematic representation of the purity of EV samples after isolation from conditioned 
cell medium using precipitation, ultracentrifugation (UC) or a density gradient 
protocol. 
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1. Introduction 
Since their discovery in the late 1960s, EVs have been linked to many physiological 
processes and are scrutinized for potential pharmaceutical applications in different areas 
(i.e. biomarker discovery [1], nucleic acid delivery [2], immunotherapy [3] and as cell 
surrogate for regenerative therapy [4]) as comprehensively overviewed in chapter 1. 
Especially the last couple of years, since the identification of EVs as nature’s own RNA 
transporters [5], interest in these vesicles as a bio-inspired nanocarrier is exponentially 
growing with many new research groups entering the field, studying their extra- and 
intracellular behavior and developing new approaches to harness these vesicles for 
therapeutic applications, e.g. as siRNA delivery vehicle.  
One of the major bottlenecks still hampering the development of EVs as nanosized 
carriers is the inability to efficiently load them with synthetic therapeutics. In chapter 2 
we critically evaluated a previously published method based on electroporation (EP) [2, 
6]. However, duplication of these experiments under identical experimental conditions 
revealed that the aforementioned siRNA encapsulation was largely due to unspecific 
aggregate formation, independent of the presence of EVs. After blocking aggregate 
formation, by virtue of an acidic citrate EP buffer or the use of polymer based EP 
cuvettes, no significant encapsulation of siRNA could be measured [7]. Alternative to EP, 
it was reported by Bryniarski and colleagues that antibody-coated EVs released by B1a 
cells could internalize free miRNA-150 after simple co-incubation at 37°C and 
subsequently functionally deliver this to effector T-cells [8, 9]. Yet this approach of 
active uptake of free RNA by EVs has not been thoroughly characterized, nor reported 
by others. In this chapter we will evaluate the extrapolation of this principle to EVs 
derived from other origins for siRNA loading. 
Besides methods to load EVs with therapeutics, tools to study their interaction with cells 
are highly desired. In this respect, fluorescence microscopy is an important tool to 
understand the cellular internalization and subsequent intracellular trafficking of EVs 
[10]. In analogy with the cell-like architecture of EVs many labeling strategies are 
equivalent to cell labeling techniques. The type of dyes most often used throughout the 
literature are equipped with a lipophilic tail allowing insertion in the lipid membrane of 
EVs (e.g. PKH26 [11], PKH67 [12-15], R18 [16, 17], DiI [18]). Alternatively, EVs have 
been labeled with carboxyfluorescein diacetate succinimidyl ester (CFDA-SE), which is a 
membrane permeable molecule responsive to esterase activity present in the lumen of 
(a subtype of) EVs. After cleavage of the acetate group the molecule can bind covalently 
to amino acids present inside the EV lumen, becomes fluorescent and membrane 
impermeable [19]. Finally, the nucleic acid cargo of EVs can be labeled using the 
membrane permeable acridine orange [20] and SYTO RNASelect dyes [21]. The above 
mentioned labeling strategies are indeed able to fluorescently tag certain EV 
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components. However, protocols to wash away unbound or non-EV associated labels are 
insufficiently characterized, which might lead to incorrect interpretation of downstream 
experimental results and observations. 
In the past, the use of stringent purification protocols was mainly emphasized in a 
diagnostic context where co-purification of non-vesicular RNAs or proteins influences the 
reproducibility of biomarker discovery [22]. In this chapter, we demonstrate how non-
EV contaminants present in EV isolates can lead to misinterpretation of downstream 
data regarding EV post-formation loading with nucleic acid based therapeutics and 
fluorescent dyes. Consequently, we postulate that stringent purification strategies, such 
as density gradient isolation, are essential to unambiguously investigate EV-mediated 
processes.  
 
2. Experimental section 
2.1. Materials 
Nucleic acids used in this chapter are listed in table 1. Exoquick-TCTM was purchased 
from SBI Biosciences. The broad range RNase inhibitor (SUPERase In™ RNase Inhibitor) 
was purchased from ThermoFisher Scientific. 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), Iodixanol (OptiprepTM) and boric acid were 
purchased from Sigma-Aldrich. Na2EDTA.2H2O and Tris(hydroxymethyl)aminomethane 
(Tris) were purchased from Merck. 
 
Table 1. Nucleic acids  
Abbreviation Modification Manufacturer Sense strand1 / Antisense strand1 
Cy5-siRNA Cy5 label2 Eurogentec 5’-UGCGCUACGAUCGACGAUGtt-3’/  
5’-CAUCGUCGAUCGUAGCGCAtt-3’ 
siRNA / Eurogentec 5’-CAAGCUGACCCUGAAGUUCtt-3’/                
5’-GAACUUCAGGGUCAGCUUGtt-3’ 
siDNA deoxyribonucleotides Eurogentec 5’-caagctgaccctgaagttctt-3’/                  
5’-gaacttcagggtcagcttgtt-3’ 
ssRNA / Eurogentec 5’-UUAUCUGUGAGCAUUCUUCUU-3’/             
N.A. 
siRNA (stabilized) stabilized3 GE Dharmacon 5’-CAAGCUGACCCUGAAGUUCUU-3’/              
5’-GAACUUCAGGGUCAGCUUGUU-3’ 
1Lowercase bold letters represent deoxyribonucleotides; 2Cy5 dye is linked at the 5’ end of the 
sense strand; 3RNA strand modified for the use in nuclease-rich environments (siSTABLE 
modification; GE Dharmacon) 
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2.2. Cell culture  
B16F10 melanoma cells (ATCC® CRL-6475™) and H1299 non-small-cell lung carcinoma 
cells (ATCC® CRL-5803™) were cultured in Dulbecco's Modified Eagle Medium (DMEM) 
(Invitrogen) supplemented with 2 mM L-glutamine, 10 % fetal bovine serum (FBS; 
HycloneTM), 1 mM sodium pyruvate (Invitrogen) and 100 U/ml penicillin, 100 µg/ml 
streptomycin. The cells were grown in a humidified atmosphere containing 5 % CO2 at 
37°C. 
2.3. EV purification 
Prior to the purification of EVs, the B16F10 melanoma cells were washed with phosphate 
buffered saline (PBS; Invitrogen) and incubated for 24h with vesicles depleted medium 
after which the conditioned cell medium was harvested for EV purification. To prepare 
vesicle depleted medium, the normal cell medium was ultra-filtrated through a 300 kDa 
filter (Millipore) using an Amicon stirred cell (Millipore) under nitrogen pressure. Using 
ultrafiltration to generate vesicle-depleted cell medium was previously described by 
Heinemann et al. [23]. Cell viability, at the moment of conditioned cell medium 
harvesting, was determined by means of trypan blue (Sigma-Aldrich) staining. The 
viability was always higher than 95 %. 
EVs were purified from conditioned cell medium by differential (ultra)centrifugation as 
schematically represented in figure 1A. Conditioned cell medium was centrifuged for 10 
minutes at 300 g and 10 minutes at 3 000 g. Next, the supernatant was concentrated 
by ultrafiltration using a 30 kDa filter (Millipore) in an Amicon stirred cell under nitrogen 
pressure. The concentrated sample was next centrifuged at 10 000 g (k = 1811) for 15 
minutes using a SW55ti rotor (Beckman instruments). Finally the supernatant was 
ultracentrifugated (UC) twice for 70 minutes at 120 000 g (k = 116) with a washing step 
in-between and resuspended in PBS.  
If indicated, EVs were further purified by iodixanol-based (OptiprepTM, Axis-Shield) 
density gradient UC. The gradient was produced by carefully laying 1 ml of different 
dilutions of iodixanol (12.5 %, 25 %, 37.5 % and 50 % in 250 mM sucrose, 1 mM  
EDTA, 10 mM Tris-HCl buffer; pH = 7.4) underneath one another, creating a density 
gradient. Next 1 ml concentrated, conditioned cell medium (after the 10 000 g UC step) 
was carefully placed on top of the gradient and centrifuged at 150 000 g (k = 92) for 
15h. Next, the gradient was fractionated per 0.5 ml. The fractions with a density 
between 1.11 and 1.15 g/ml were diluted 10x in PBS buffer and centrifuged at 150 000 
g for 150 minutes. Finally, the pellet was washed one more time and resuspended in 
PBS buffer. 
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2.4. Concentration measurements 
The amount of EVs obtained after purification was estimated by measuring the total 
amount of proteins using a PierceTM BCA protein determination assay (Thermo scientific) 
as prescribed by the manufacturer. The absolute amount of EVs was determined by 
scattering-based single particle tracking (SPT) using a Nanosight LM10 device equipped 
with the NTA 3.0 software (Malvern). Alternatively, fluorescently labeled EV 
concentrations were determined by recording videos (31.5 f/s) using a Nikon C1si 
confocal scanning module installed on a motorized TE2000-E inverted microscope (35 
µm slit; Nikon), equipped with a 60x oil immersion objective lens (NA 1.4; Nikon), using 
a 488 nm laser line. Fluorescent particle concentration was estimated using previously 
published software [24]. 
2.5. Size and zeta potential measurements 
The size of the EVs was determined via scattering-based SPT using a NanoSight LM10 
instrument (Malvern). Movies of 60 seconds were recorded and analyzed with the NTA 
version 3.0 software (Malvern). 
The zeta-potential was measured by dynamic light scattering (DLS) using a Zetasizer 
Nano ZS (Malvern), equipped with Dispersion Technology Software. The samples were 
diluted in HEPES buffer (20 mM; pH 7.4). 
2.6. Gel retention assay 
Association between EVs and small nucleic acids was assessed by polyacrylamide gel 
electrophoresis (PAGE). Ten pmol siRNA (or, if indicated, another small nucleic acid) was 
incubated with increasing amounts of EVs for 1h at 37°C (unless otherwise indicated) in 
PBS (unless otherwise indicated) after which a 10x gel loading solution (AM8556; 
Ambion) was added to each sample. The samples were loaded onto a 20 % non-
denaturing polyacrylamide gel prepared in TBE-buffer (10.8 g/L Tris base, 5.5 g/L boric 
acid, 0.74 g/L Na2EDTA.2H2O). Electrophoresis was performed at 120 V during 40 
minutes. Free migrating nucleic acids were visualized by incubating the gel in SYBR 
Green II RNA staining solution (ThermoFisher Scientific) for 45 minutes at room 
temperature followed by UV transillumination and gel photography. Gel images were 
cropped for clarity using ImageJ software. 
2.7. Immunoblotting 
The EV pellet was resuspended in RIPA buffer (Sigma-Aldrich) supplemented with MS-
SAFE protease and phosphatase inhibitor cocktail (Sigma-Aldrich), vortexed and placed 
on ice for 30 minutes. Next, the samples were placed in a sonication bath (Branson 
2510) for 3x 5 minutes with vortexing in-between. The protein concentration was 
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determined using the DCTM protein assay (Bio-Rad) according to the manufacturer’s 
instructions. The samples were diluted in 2x laemmli buffer (Bio-Rad) with 5 % 2-
mercaptoethanol (Sigma-Aldrich) and heated to 95°C for 5 minutes. Ten µg protein was 
loaded on a 10 % mini-protean TGX precasted gel (Bio-Rad). Proteins were separated at 
100 V for 60 minutes in running buffer (Tris-Glycine-SDS). Blotting was done on an 
immune-blot® PVDF 0.2 µm membrane (Bio-Rad) at 100 V for 90 minutes in blotting 
buffer (Tris-Glycine-Methanol-SDS). The blot was blocked for 1h in PBS supplemented 
with 3 % bovine serum albumin (BSA) and 0.1 % Tween20. Next, the anti-Hsp70 
antibody (1/1000; LS-C24142; LS biosciences Inc.) was incubated overnight at 4°C 
under gentle shaking. The secondary antibody (1/50 000; AP307P; Millipore), 
conjugated to Horseradish peroxidase, was incubated for 1h at room temperature. 
Visualization was done using the SuperSignal West Dura chemiluminescent kit (Thermo-
Scientific). To estimate the protein size, a precision plus protein dual color standard 
(Bio-Rad) was ran along with the sample. Protein bands were cropped for clarity using 
ImageJ software. 
2.8. Dynabead® assay 
Thirty µg isolated EVs (after incubation with Cy5-labeled siRNA if indicated) were mixed 
with anti-CD63 coated dynabeads® (Invitrogen) and incubated overnight at 4°C under 
gentle shaking according to the manufacturer’s protocol. The next day, samples were 
incubated with anti-CD63-FITC (312003; Biolegend), FITC-labeled isotype control 
(400107; Biolegend) or immediately washed. Bead-associated FITC or Cy5 fluorescence 
was quantified by flow cytometry (FACSCalibur; BD Biosciences).  
2.9. Fluorescent labeling 
B16F10-derived concentrated conditioned cell medium (after the 10 000 g spin) was 
mixed with an equal volume of 6 µM PKH67 (Sigma-Aldrich) in Diluent C (Sigma-Aldrich) 
and incubated for 30 minutes at 37°C. Next, the samples were divided in three equal 
volumes and further purified according to one of the protocols (i.e. precipitation, UC and 
density gradient) as schematically represented in figure 6. 
2.10. Density gradient flotation (bottom-up) 
Fluorescently labeled EV samples were mixed with the iodixanol stock to obtain a 50 % 
iodixanol solution (1 ml). This mixture was carefully placed underneath the previously 
described 0 – 37.5 % iodixanol gradient and centrifuged for 15h at 150 000 g. Next, 
250 µl fractions (20 fractions per gradient) were carefully collected and pipetted in a 
black 96-well plate (Greiner bio-one) and fluorescence was evaluated in each fraction 
using an EnVision plate reader (PerkinElmer). 
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2.11. Quantification of the background fluorescence 
Movies of 150 frames (31.5 f/s) were recorded from labeled and purified EV samples 
using a Nikon C1si confocal scanning module installed on a motorized TE2000-E inverted 
microscope (35 µm slit; Nikon), equipped with a 60x oil immersion objective lens (NA 
1.4; Nikon). In each frame the average background fluorescence (i.e. after exclusion of 
the detected nanoparticles) was determined as a measure for non-EV associated dye. 
2.12. Cell uptake experiments 
H1299 cells (1.36 x 104 cells per cm2) were grown in a 24-well plate and allowed to 
attach overnight. The next day, cells were incubated with an equal amount (determined 
by scattering-based SPT, section 2.4) of labeled EVs in OptiMEM reduced serum 
medium (Invitrogen) for the indicated time period. Next, the sample containing medium 
was removed and the cells were washed with PBS before being detached by means of 
trypsin/EDTA (Invitrogen). The detached cells were washed twice with flow buffer (1 % 
BSA, 0.1 % sodium azide in PBS) and analyzed for PKH67 fluorescence by flow 
cytometry (CytoFLEX; Beckman Coulter) recording at least 10 000 events per sample. 
Alternatively, H1299 cells were plated at the same cellular density in glass bottom 
plates for microscopy (Greiner bio-one). After sample incubation, the cells were washed 
thrice with PBS after which the cells were incubated with CellMaskTM deep red plasma 
membrane stain (ThermoFisher Scientific) for 10 minutes at room temperature. Finally, 
the cells were again washed with PBS and fixed using 4 % paraformaldehyde for 15 
minutes at room temperature, washed 3x with PBS and mounted with Vectashield 
Antifade mounting medium containing DAPI (Vector Laboratories). Images were 
recorded using a Nikon C1si confocal scanning module installed on a motorized TE2000-
E inverted microscope (35 µm slit; Nikon), equipped with a 60x oil immersion objective 
lens (NA 1.4; Nikon), using a 405 nm, 488 nm and 637 nm laser line for the excitation 
of DAPI, PKH67 and CellMaskTM deep red, respectively. 
2.13. Statistical analysis 
When applicable, statistical data analysis was done with GraphPad Prism 6 (GraphPad 
Software). Comparing multiple conditions was done using an ANOVA-test followed by a 
Tukey post hoc test. Direct comparison between two conditions was done using a 
student t-test. P-values < 0.05 were considered as statistically significant. The degree of 
significance is indicated using ns (p ≥ 0.05), *(p < 0.05), **(p < 0.01), ***(p < 
0.001), ****(p < 0.0001). 
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3. Results  
3.1. EVs purified by conventional UC contain considerable nuclease activity  
EVs were isolated out of conditioned cell culture medium from in vitro cultured B16F10 
melanoma cells utilizing the currently most adopted protocol, which is based on 
differential UC [25]. The sequential centrifugation steps are depicted in figure 1A and 
exist initially out of low centrifugal forces to remove dead cells and larger vesicles such 
as apoptotic bodies. Theoretically, all vesicles larger than 350 nm should be pelleted in 
the described set-up considering a particle density of 1.14 g/ml [26]. Next, the smaller 
sized vesicles (exosomes and remaining ectosomes) are pelleted using high speed UC. 
Isolated EVs showed a typical size ranging from 30 nm up to 350 nm as determined by 
scattering-based SPT (figure 1B), and a negative zeta potential of around -20 mV 
(figure 1C). Moreover, the presence of the tetraspanin CD63 (an exosomal marker) 
was shown by bead-based flow cytometry (figure 1D) and the presence of Hsp70 was 
shown by immunoblotting (figure 1E). 
Loading purified EVs with synthetic nucleic acids is the subject of intensive research [2, 
6, 8, 27, 28]. This can be driven by the objective to attribute a certain effect to EV-
mediated transport/delivery of nucleic acids or to exploit EVs as a drug delivery vehicle. 
To date, few methods are available that allow to load purified vesicles with exogenous 
macromolecules. The previously reported method of EP [2, 29, 30] appears very 
inefficient (chapter 2) [7]. Likewise, loading EVs by mixing them with synthetic 
lipofection agents has important limitations as it significantly alters the EV composition 
[31]. A report from Bryniarski et al. indicated that simple mixing of synthetic miRNA 
with purified vesicles at 37°C is sufficient to load EVs with the respective miRNA [8, 9]. 
Indeed, when mixing siRNA with mounting concentrations of B16F10 EVs at 37°C, siRNA 
appears to bind to the vesicles, as demonstrated by a gel retention assay (figure 2A). 
This assay is often used in the field of synthetic drug carriers to verify the association 
between a nanocarrier and the nucleic acid cargo as only non-associated RNA is small 
enough to migrate through the gel pores and hence can be visualized [32]. Moreover, 
we observed that the outcome of the gel retention assay was dependent on the nucleic 
acid type, incubation temperature and pH, suggesting an active process (figure 2B-D). 
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Figure 1. Purification and characterization of extracellular vesicles (EVs) isolated from 
B16F10 melanoma cells. [A] Schematic overview of the UC-based purification protocol. [B] 
Representative size and [C] zeta potential distribution of purified B16F10-derived EVs. [D] Flow 
cytometry analysis of anti-CD63 coated dynabeads® incubated with B16F10-derived EVs and mixed with 
FITC anti-CD63 (red) or FITC control antibody (blue), respectively. [E] Immunoblotting of isolated EVs 
using an anti-Hsp70 antibody. The molecular weight of the reference ladder proteins is indicated in kDa.  
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Figure 2. The influence of incubation conditions on small nucleic acid ‘retention’ by EVs, 
evaluated by a gel retention assay. [A] Representative PAGE of siRNA mixed with different amounts 
of B16F10 EVs after one hour incubation at 37°C. [B] Influence of small nucleic acid type (siRNA = a 
small RNA duplex, siDNA = a small DNA duplex and ssRNA = a single stranded small RNA; see table 1) 
on the retention by increasing amounts of EVs at 37°C and pH 7.4. [C] Influence of incubation 
temperature on the retention of siRNA when co-incubating 10 pmol siRNA and 5 µg EVs at pH 7.4. [D] 
Influence of pH during co-incubation of 10 pmol siRNA and 5 µg EVs at 37°C. Nucleic acids were 
visualized by incubating the gel in SYBR Green II staining solution. 
 
However, as the gel retention assay does not provide conclusive evidence regarding the 
association between EVs and siRNA, we incubated B16F10-derived EVs with Cy5-labeled 
siRNA prior to capturing the EVs with CD63-coated dynabeads®. As shown by figure 3, 
no bead-associated Cy5 fluorescence could be observed via subsequent flow cytometric 
analysis, indicating that the siRNA is not associated with CD63-positive EVs. To verify if 
the observations in figure 2 could be explained by remaining nuclease activity in the 
purified vesicle samples (as this can also explain the disappearance of siRNA bands on 
PAGE), we repeated the loading experiment following a heat-inactivation step or 
addition of a broad range RNase inhibitor. A short heat treatment of the EV sample to 
inhibit enzymatic activity prior to the incubation with siRNA corroborated the lack of 
interaction with the vesicles (figure 4A). As the vesicle structure was not compromised 
during heat inactivation (figure 4A), the latter results are suggestive of nuclease 
contamination in the EV isolates. Indeed, upon inactivation of nuclease activity through 
addition of a broad range RNase inhibitor, no association of siRNA with EVs could be 
detected (figure 4B) which was further confirmed by the inability of chemically 
stabilized siRNA to be retained by EVs on a gel retention assay (figure 4C). 
 Chapter 3│ 109 
 
 
Figure 3. Anti-CD63 bead-based assay to determine EV-siRNA association. Anti-CD63 antibody 
coated dynabeads® were incubated with an EV + Cy5-siRNA mixture (black line), EVs only (gray full) 
and Cy5-siRNA without EVs (gray dotted line), respectively. 
 
 
Figure 4. Nuclease activity in B16F10-derived EVs purified by differential UC. [A] (upper) PAGE 
of 10 pmol siRNA with and without 10 µg heat-inactivated EVs. (lower) Characterization of heat-
inactivated EVs. Size, zeta potential and concentration of the vesicles before and after heat inactivation. 
Error bars represents the standard deviation of three technical replicates. [B] Gel retention assay of EV-
siRNA with and without a nuclease inhibitor (N.I). The ladder contains strands of  25, 21 and 17 base 
pairs, respectively. [C] Comparing the behavior of unmodified and stabilized siRNA (siSTABLE, GE 
Dharmacon, table 1) after incubation with mounting concentrations of UC-purified EVs. 
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3.2. Density gradient purification removes non-EV associated nuclease activity 
To verify if the observed nuclease activity is associated to vesicles (as previously 
reported for other enzymes [33-37]) or whether it is merely a contamination in our EV 
isolate, a more stringent purification protocol was used. To this end, following the 
differential centrifugation steps, the EV concentrate was layered on top of an iodixanol 
density gradient and fractionated by overnight UC to obtain higher purity vesicles and 
minimize co-purification of e.g. protein aggregates. Interestingly, the vesicles obtained 
via a density gradient contained much lower nuclease activity compared to conventional 
UC purified vesicles (figure 5), suggesting that nucleases are not associated with the 
vesicular membrane. However, as nucleic acid degradation could not be completely 
avoided, it is advisable to work with chemically modified RNA as this was shown to be 
resistant to degradation by nuclease present in EV samples (figure 4C). 
 
Figure 5. Comparing nuclease activity in EV isolates purified by differential UC (upper) and 
density gradient ultracentrifugation (lower). The ladder contains strands of  25, 21 and 17 base 
pairs, respectively. The samples were incubated for 2h at 37°C. Nucleic acids were visualized by 
incubating the gel in SYBR Green II staining solution. 
 
3.3. The fluorescent labeling of EVs requires stringent purification protocols 
The observation that non-vesicular components co-isolate with EVs when using 
differential UC, i.e. a method often used to wash away non incorporated molecules (e.g. 
fluorescent dyes) [13, 38, 39], lead us to hypothesize that free or non-vesicular 
associated fluorescent dye might remain in the EV isolate, possibly leading to false 
assumptions regarding EV uptake and intracellular trafficking. To this end we compared 
three purification strategies (i.e. precipitation [40], UC [41, 42] and density gradient 
[43, 44]) for their efficiency to render high purity isolates. All three techniques have 
previously been used in the literature and their theoretical background has been 
discussed in chapter 1.  
Conditioned cell medium from B16F10 melanoma cells was again deprived of larger 
particles by sequential centrifugation and the sample was concentrated (~130x) to 
workable volumes by ultrafiltration (30 kDa). Next, the concentrated conditioned cell 
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medium (cCCM) was incubated with a lipophilic dye. In this chapter we opted for PKH67 
as a fluorescent dye as this is often used throughout the literature to evaluate and 
quantify the interaction of EVs with recipient cells [13, 45-47]. Next, the labeled cCCM 
was divided in three equal fractions and purified with one of the following methods: (1) 
precipitation using a commercial kit (i.e. Exoquick-TCTM), (2) pelleting by UC (120 000 g 
– 70 minutes) and (3) density gradient purification (0.0 % – 50.0 % iodixanol gradient) 
as schematically represented in figure 6.  
 
 
Figure 6. Schematic representation of the different purification strategies used to wash away 
non-EV associated PKH67 dye.  
 
EV isolation by precipitation results in the highest number of particles (~2.4x) followed 
by UC (~1.9x) and density gradient (normalized to 1.0), as measured by scattering-
based SPT (figure 7). The same trend is seen for the total amount of fluorescence that 
is retained, yet the fold increase relative to density gradient purification is much more 
pronounced (36.4x and 3.4x using precipitation and UC, respectively) (figure 7). This 
can have two distinct reasons: (1) The precipitation method isolates EVs with more 
fluorescent molecules per vesicle compared to UC and density gradient purification. 
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However this is unlikely as one batch of (an equal volume of) PKH67-labeled cCCM was 
applied as starting material for all three isolation strategies (figure 6). (2) Alternatively, 
the additional fluorescence of the precipitation- and UC-obtained isolates is a 
consequence of free or non-EV associated (e.g. albumin) dye which would imply that 
precipitation, and to a lesser extent UC, leads to less pure isolates compared to density 
gradient purification confirming our results for nuclease contamination in differential UC 
purified isolates (section 3.2).  
 
Figure 7. Particle and fluorescence yield using different purification protocols. The relative 
amount of particles (left axis) obtained for each purification strategy using scattering-based SPT 
(Nanosight, Malvern instruments) normalized to the amount of particles obtained using the density 
gradient purification protocol. For each purification strategy the relative amount of fluorescence is 
indicated (right axis; green) again normalized to density gradient purification. The data is represent the 
mean ± SD (n=3). 
 
In order to verify the latter hypothesis, the vesicular purity of each isolation strategy 
was estimated by plotting the amount of scattering particles (i.e. a measure for the 
amount of retained EVs) relative to the total amount of proteins. This methods was 
proposed by Webber and Clayton as a semi-quantitative method to express the vesicular 
purity [48] and clearly shows that the purity is inversely proportional to the total 
amount of retained fluorescence (figure 8A). This is a first indication that precipitation 
and, to a lesser extent, UC are insufficient to wash away non-EV associated or even free 
fluorescent dye. To confirm this, fluorescent confocal images of the isolated, labeled 
samples were recorded using a swept field confocal microscope in combination with 
particle detection, using in-house developed software as previously described by 
Deschout et al. [49]. This allows to determine the background fluorescence which can 
be used as a measure for the amount of non-nanoparticle associated PKH67 label 
(figure 8B). Here, again the same trend could be observed with a high background 
signal for the precipitation obtained EV isolate followed by UC and finally density 
gradient purification not showing a significant difference from the non-fluorescent 
 Chapter 3│ 113 
 
control (i.e. PBS) indicating that all non-incorporated PKH67 was efficiently washed 
away.  
 
Figure 8. Characterization of the purity of each isolation strategy. [A] Particle concentration 
(measured via scattering-based SPT) over protein concentration (measured via a BCA-protein assay 
kit). The data is represented as mean ± SD (n=3). [B] Fluorescent background signal (i.e. the average 
fluorescence per frame excluding the particles). The results (mean ± SD) represent two independent 
experiments analyzing > 3000 frames per condition. [C] Relative PKH67-derived fluorescence for each 
fraction (20 fractions in total, fraction 1 being the lowest density) after a bottom-up density gradient 
flotation over a 0 - 50 % iodixanol gradient for each purification strategy. The results are represented 
as mean ± SD (n=3). [D] Relative PKH67-derived fluorescence for each fraction after bottom-up 
density gradient flotation of unbound PKH67 and BSA-bound PKH67. 
 
In an attempt to better understand the association profile of the non-vesicular PKH67, 
the labeled isolates were floated (bottom-up) on a density gradient (0 – 50 % 
iodixanol). A clear difference in fluorescence distribution over the density gradient is 
apparent between the different isolation strategies (figure 8C). For both UC and 
precipitation a large fraction of the fluorescence is present at higher densities. A recent 
observation by Willms et al. shows that using this bottom-up flotation approach, a 
higher density EV fraction can be separated from the ‘normal’ EV density fraction (i.e. 
fraction 9 – 10, see chapter 4), which is not visible using the top-down approach [50]. 
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However, we observed (via scattering-based SPT) that this higher density fractions 
contain far less particles (~18 % and ~21 % for precipitation and UC, respectively) 
compared to the EV fraction (i.e. fraction 9 and 10) whereas the fluorescence 
(expressed as AUC) is around 2 times higher, implying that next to vesicles it are mainly 
other components that are associated to PKH67 and hence responsible for the flotation 
of the dye at higher densities. Likely, albumin is one of these contaminants as we 
(figure 8D) and others [51] confirmed that albumin floats at higher densities. 
Moreover, the presence of albumin in both UC and precipitation isolates has been 
described in the literature while this is not the case for density gradient-based isolates 
[43]. The fluorescent peak visible at fraction 4 and 5 using the precipitation protocol 
appeared not of vesicular origin (<1 % vesicles for 1.5x fluorescence, compared to the 
EV fraction) yet can originate from dye associated to alternative components as free dye 
does not float (figure 8D).  
Based on the obtained results it appears that, dependent on the used isolation strategy, 
the fluorescent dye can be present under different forms (i.e. EV-associated, 
protein(complex) associated, …). It is likely that this altered association profile interferes 
with cell interaction experiments. To this end, equal amount of scattering particles from 
each purification strategy were added to H1299 lung carcinoma cells as a model 
recipient cell. It is interesting to note that normalization (i.e. diluting the isolates to 
obtain an equal amount of EVs for each purification strategies) on the amount of 
scattering nanoparticles corresponds with normalization on the amount of fluorescent 
nanoparticles for the EVs purified with UC and density gradient (data not shown). For 
isolates obtained using precipitation, the fluorescence-based SPT approach 
underestimates the amount of particles relative to the scattering-based SPT which is 
likely due to the high PKH67 background (figure 8B) making some weakly labeled 
particles disappear in the fluorescent background.  
When quantifying the uptake of EVs in recipient cells as a function of time, a comparable 
profile was seen between UC and precipitation with a fast internalization of fluorescent 
label. In contrast, the gradient-purified EVs show a much slower, linear uptake profile. 
When analyzing free PKH67 dye in the same concentration as present in the EV isolates, 
the fast uptake profile of the UC and precipitation obtained samples could be mimicked 
(figure 9A). Looking in more detail to the cellular uptake using confocal microscopy, 
the intracellular distribution following 20h co-incubation appears comparable between 
the different purification strategies (figure 9B). However, we believe drawing reliable 
conclusions regarding the origin of this dotted profile is not feasible as we observed a 
comparable punctuated appearance for the free PKH67 dye as well (figure 9B). 
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Figure 9. Uptake of PKH67-labeled B16F10-derived EVs by H1299 cells after different 
isolation strategies. Percentage positive H1299 cells after co-incubation with the same concentration 
(measured by scattering-based SPT; ~1.5 x 1010 particles/ml) of PKH67-labeled EVs purified by 
precipitation, UC and density gradient, respectively. The dotted lines indicate the uptake of unbound 
PKH67 incubated with the cells at the same concentration as present in the respective EV fractions 
(determined by fluorescence intensity). Representative confocal microscopy images of H1299 cells after 
20h incubation with PKH67-labeled EVs (green) purified using the indicated isolation strategy or 
unbound PKH67. The nuclei are labeled with DAPI (blue) and cells are labeled with CellMaskTM deep red 
plasma membrane stain (red). The scale bars represents 20 µm. 
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4. Discussion 
Our results demonstrate that the currently most used purification protocol (i.e. 
differential UC followed by a washing step) is prone to co-purification of (protein) 
contaminants including ribonucleases (RNase), i.e. endogenously present in FBS 
supplemented medium and/or secreted by cultured cells [52]. In this respect, it is 
important to note that standard approaches to determine the association between the 
therapeutic nucleic acid cargo and a nanocarrier (e.g. a gel retention assay, as often 
used in the field of synthetic drug delivery vehicles [32]) have to be interpreted with 
caution, especially when no measures have been taken to block this nuclease activity 
(e.g. working at 4°C as was done in chapter 2). By performing additional control 
experiments (e.g. an antibody-based EV capture approach), we were able to show that 
loading purified EVs by simple incubation with small RNA duplexes, as previously shown 
for Ba1 cell-derived EVs and miR-150 [9], is not an universal mechanism applicable to 
all EVs and small RNA duplexes. Likely this phenomenon is limited to a certain niche of 
EVs, RNAs or specific circumstances. Additionally, the unanticipated detection of RNase 
activity in EV isolates prompted us to switch from unmodified to chemically stabilized 
siRNA as therapeutic cargo in the next chapter and underscores the importance of EV 
isolate purity, e.g. when contemplating downstream (post-formation) loading with 
nucleic acid therapeutics. 
In the literature, the importance of EV purity is mainly emphasized in biomarker 
identification studies as it appears to severely affect the reproducibility of biomarker 
identification [43, 53]. However, we demonstrated here that EV isolates of high purity 
are not only important in a diagnostic context but are also vital to reliably probe the 
physiological behavior of EVs. Fluorescent labeling of EVs is an important tool to study 
the interaction between EVs and cells, e.g. to quantify the uptake of (drug-loaded) EVs, 
to evaluate intracellular trafficking and to assess cell type specificity of EV-cell 
interactions. Unfortunately, the strategies to remove non-EV incorporated or free dye 
are often insufficiently characterized before downstream experiments are executed. In 
this respect, three purification approaches were evaluated in a comparative analysis for 
the overall purity of the final isolate and their ability to wash away non-incorporated 
fluorescent dye. In addition to the biological relevance of studying the dye-EV 
association, the addition of a fluorescent dye prior to the actual purification appeared an 
elegant tool to study the purity of the final EV isolate. 
We observed that precipitation and UC retained a higher amount of fluorescence 
compared to density gradient purification. This appeared not only to be due to a 
difference in EV yield but was mainly a consequence of contaminating, non-EV-
associated dye. The particle to protein ratio gave a first indication that density gradient 
purification renders isolates with the highest purity. This was further confirmed by 
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background fluorescence analysis and corroborates with other reports in the literature 
[43, 54]. This implies that the fluorescent dye not only associates with EVs but also with 
non-vesicular components. Importantly, this unspecific dye association and difference in 
purity translates into a modified uptake profile in recipient cells as a function of time. 
We observed that the EVs isolated with techniques categorized as less stringent (i.e. 
precipitation and to a lesser extent UC) show a very fast cellular uptake, which is 
comparable to free PKH dye. On the other hand, EVs purified using more stringent 
purification protocols (i.e. density gradient) showed a much slower, linear uptake 
profile. As the vesicle isolate obtained via density gradient purification contains the least 
non-EV associated label, this likely is more representative for the actual uptake profile. 
However, it is also possible that the density gradient purification protocol impairs the 
EV-cell interactions. Yet, we consider this as less likely as a comparable protocol has 
recently been used to purify adeno-associated viruses and showed that they maintained 
their ability to functionally deliver their gene content to receptive cells [55].  
Due to the commercialization of the easy-to-use precipitation kits, often these low 
quality EV isolates are used as EV source for further experiments. For example the use 
of Exoquick-TCTM is advised by the manufacturer to wash away non-incorporated label 
[56] which, based on our data, is insufficient to obtain clean isolates of labeled EVs. 
Consequently, this can have a strong impact on studies evaluating EV-cell interaction 
specificity [10]. Other purification strategies, including size based purification strategies 
(chapter 1), are likely also able to remove non-incorporated dye. Generally, these 
techniques are, just as density gradient, categorized as stringent [57, 58] and from our 
own experience with amphiphilic molecules (MPLA adjuvant; figures S1) we know that 
size exclusion chromatography (SEC) is able to wash away non-EV associated 
components.  
It is also interesting to note that EVs can be labeled using fusion protein constructs 
consisting of an inherent EV-associated protein (e.g. CD63) and a fluorescent protein 
(e.g. GFP) [59, 60]. This restricts the fluorescent molecule to EVs with no background 
fluorescence, yielding reliable information on cellular interaction (e.g. uptake and 
intracellular trafficking) [61]. However, such an approach could restrict labeling to 
certain EV subtypes and moreover requires the biotechnological alteration of the EV 
producer cell which is not always feasible (e.g. when working with EVs obtained from 
biofluids or working with difficult-to-transfect cells). 
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5. Conclusion 
Overall our data demonstrate that inadequate purification strategies can lead to 
misinterpretation of downstream experiments on EV isolates, e.g. post-formation 
loading with nucleic acid therapeutics and fluorescent labeling. From the here tested 
purification strategies, density gradient purification rendered EV isolates with the 
highest purity followed by UC and finally precipitation. 
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Supporting information 
The experiments represented in figure S1 were conducted in the context of EV-based 
immunotherapy using tumor-derived EVs. In this respect the goal was to load EVs with 
toll-like receptor (TLR) agonists, in this case monophosphoryl lipid A (MPLA; a TLR4 
agonist). The data are presented in this chapter as they illustrate the ability of size 
exclusion chromatography (SEC) to wash away non-incorporated amphiphilic molecules. 
The graph indicates the amount of MPLA (expressed as MPLA-induced dendritic cell 
maturation by virtue of CD86 expression) that was retained after the indicated 
purification strategies (i.e. UC or SEC). A single UC step is not sufficient to wash away 
free MPLA as is evident from the high amount of maturation induced in the absence of 
EVs. An additional UC washing step already deprived a large fraction of the non-
incorporated MPLA, yet is not sufficient to inhibit all maturation. SEC on the other hand 
was able to completely abrogate MPLA-induced maturation in the absence of EVs. When 
EVs are present, MPLA is incorporated in the EV membrane and MPLA-loaded EVs are 
able to induce DC maturation. The DC isolation protocol, culture conditions and CD86 
expression assay were conducted according to ref. [62]. 
 
Figure S1. Associating an amphiphilic components (i.e. MPLA) to EVs requires sufficient 
stringent purification protocols to wash away non-incorporated molecules. Mouse bone 
marrow-derived dendritic cells (DC) were incubated (overnight) with EVs, MPLA (1 µg/ml; Avanti polar 
lipids), MPLA washed by UC (70 minutes – 120 000 g), MPLA incubated with B16F10-derived EVs (1 µg 
MPLA per 10 µg EV) for 1h at 37°C followed by an UC wash, MPLA washed 2x by UC, MPLA incubated 
with EVs and washed 2x by UC, flow-through of MPLA over a commercially available SEC column 
(Exosome Spin Columns; Invitrogen) or flow-through of MPLA incubated with EVs over a SEC column. 
After incubation, the expression of CD86 (a marker for DC maturation) was evaluated using flow 
cytometry and expressed relative to the CD86 expression induced by Escherichia coli derived 
lipopolysaccharide (LPS; 1 µg/ml). The data are represented as mean ± SD (n=3). 
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Abstract 
Exosome-like vesicles (ELVs) play an important role in intercellular communication by 
acting as natural carriers for biomolecule transfer between cells. This unique feature 
rationalizes their exploitation as bio-inspired drug delivery systems. However, the 
therapeutic application of ELVs is hampered by the lack of efficient and reproducible 
drug loading methods, in particular for therapeutic macromolecules. To overcome this 
limitation, we present a generic method to attach siRNA to the surface of isolated ELVs 
by means of a cholesterol anchor. Despite a feasible uptake in both a dendritic and lung 
epithelial cell line, B16F10- and JAWSII-derived ELVs were unable to functionally deliver 
the associated small RNAs, neither exogenous cholesterol-conjugated siRNA nor 
endogenous miRNA derived from the melanoma producer cell. The latter results were 
confirmed both for purified ELVs and ELVs delivered via a transwell® co-culture set-up. 
In contrast, simple anionic fusogenic liposomes were able to induce a marked siRNA-
mediated gene knockdown under equal experimental conditions, both indicating 
successful cytosolic delivery of surface-bound cholesterol-conjugated siRNA and further 
underscoring the incapacity of the here evaluated ELVs to guide cytosolic delivery of 
small RNAs. In conclusion, we demonstrate that a more in-depth understanding of the 
biomolecular delivery mechanism and specificity is required before ELVs can be 
envisioned as a generic siRNA carrier. 
 
 
Schematic representation of the intracellular fate of RNAi-based therapeutics after 
delivery by exosome-like vesicles and CHEMS:DOPE liposomes. 
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1. Introduction 
As already highlighted in chapter 1 and 2, extracellular vesicles (EVs) are being 
intensively explored as bio-inspired drug delivery vehicles [1, 2]. Yet an efficient loading 
strategy for macromolecular drugs is still missing. In chapter 3, we also showed the 
importance of an adequate purification strategy to prevent experimental misconceptions 
due to co-isolation of non-EV components. In this respect, density gradient purification 
appeared a valuable technique to obtain high-purity EV isolates. This technique focusses 
on EVs with a specific buoyant density typically attributed to exosomes [3]. 
Nonetheless, also ectosomes (partially) float at this density, consequently leading to a 
mixture of both vesicle types. Additionally, exosomes and ectosomes share many 
physicochemical characteristics, and selective markers to discriminate both vesicle types 
are currently lacking [3, 4]. Therefore, we will use the term exosome-like vesicles 
(ELVs) throughout the next two chapters to indicate EVs purified by a density gradient 
protocol [4, 5]. 
The role of ELVs as a waste disposal mechanism to maintain cellular homeostasis has 
long been recognized [6]. Nonetheless, their involvement in intercellular 
communication, thus contribution to many physiological and pathological processes, has 
only recently been appreciated [7]. The ability of ELVs to functionally transfer 
biomolecules (lipids, proteins, nucleic acids) to recipient cells evoked a surge of interest 
within the drug delivery community to exploit ELVs as delivery systems, e.g. to enhance 
the cellular delivery of therapeutic nucleic acids like siRNA and miRNA [8]. Such small 
RNA-based therapeutics harbor great promise because of their ability to selectively 
silence disease-causing genes [9]. Delivery of siRNA across cellular barriers is typically 
facilitated by synthetic polymer- or lipid-based nanomedicines [10]. Unfortunately, such 
delivery systems often fail to merge biocompatibility and efficacy [11]. Owing to both 
their endogenous nature as well as their intrinsic physiological activity and cell 
transfection properties, ELVs could be regarded as a bio-inspired alternative for siRNA 
delivery. 
When envisioning ELVs as nucleic acid delivery systems, one of the most important 
issues to address is the feasibility of loading them with nucleic acids of interest. As 
mentioned previously, ELVs share important physicochemical features with synthetic 
liposomes, i.e. a (phospho)lipid bilayer that encloses an aqueous lumen [12]. However, 
in contrast to liposomes, ELVs are not optimally suited for encapsulating exogenous 
hydrophilic macromolecules. To date, different loading strategies have been explored 
which can largely be categorized in pre- (during ELV biogenesis) and post- (after ELV 
isolation) formation loading methods [13]. In a pre-formation loading approach, the 
endogenous cell machinery for RNA sorting in ELVs is exploited. Several studies 
evaluated the feasibility of transfecting cells with high concentrations of small RNAs, 
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followed by their ELV-mediated secretion in the extracellular fluid [14-16]. However, as 
the mechanisms for RNA sorting in ELVs are not yet fully understood [17-20], such a 
loading approach is difficult to control and rather inefficient [13, 21, 22]. A valuable 
alternative might be a post-formation loading approach. In this respect, two distinct 
methods have been previously reported. Employing a commercial fusogenic lipofection 
reagent to transfer complexed siRNA to purified ELVs requires cumbersome additional 
purification steps and might drastically alter the original vesicle composition [23]. A 
second, more widely-adopted approach involves loading of siRNA into ELVs through 
electroporation [23-25]. However, as thoroughly investigated and discussed in chapter 
2 we have strong doubts regarding the efficiency and validity of this approach [26]. 
Considering the above, alternative methods to load ELVs with hydrophilic 
macromolecular drugs like siRNA are required to evaluate their drug delivery potential. 
In this chapter we envisage a distinct post-formation loading method based on the 
insertion of a lipid-modified siRNA [27] in the vesicular membrane of isolated ELVs. 
Here, we successfully demonstrated the association of cholesterol-modified siRNA with 
ELVs from both a melanoma and a monocyte/dendritic cell (DC) line and assessed their 
siRNA delivery potential in distinct target cells. In addition, given the structural analogy 
between ELVs and liposomes [12, 28], which have been widely investigated as drug 
delivery carriers, we also aimed to compare the ELV-mediated siRNA delivery efficiency 
with state-of-the-art anionic fusogenic liposomes by employing the same loading 
approach. This is of pivotal importance to truly assess the efficacy with which ELVs 
transfect cells. Finally, we also evaluated the cellular delivery of endogenously 
encapsulated miRNAs by melanoma ELVs. 
 
2. Experimental section 
2.1. Cell lines and culture conditions 
The JAWSII cell line (ATCC® CRL-11904™) is composed of immortalized DCs and 
monocytes and was cultured in RPMI 1640 (Invitrogen) supplemented with 2 mM L-
glutamine (Gibco), 10 % fetal bovine serum (FBS, HycloneTM), 0.05 mM 2-
mercaptoethanol (Invitrogen), 100 U/ml penicillin, 100 µg/ml streptomycin (Gibco), 1 
mM sodium pyruvate (Gibco) and 5 ng/ml murine GM-CSF (PeproTech). B16F10 
melanoma cells (ATCC® CRL-6475™) cells and H1299 non-small-cell lung carcinoma 
cells (ATCC® CRL-5803™) were cultured in Dulbecco's Modified Eagle Medium (DMEM) 
(Gibco) supplemented with 2 mM L-glutamine, 10 % FBS, 1 mM sodium pyruvate 
(Gibco) and 100 U/ml penicillin, 100 µg/ml streptomycin. H1299_eGFP cells stably 
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express the enhanced green fluorescent protein (eGFP) [29]. All cells were grown in a 
humidified atmosphere containing 5 % CO2 at 37 °C.   
Prior to ELV purification, the cells were washed with phosphate buffered saline (PBS) 
(Invitrogen) and incubated for 24h in vesicle-depleted medium after which the thus 
obtained conditioned cell medium was harvested for ELV purification. To prepare vesicle-
depleted medium, cell culture medium was ultrafiltrated through a 300 kDa filter 
(Millipore) using an Amicon stirred cell (Millipore) under nitrogen pressure [30]. Cell 
viability, at the moment of medium harvesting, was determined by means of 0.4 % 
Trypan blue (Sigma-Aldrich) staining. The cell viability was always higher than 95 %. 
2.2. ELV purification, concentration measurements and fluorescent labeling 
ELVs were purified from conditioned cell medium by differential centrifugation followed 
by density gradient ultracentrifugation (UC). Conditioned cell medium was centrifuged 
for 10 minutes at 300 g and 10 minutes at 3 000 g (Heraeus Multifuge 1S-R). Next, the 
supernatant was concentrated by ultrafiltration using a 30 kDa filter (Millipore) in an 
Amicon stirred cell (Millipore) under nitrogen pressure. Next, the concentrated sample 
was centrifuged at 10 000 g for 15 minutes using a SW55ti rotor in a L8-M Beckman 
ultracentrifuge. One milliliter of this concentrated cell medium was placed on top of an 
iodixanol (OptiPrepTM, Axis-Shield) density gradient. The gradient was produced 
according to the manufacturer’s instruction. Briefly, by careful placing 1 ml of different 
iodixanol dilutions (12.5 %, 25 %, 37.5 % and 50 % in 250 mM sucrose, 1 mM EDTA, 
10 mM Tris-HCl buffer; pH = 7.4) underneath one another, a density gradient was 
created. The gradient was subjected to UC at 150 000 g for 15h. Next, the gradient was 
fractionated per 0.5 ml, diluted 10x in PBS and centrifuged again at 150 000 g for 150 
minutes. Finally, the pellet was washed and resuspended in PBS. The average density of 
the individual fractions was determined by diluting each fraction 2x in ultrapure water 
(Milli-q, Millipore) and measuring the absorbance at 340 nm using an EnVision plate 
reader (PerkinElmer). 
To estimate the amount of ELVs obtained after purification, a PierceTM BCA protein 
determination assay (ThermoFisher Scientific) was executed as described by the 
manufacturer. Alternatively, the absolute amount of particles was determined by 
scattering-based single particle tracking using a NanoSight LM10 device equipped with 
the NTA 2.3 software (Malvern). 
ELVs were fluorescently labeled using the membrane permeable Syto RNASelect dye 
(Molecular Probes, Invitrogen) to label the RNA present inside the vesicles. The labeling 
was done as described by the manufacturer. Briefly, purified ELVs were incubated at 
37°C for 20 minutes with Syto RNASelect at a final concentration of 40 µM. Next, the 
remaining free dye was removed by an exosome spin column (MWCO 3 000, 
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Invitrogen). Alternatively, ELVs (diluted in Diluent C) were incubated with 4 µM PKH26 
(Sigma-Aldrich) for 15 minutes at 37°C. Non-associated dye was washed away using UC 
(120 000 g for 70 minutes in Diluent C). The quality of the fluorescent labeling was 
assessed each time by fluorescent single particle tracking using a swept field confocal 
microscope (LiveScan SFC, Nikon) equipped with a 100x oil immersion lens (NA 1.40; 
Nikon). The ELVs were irradiated with 488 nm (Syto RNASelect) or 561 nm (PKH26) 
laser light and movies of labeled ELVs were recorded with an iXon Ultra EMCCD camera 
(Andor) as an additional control to verify the labeling quality.  
2.3. Immunoblotting 
Cells were washed 3 times with ice cold PBS and detached by means of a cell scraper. 
Next, the cells were centrifuged for 5 minutes at 300 g and resuspended in RIPA buffer 
(Sigma-Aldrich) supplemented with MS-SAFE protease and phosphatase inhibitor 
cocktail (Sigma-Aldrich), vortexed and placed on ice for 30 minutes. Next, the cells were 
sonicated 3x 5 minutes with vortexing in between. Finally, the cell lysate was 
centrifuged at 13 000 g for 5 minutes and the supernatant retained for further analysis. 
The same protocol was used for ELV sample preparation. 
The protein concentration was determined using the DCTM protein assay (Bio-Rad) 
according to the manufacturer’s instructions. Samples were diluted in 2x laemmli buffer 
(Bio-Rad) with or without 5 % 2-mercaptoethanol (Sigma-Aldrich) and heated to 95°C 
for 5 minutes. Equal protein amounts (10 µg per lane) were loaded on a 10 % mini-
protean TGX precasted gel (Bio-Rad). Proteins were separated at 100 V for 60 minutes 
in running buffer (Tris-Glycine-SDS). Blotting was done on an immune-blot® PVDF 0.2 
µm membrane (Bio-Rad) at 100 V for 90 minutes in blotting buffer (Tris-Glycin-
Methanol-SDS). The blot was blocked for 1h in PBS supplemented with 3 % bovine 
serum albumin (BSA) and 0.1 % Tween20. Next, primary antibodies (table 1) were 
incubated overnight at 4°C under gentle shaking. The secondary antibody, conjugated 
to horseradish peroxidase (HRP), was incubated for 1h at room temperature. 
Visualization was done using the SuperSignal West Dura chemiluminescent kit 
(ThermoFisher Scientific) in combination with a VersaDocTM imaging system (Bio-Rad).  
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Table 1. Antibodies used for immunoblotting. 
Target Dilution Supplier Cat.# Reducing 
conditions 2 
CD81 1:1 000 LS biosciences Inc. LS-C108453 No 
CD63 1:500 Tebu-bio GTX37555 No 
-actin 1:1 000 Cell Signaling Techn. #4970 Yes 
Hsp70 1:1 000 LS biosciences Inc. LS-C24142 Yes 
Calnexin 1:1 000 LS biosciences Inc. LS-C92236 Both 
GM130 1:14 000 LS biosciences Inc. LS-C49800 Both 
Rabbit IgG1  1:50 000 Millipore AP307P / 
1The secondary antibody is conjugated to horseradish peroxidase; 2Samples are mixed with 5 % 
2-mercaptoethanol and heated at 95°C for 5 minutes 
 
2.4. siRNA 
An overview of the siRNAs used throughout this chapter can be found in table S1. Chol-
siRNA was fluorescently labeled by means of a covalent coupling with Cy5 dye using a 
Label IT siRNA tracker kit (Mirus Bio). The coupling was done according to the 
manufacturer’s instructions. The final RNA concentration was determined with a 
Nanodrop 2000c (ThermoFisher Scientific) spectrophotometer at 260 nm. 
2.5. Preparation of CHEMS:DOPE liposomes 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and 3β-hydroxy-5-cholestene 
3-hemisuccinate (CHEMS) were purchased from Avanti Polar Lipids and Sigma-Aldrich, 
respectively. Both lipids were dissolved in chloroform and mixed in a molar ratio of 6:4 
(DOPE:CHEMS) in a round-bottomed flask. A lipid film was formed by evaporating the 
chloroform under vacuum at 45°C. The film was hydrated in PBS reaching a final lipid 
concentration of 10 mg/ml. To obtain uniformly sized liposomes, the lipids were 
extruded 21x through a 200 nm pore sized polycarbonate filter (Whatmann). 
Concentration measurements were done by scattering-based single particle tracking 
using a NanoSight LM10 device equipped with the NTA 2.3 software (Malvern). The zeta 
potential was measured in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
buffer (20 mM, pH 7.4) by dynamic light scattering using a Zetasizer Nano ZS 
(Malvern), equipped with Dispersion Technology Software. Liposomes were labeled 
using PKH26 (Sigma-Aldrich) as described for ELV labeling using the same particle to 
dye ratio. 
2.6. Gel retention assay 
Semi-quantification of (chol-)siRNA retained by ELV/liposomes was assessed by 
polyacrylamide gel electrophoresis (PAGE). Ten pmol (chol-)siRNA was incubated with 
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increasing amounts of ELVs/liposomes for 1h at 37°C in PBS after which 10x gel loading 
solution (AM8556, Ambion) was added to each sample. The samples were loaded onto a 
20 % non-denaturing polyacrylamide gel prepared in TBE buffer (10.8 g/L Tris-base, 5.5 
g/L boric acid, 0.74 g/L Na4EDTA.2H2O). Electrophoresis was performed at 120 V during 
40 minutes. (Chol-)siRNA was visualized by SYBR Green II RNA staining solution 
(Molecular Probes, Invitrogen) for 45 minutes at room temperature followed by UV 
transillumination and gel photography. Band density of the free migrating nucleic acids 
was determined by ImageJ software and compared to non-retained siRNA to estimate 
the amount of vesicle associated siRNA. 
2.7. Anti-CD63 dynabeads® assay 
Qualitative association between ELVs and Cy5-labeled (chol-)siRNA was assessed by 
bead-based flow cytometry. Chol-siRNA loaded ELVs were subjected to UC (120 000 g – 
70 minutes) to wash away non-incorporated chol-siRNA. The respective sample and 
controls were mixed with anti-CD63 coated dynabeads® (Invitrogen) and incubated 
overnight at 4°C under gentle mixing (HulaMixer®, ThermoFisher Scientific) according to 
the manufacturer’s protocol. Bead-associated Cy5 fluorescence was quantified by flow 
cytometry (FACSCalibur; BD Biosciences).  
2.8. Density gradient co-localization 
Binding of Cy5-labeled chol-siRNA to isolated ELVs was additionally assessed by density 
gradient co-localization. To this end, 30 µg ELVs were incubated with 20 pmol Cy5-
labeled chol-siRNA for 1h at 37°C. Next, the samples were placed on top of an 
iodixanol-based density gradient and centrifuged for 15h at 150 000 g. Fractions of 0.5 
ml were carefully pipetted and analyzed for Cy5 fluorescence on an EnVision plate 
reader (PerkinElmer). The same procedure was followed to assess the buoyant density 
of free chol-siRNA and Syto RNASelect labeled ELVs and represented as normalized 
fluorescence intensity per fraction. 
2.9. Quantification of ELV and chol-siRNA cell uptake by flow cytometry  
JAWSII cells (4.5 x 104 cells per cm2) and H1299 cells (1.36 x 104 cells per cm2) were 
seeded in a 24-well plate and allowed to attach overnight. The next day, cells were 
incubated with the respective fluorescently labeled sample in vesicle-depleted cell 
medium. After 24h, the sample containing medium was removed and the cells were 
washed with PBS before being detached by means of 0.05 % Trypsin/EDTA (Gibco). 
Next, the detached cells were washed twice in flow buffer (1 % BSA, 0.1 % sodium 
azide in PBS) and analyzed for chol-siRNA (Cy5) or ELV (Syto RNASelect, PKH26 or 
CD63-GFP) fluorescence by flow cytometry (CytoFLEX; Beckman Coulter or 
FACSCalibur; BD Biosciences) recording at least 10 000 events per sample. 
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2.10. Visualization of ELV and liposome cell uptake by confocal microscopy 
JAWSII cells (4.5 x 104 cells per cm2) and H1299 cells (1.36 x 104 cells per cm2) were 
plated in 8-well Lab-Tek Chamber Slides (ThermoFisher Scientific). The next day, cells 
were incubated with Cy5-labeled chol-siRNA, chol-siRNA loaded liposomes, chol-siRNA 
loaded ELVs in vesicle-depleted cell medium. After 24h incubation, the samples were 
removed and the cells were washed thrice with PBS after which the cells were incubated 
with fresh cell medium supplemented with Hoechst 33342 (ThermoFisher Scientific) for 
30 minutes at 37°C. Finally, cells were again washed with PBS and fixed using 4 % 
paraformaldehyde for 15 minutes at room temperature. Images were recorded using a 
Nikon C1si confocal scanning module installed on a motorized TE2000-E inverted 
microscope (22 µm slit; Nikon), equipped with a 100x oil immersion objective lens (NA 
1.4; Nikon), using a 405 nm, 561 nm and 637 nm laser line for the excitation of Hoechst 
33342, PKH26 and Cy5, respectively.  
2.11. CD45 gene silencing assay 
JAWSII cells were plated in a 24-well plate (4.5 x 104 cells per cm2) and allowed to 
attach overnight. Next, the cell medium was replaced by vesicle-depleted medium. The 
cells were co-cultured for 24h with chol-siRNA loaded ELVs, chol-siRNA loaded liposomes 
or chol-siRNA at the indicated concentration. Next, the cells were washed with PBS and 
cultured for an additional day in full cell medium before being detached with non-
enzymatic cell dissociation buffer (Sigma-Aldrich), incubated for 5 minutes in blocking 
buffer (5 % FBS in PBS) and stained with PerCP-Cy™5.5 Rat Anti-Mouse CD45 (BD 
biosciences) for 45 minutes on ice. After 3 washing steps, fluorescence was monitored 
via flow cytometry (FACSCalibur, BD Biosciences). A minimum of 10 000 events was 
recorded for each sample. For the long term silencing conditions, the cells were 
detached and replated at half the cell density every two days. Lipofectamine RNAiMAX 
(Invitrogen) was used as a positive control following the manufacturer’s instructions. 
The chol-siCD45 induced gene silencing was normalized to CD45 expression obtained 
after identical treatment of the cells with chol-siCTRL. 
2.12. eGFP gene silencing assay 
H1299_eGFP cells were plated in a 24-well plate (1.36 x 104 cells per cm2) and allowed 
to attach overnight. Next, the cell medium was replaced by vesicle-depleted medium. 
The same samples and procedures were followed as indicated above (section 2.11). To 
quantify eGFP expression, cells were detached using 0.05 % trypsin/EDTA (Gibco), 
washed with flow buffer and eGFP fluorescence was monitored (MFI of ≥ 10 000 events) 
using a flow cytometer (CytoFLEX, Beckman Coulter). The chol-siGFP induced eGFP 
silencing was normalized to eGFP expression after identical treatment with chol-siCTRL. 
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2.13. Chloroquine treatment to induce endolysosomal destabilization 
H1299_eGFP cells were plated in a 24-well plate (1.36 x 104 cells per cm2) and allowed 
to attach overnight. Next, the cell medium was replaced by vesicle-depleted medium 
and incubated with chol-siRNA (50 nM) loaded ELVs. After 6h, the samples were 
removed and replaced by cell medium in the absence or presence of 40 µM chloroquine 
(Sigma-Aldrich) for 12h after which the medium was again replaced by fresh culture 
medium. After an additional 24h of incubation, eGFP expression was quantified via flow 
cytometry (CytoFLEX, Beckman Coulter). The chol-siGFP induced eGFP silencing was 
normalized to eGFP expression obtained after identical treatment with chol-siCTRL. 
2.14. Luciferase assay using purified ELVs 
JAWSII and H1299_eGFP cells were transfected using lipofectamine 2000 (Invitrogen) in 
24-well plates (4.5 x 104 or 1.36 x 104 cells per cm2, respectively) with 100 ng or 20 ng 
of a reporter plasmid containing a HMGA2 3'UTR wt luciferase (Luc-wt) (Addgene 
plasmid # 14785) or HMGA2 3'UTR m7 luciferase (Luc-m7) (Addgene plasmid # 14788) 
insert, respectively [31]. Twenty-four hours later, cells were incubated with 3.3 x 1011 
B16F10-derived ELV per ml for 24h in vesicle-depleted cell medium or with miRIDIAN 
mmu-let-7a miRNA mimic (GE Dharmacon) complexed to lipofectamine RNAiMAX 
(Invitrogen) in OptiMEM reduced serum medium for 4h. Next, the cells were washed 
with PBS and cultured for an additional day before analyzing the luciferase expression 
using the Renilla luciferase assay (Promega) with a GloMax®96 microplate luminometer 
(Promega) according to the manufacturer’s instructions. The HMGA2 3'UTR wt luciferase 
expression is normalized to the HMGA2 3'UTR m7 luciferase expression for each 
condition. 
2.15. Luciferase assay using a transwell® insert 
H1299_eGFP cells were plated in a 6-well plate (1.36 x 104 cells per cm2) and 
transfected with a luc-wt or luc-m7 plasmid using lipofectamine 2000 as stated above. 
An equal number of B16F10 melanoma cells were plated in a transwell® permeable 
support (24 mm – pore size 3 µm, Corning) and co-cultured with the plasmid-
transfected H1299_eGFP cells. After 3 days, luciferase expression in H1299_eGFP cells 
was evaluated as described above.  
2.16. Statistical analysis 
Statistical analysis was done with GraphPad Prism 6 (GraphPad Software). Comparing 
multiple conditions was done using an ANOVA-test followed by a Tukey post hoc test. 
Direct comparison between two conditions was done using a student t-test. A p-value < 
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0.05 is regarded as statistically significant. The degree of significance is indicated using 
ns (p ≥ 0.05), *(p < 0.05), **(p < 0.01), ***(p < 0.001), ****(p < 0.0001). 
 
3. Results 
3.1. Isolation and characterization of ELVs 
Exosome-like vesicles (ELVs) were isolated from conditioned cell medium of B16F10 
melanoma cells and JAWSII immortalized monocyte/DC using an iodixanol-based 
density gradient UC protocol [32]. After overnight UC, the density gradient was collected 
in 10 fractions. Screening each fraction by immunoblotting revealed that especially 
fractions 4 to 6 contained the conventional ELV-associated markers (Hsp70, CD63, β-
actin and CD81) (figure 1A). Fractions 4 and 5 are typically selected for further 
experiments as they show the highest vesicle purity, expressed as the ratio of vesicle 
number to total protein concentration (figure 1B) [33]. Moreover, the density of these 
fractions lies around 1.12 to 1.14 g/ml and corresponds to the typical buoyant density of 
exosomes [34]. Furthermore, these fractions are devoid of protein markers for 
intracellular organelles (i.e. calnexin and GM130 for the endoplasmic reticulum and 
Golgi apparatus, respectively) providing additional evidence of the isolate’s purity 
(figure 1C). Pooling of both ELV fractions and collection via UC revealed a size 
distribution ranging from 30 to 300 nm as measured with single particle tracking, 
comparable to the size distribution observed by cryo-TEM imaging and corroborating 
earlier reports in the literature (figure 1D and 1E) [32]. 
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Figure 1. Characterization of gradient-purified B16F10-derived ELVs. [A] Amount of particles 
and ELV-associated protein markers in the different fractions of an iodixanol density gradient after 
overnight UC. [B] Quantification of the vesicle purity of the ELV-containing fractions (i.e. 4, 5 and 6) by 
measuring the amount of particles by scattering-based single particle tracking relative to the protein 
concentration. The purity is thus expressed as particles/µg total protein as suggested by ref. [33]. The 
data is represented as mean ± SD (n=4). [C] Immunoblotting of GM130 and calnexin on 10 µg B16F10 
cell- and 10 µg ELV-lysate (derived from fraction 4 and 5) under (non-) reducing (red) conditions. [D] 
Representative size distribution of density gradient purified B16F10-derived ELVs measured by 
scattering-based single particle tracking. [E] Cryo-TEM image of density gradient purified B16F10 ELVs. 
The scale bar indicates 100 nm. 
  
3.2. Cholesterol conjugation enables siRNA association to isolated ELVs 
In analogy with earlier reports on lipophilic siRNAs [27], we used cholesterol-conjugated 
siRNA (chol-siRNA) to allow post-formation loading of ELVs via insertion into the outer 
vesicular membrane. In addition, we opted for a nuclease resistant siRNA backbone 
(table S1) to avoid siRNA degradation by possible nuclease contamination of the 
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sample (chapter 3). To validate that chol-siRNA was indeed bound to the ELVs, three 
distinct yet complementary methods were used. First, efficient binding of chol-siRNA to 
B16F10 ELVs was demonstrated by a polyacrylamide gel retention assay (figure 2A). 
Semi-quantitative analysis of the unbound chol-siRNA revealed that 15 µg of ELVs, 
which relates to ~6.6 x 1010 vesicles, is able to bind ~80 % of the 10 pmol chol-siRNA 
(i.e. ~8 pmol), corresponding with about 73 chol-siRNA molecules per vesicle. 
Importantly, unconjugated siRNA did not show any interaction with the ELVs under the 
given experimental conditions, implying that the cholesterol moiety governs the siRNA-
ELV association (figure S1). Second, an immunobead-based assay was developed in 
which we aimed to exploit the CD63 expression on (a subpopulation of) ELVs [32, 35]. 
To this end, purified ELVs were mixed with Cy5-labeled chol-siRNA prior to incubation 
with anti-CD63-functionalized micrometer beads. Flow cytometric analysis of the beads 
indeed revealed a clear Cy5 fluorescent signal indicating the association of chol-siRNA to 
CD63-positive ELVs (figure 2B). Finally, a mixture of ELVs and Cy5-labeled chol-siRNA 
was placed on top of an iodixanol density gradient and subjected to overnight UC. 
Figure 2C shows that the chol-siRNA largely migrates to the fraction that  
corresponding with the typical buoyant density of the ELVs, of which the presence was 
additionally confirmed by immunoblotting. In contrast, in the absence of ELVs, the 
labeled chol-siRNA could only be detected in the upper, low density fractions (figure 
S2). Moreover, the profile of the ELV-associated chol-siRNA corresponds well with the 
fluorescence profile obtained by tracking ELVs labeled with Syto RNASelect, i.e. a 
membrane-permeable RNA dye (figure 2C) [36]. Altogether, these data clearly indicate 
the anchoring of siRNA to the surface of isolated ELVs through insertion of the 
cholesteryl moiety in the vesicular membrane. The same method for loading ELVs with 
siRNA proved also feasible for vesicles derived from a JAWSII cell line (figure S3). 
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Figure 2. Chol-siRNA association to B16F10-derived ELVs. [A] Percentage of chol-siRNA retained 
by the ELVs after 1h incubation at 37°C, as analyzed via a polyacrylamide gel retention assay. In each 
well 10 pmol chol-siRNA, mixed with the indicated amount of ELVs, was loaded. The data are 
represented as mean ± SD (n=3). The free, migrating chol-siRNA bands of one representative PAGE 
experiment is displayed underneath. [B] Flow cytometry of anti-CD63 coated dynabeads® incubated 
with Cy5-labeled chol-siRNA loaded ELVs (red), ELVs (gray) and Cy5-labeled chol-siRNA without ELVs 
(blue), respectively. [C] Relative Cy5 (chol-siRNA-associated) and Syto RNASelect (ELV-associated) 
fluorescence intensity for each density fraction after laying chol-siRNA loaded ELVs and Syto RNASelect 
labeled ELVs on top of an iodixanol density gradient after overnight UC. Data is represented as mean ± 
SD (n=3). For each fraction immunoblotting against ELV markers (Hsp70 and β-actin) was done to 
confirm the presence of the vesicles.  
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3.3. Anionic fusogenic liposomes outperform ELVs in chol-siRNA delivery in 
vitro 
Having optimized ELVs as carriers for chol-siRNA, we next sought to evaluate their 
potential to deliver the associated siRNA into recipient cells, including JAWSII (a 
monocytic cell line) and H1299 (a non-small cell lung carcinoma cell line). In addition, 
we aimed to compare the siRNA delivery efficiency of the ELVs with synthetic fusogenic 
liposomes, equipped with a pH-sensitive fusogenic lipid (i.e. cholesteryl hemisuccinate; 
CHEMS) [37]. These liposomes displayed comparable physicochemical characteristics as 
the ELVs, i.e. a negative surface charge and a comparable size distribution and 
polydispersity (figure 3A and 3B) and equally have the ability to retain chol-siRNA 
(figure 3C).  
 
Figure 3. CHEMS:DOPE liposome characterization and chol-siRNA loading. [A] Size distribution 
and [B] zeta potential of CHEMS:DOPE (4:6 molar ratio) liposomes determined by scattering-based 
single particle tracking and dynamic light scattering, respectively. [C] Chol-siRNA retention by 
CHEMS:DOPE liposomes evaluated using a polyacrylamide gel retention assay. The quantification was 
performed in triplicate, of which one representative gel is shown underneath the graph. For each well 10 
pmol chol-siRNA, incubated with the indicated amount of liposomes, was loaded. Data is represented as 
mean ± SD (n=3). 
 
First, cellular uptake of B16F10-derived ELVs and CHEMS:DOPE liposomes by two 
recipient cells (i.e. JAWSII and H1299) was verified by confocal fluorescence microscopy 
and flow cytometry, for which the ELV and liposomal membrane was stained by 
insertion of the lipophilic dye PKH26 (figure S4A and S4B). To confirm that the 
observed ELV uptake was not an artifact of the here used labeling approach (i.e. 
lipophilic insertion in the membrane), ELVs were fluorescently labeled by different 
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approaches. To this end, B16F10 cells were stably transfected with a CD63-GFP plasmid 
(see supporting information). ELVs purified from this cell line were equipped with a GFP-
tag which allowed to track the uptake in JAWSII cells (figure S4C). Another approach 
using a membrane permeable, RNA binding dye (Syto RNASelect) again corroborates 
the ELV (and its endogenous RNA cargo) internalization by JAWSII cells [38, 39]. 
Furthermore, comparing the uptake of chol-siRNA loaded ELVs to unloaded ELVs showed 
no influence of the chol-siRNA cargo on the vesicle uptake by JAWSII cells (figure S5).  
 
Figure 4. Chol-siRNA delivery by B16F10-derived ELVs and CHEMS:DOPE liposomes. [A] 
Confocal imaging of Cy5-labeled (red) chol-siRNA (free, associated to ELVs or liposomes) uptake (50 
nM) by JAWSII and H1299 cells (nucleus labeled with Hoechst 33342 (blue)) after 24h incubation. The 
scale bar indicates 10 µm. Quantification by flow cytometry of Cy5-labeled chol-siRNA uptake by [B] 
JAWSII and [C] H1299 cells after 24h incubation. The ratio vehicle:chol-siRNA (i.e. 6.6 x 109 
particles/pmol chol-siRNA) was constant for each condition. MFI is the mean fluorescent intensity is 
expressed in arbitrary units. The error bars represent the SD (n=3). 
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In agreement with the cellular uptake observed for the B16F10 ELVs and CHEMS:DOPE 
liposomes, the associated chol-siRNA was likewise internalized by both JAWSII and 
H1299 cells (figure 4). When quantifying and comparing the chol-siRNA delivery 
potential of ELVs and liposomes between both recipient cells, it is clear that JAWSII cells 
take up more chol-siRNA compared to H1299 cells. This corresponds with the vesicle 
uptake microscopy data (figure S4A) and is likely related to the phagocytic activity of 
the monocytic/DC cell line. The fact that phagocytic cells tend to take up more ELVs is 
also in agreement with previous reports [40]. Additionally, the fusogenic liposomes 
deliver noticeably more chol-siRNA compared to ELVs in JAWSII cells whereas in H1299 
cells the opposite holds true for the highest chol-siRNA concentration tested, though less 
pronounced (figure 4B and 4C). Overall, both cell lines effectively internalize both ELVs 
and anionic liposomes with their respective cargo, yet to a different extent. 
Next, the functional in vitro siRNA delivery capacity of the chol-siRNA loaded ELVs was 
evaluated, again using different ELV producer-recipient cell pairs. Chol-siRNA delivery 
via B16F10-derived ELVs was assessed in JAWSII cells and in H1299_eGFP cells, using 
the CD45 pan-leucocyte marker (chol-siCD45) and eGFP (chol-siGFP) as a model gene 
target, respectively [29]. Additionally, JAWSII-derived ELVs were tested for autocrine 
siRNA delivery in recipient JAWSII cells. Remarkably, comparing equal particle and 
siRNA concentrations, only the fusogenic liposomes were able to downregulate gene 
expression both in JAWSII (CD45) and H1299_eGFP (GFP) target cells (figure 5A and 
5B). This inability of B16F10-derived ELVs to functionally deliver the associated chol-
siRNA was also confirmed as a function of time (up to 6 days after co-incubation) 
(figure 5C). Comparable results were obtained for ELVs derived from the JAWSII cells 
(figure S6). Of note, 50 nM chol-siRNA in the absence of a nanocarrier induced a 
moderate knockdown in H1299_eGFP cells, yet following association to ELVs this effect 
was largely lost (figure 5B). This not only shows the inability of ELVs to functionally 
deliver chol-siRNA when attached to the vesicular surface, it also provides indirect proof 
of the stability of the association between ELVs and the chol-siRNA under the reported 
culturing conditions. Interestingly, when incubating the ELV-transfected cells with 
chloroquine, an endosomolytic compound [41], the eGFP expression was silenced to a 
comparable level as achieved by the CHEMS:DOPE liposomes (figure 6). 
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Figure 5. Chol-siRNA mediated gene silencing. Target gene expression in [A] JAWSII cells and [B] 
H1299_eGFP cells after treatment (24h) with chol-siRNA, chol-siRNA associated to liposomes or chol-
siRNA associated to ELVs. The target gene expression levels following chol-siCD45 or chol-siGFP 
treatment are normalized to the levels obtained with chol-siCTRL. [C] Time-dependent CD45 knockdown 
in JAWSII cells after treatment with chol-siRNA (50 nM), chol-siRNA loaded liposomes, chol-siRNA 
loaded ELVs or chol-siRNA complexed to lipofectamine RNAiMAX. The ratio vesicle:chol-siRNA (i.e. 6.6 x 
109 particles/pmol chol-siRNA) was constant for each condition. All data are represented as mean ± SD 
(n=3). 
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Figure 6. Chol-siRNA loaded ELVs induce gene silencing in the presence of an endosomolytic 
agent. eGFP expression in H1299_eGFP cells after treatment with chol-siRNA associated to B16F10-
derived ELVs followed by overnight incubation with cell culture medium supplemented with or without 
chloroquine. The target gene expression levels following chol-siGFP treatment are normalized to the 
levels obtained with chol-siCTRL.  
 
3.4. Functional delivery of endogenous ELV-associated miRNA 
Many reports in the literature describe functional ELV-mediated transfer of endogenous 
miRNAs [7, 42]. Therefore, we aimed to assess if the isolated B16F10 ELVs can 
successfully deliver their miRNA payload to recipient cells. To identify the predominant 
miRNA species in melanoma ELVs, a high-throughput miRNA analysis was performed 
(figure S7). For the most abundant miRNAs (figure 7), experimentally validated target 
transcripts were determined using the miRTarBase database (table 2) [43]. Next, the 
expression of different selected target transcripts was assessed via RT-qPCR in JAWSII 
recipient cells after 24h incubation with the purified B16F10-derived ELVs. High mobility 
group A2 mRNA (HMGA2) is a known target for mmu-let-7a miRNA, which is abundantly 
present in B16F10 ELVs (figure 7). The latter seemed to enable functional let-7a 
delivery into JAWSII cells, judging from the two-fold knockdown of HMGA2 transcripts. 
However, and more importantly, when summarizing data for all selected transcripts, no 
clear trend could be observed as some validated targets show significant downregulation 
as a function of the ELV concentration (e.g. HMGA2, MTPN, Ywhaz), while others show 
no response (e.g. Bcl2, CDC25c, ARL2) or are even markedly upregulated (e.g. 
MAPK14) (figure 8 and S8). We anticipate that the lack of a negative control to 
account for vesicle induced off-target effects substantially impedes unambiguous 
analysis of miRNA-related target transcript silencing.  
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Figure 7. Overview of the most abundant miRNAs present in B16F10-derived ELVs determined 
by the nCounter miRNA expression assay. Error bars indicate the SD of 2 technical replicates of 3 
pooled biological replicates.    
 
Table 2. Experimentally validated targets of a selection of the most abundant miRNA 
present in B16F10-derived ELVs [43]. 
miRNA Gene Target 
mmu-miR-22 Ywhaz 
mmu-miR-15a Bcl2 
mmu-miR-22 IRF8 
mmu-let-7a HMGA2 
mmu-let-7b Bsg 
mmu-miR-15b; mmu-miR-16 Arl2 
mmu-miR-181a; mmu-miR-9; mmu-miR-199-3p Runx1 
mmu-miR-29a Dnmt3 
mmu-miR-20a+20b; mmu-miR-17 MAPK14 
mmu-miR-22 ERBB3 
mmu-miR-106a; mmu-miR-17; mmu-miR-93; mmu-miR-125b-5p Stat3  
mmu-let-7c; mmu-miR-451; mmu-miR-709 Myc 
mmu-miR-22 CDC25c 
mmu-let-7b MTPN 
 
To resolve this issue, a luciferase reporter assay was utilized for mmu-let-7a, using a 
reporter construct that contains the 3’-UTR of the murine HMGA2 transcript that is 
appended to the renilla luciferase ORF [31]. Luciferase expression is compared with a 
control plasmid containing a HMGA2 3’-UTR in which all seven mmu-let7 binding sites 
are mutated. Both JAWSII and H1299_eGFP cells were transfected with the above 
mentioned plasmids, prior to 24h co-culture with B16F10 ELVs. As JAWSII cells 
appeared to be highly refractory to plasmid transfection with commercial lipofection 
reagents (i.e. lipofectamine 2000, data not shown), we focused on the H1299_eGFP 
cells as recipient cells. The same amount of B16F10 ELVs as used in the previous 
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experiments was incubated for 24h with H1299_eGFP cells, which were transfected 
beforehand with the luciferase reporter plasmids. In contrast to the HMGA2 knockdown 
previously observed, no significant downregulation of luciferase activity, normalized to 
the mutated control construct, was measured. As a positive control for this assay, a 
commercial lipofection reagent (i.e. lipofectamine RNAiMAX) was employed to complex 
synthetic mmu-let-7a and was incubated with the plasmid-transfected H1299_eGFP 
cells, which resulted in a significant reduction in luciferase expression (figure 9A). 
 
Figure 8. Alternations in gene expression profile in JAWSII cells after treatment with 
B16F10-derived EVs. Relative expression levels (determined by RT-qPCR) of the indicated genes in 
JAWSII cells after incubation for 24h with B16F10-derived ELVs. The data are reported as mean ± SD 
(n=4). 
 
Additionally, in an attempt to more closely mimic the in vivo situation and to circumvent 
the harsh ELV purification protocol, a cell co-culture experiment using a transwell® 
insert (pore size: 3 µm) was initiated. B16F10 cells were seeded in the transwell® insert 
while an equal amount of plasmid-transfected H1299_eGFP cells were seeded at the 
bottom. Using this set-up, transport of CD63-positive B16F10 ELVs through the pores of 
the insert and subsequent internalization by H1299_eGFP cells in the bottom 
compartment was confirmed by using a B16F10 melanoma cell line stably expressing 
CD63-GFP (figure S9). Following 3 days of co-culture, luciferase expression in the 
recipient cells was evaluated. However, also via this experimental set-up, no functional 
ELV-mediated transfer of mmu-let-7a could be observed (figure 9B). 
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Figure 9. Mmu-let-7a responsive luciferase reporter assay. Relative luciferase signal (expressed 
as wt- over m7-signal) in plasmid-transfected H1299_eGFP cells after co-culture with [A] purified 
B16F10-derived ELVs (24h incubation; 3.3 x 1011 particles/ml), [B] B16F10 cells seeded in a transwell 
insert (72h incubation; cell ratio 1:1) or synthetic mmu-let-7a miRNA complexed to lipofectamine 
RNAiMAX (4h). The data are reported as mean ± SD (n=4). 
 
4. Discussion 
In this chapter an efficient and reproducible post-formation loading method is reported 
to associate exogenous siRNA to ELVs by means of a cholesterol anchor. ELVs are under 
intensive scrutiny for biomedical purposes, e.g. as diagnostic biomarkers and as bio-
inspired drug delivery nanocarriers [44]. The latter application originates from the 
observation that ELVs can efficiently transfer biomolecules (nucleic acids, lipids or 
proteins) from a donor cell to a recipient cell, thus playing an important role in 
intercellular communication [7]. However, to exploit ELVs as a generic nanocarrier for 
delivery of exogenous macromolecular therapeutics, like siRNA, novel methods to 
efficiently load isolated ELVs with the siRNA of interest are highly sought after [12, 13, 
28]. 
Wolfrum et al. previously observed that cholesterol-modified siRNA (chol-siRNA) 
efficiently binds to lipoprotein particles such as high and low density lipoprotein (HDL 
and LDL), which are rich in phospholipids and cholesterol, leading to functional siRNA 
delivery in vitro and in vivo [27, 45]. Interestingly, cancer-derived EVs likewise contain 
high amounts of phospholipids and cholesterol [46]. Hence, we anticipated that a 
cholesterol moiety (covalently linked to the siRNA of interest) could similarly insert in 
the outer leaflet of the ELV lipid bilayer, thus anchoring the siRNA to the surface of the 
vesicles. Analogous to HDL and LDL, we could clearly demonstrate efficient binding of 
chol-siRNA to the surface of B16F10- and JAWSII-derived ELVs using three 
complementary methodologies. Of note, the ELVs were purified according to state-of-
the-art density gradient UC and subjected to extensive characterization prior to use, in 
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order to minimize chol-siRNA binding to co-purified protein aggregates. We also opted to 
work with stabilized siRNAs to exclude possible nuclease degradation during sample 
preparation (chapter 3). Moreover, all cell experiments were performed in vesicle-
depleted cell culture medium (see materials and methods) to avoid interference of ELVs 
or lipoproteins endogenously present in bovine serum.  
ELVs express a variety of membrane proteins on their surface, some of which engage in 
specific receptor-ligand interactions with recipient cells [47, 48]. The molecular 
expression pattern of ELVs is believed to be producer cell-type dependent and, in 
concert with the type of recipient cell, this further defines the nature of the receptor-
ligand binding as well as the downstream cellular processing. Hence, as the choice of 
producer-recipient cell pair might influence the efficiency of ELV-mediated biomolecule 
transfer, we selected cancer cell-DC [49, 50], DC-DC [51, 52] and cancer cell-cancer 
cell [53-56] pairs, previously reported in the literature as enabling a functional, ELV-
based intercellular interactions. Moreover, Parolini et al. showed that melanoma-derived 
ELVs display considerable fusogenic properties, further contributing to the hypothesis 
that melanoma-derived ELVs are efficient toward intercellular biomolecule delivery [54]. 
Although our results indicate efficient binding of chol-siRNA to isolated ELVs and efficient 
cellular delivery of the siRNA cargo to recipient cells, we could not observe a significant 
knockdown effect. In contrast, employing the exact same protocol to formulate chol-
siRNA in synthetic liposomes did result in significant downregulation of target gene 
expression. Here, we opted for CHEMS:DOPE liposomes as a control liposomal 
formulation as it mimics the most important physicochemical features of ELVs, i.e. size, 
surface charge and fusogenic properties. Thus, a simple synthetic anionic and fusogenic 
liposomal formulation clearly outperformed our purified ELVs in terms of functional chol-
siRNA delivery. 
We hypothesized that this inability to functionally deliver the chol-siRNA might pertain to 
the cargo location. Our post-formation loading approach inherently confines the siRNA 
on the surface of the vesicle while endogenously the miRNA cargo is likely present inside 
the ELV lumen [7]. We therefore sought to investigate if the B16F10-derived ELVs were 
able to functionally deliver their natural miRNA payload. The miRNA profile obtained for 
B16F10-derived vesicles is comparable to what was previously reported for highly 
metastatic cancer cell lines, e.g. a strong abundance of the let-7 miRNA family [57, 58]. 
Following exposure of JAWSII cells with the isolated melanoma ELVs, the change in 
expression levels of validated target transcripts for the most abundant ELV miRNAs 
varied substantially. Indeed, where the expression of some target genes was 
significantly suppressed, the expression of others remained unaffected or was even 
markedly upregulated. These inconsistent results can likely be explained by unspecific 
effects induced by ELV-associated lipids and proteins which might influence the 
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expression profile of the examined target gene [59, 60]. Therefore, we subsequently 
implemented a luciferase reporter assay in the recipient cells. Using a luciferase reporter 
construct containing the wild-type 3’-UTR of the HMGA2 transcript (a documented let-7 
target) and a mutated 3’-UTR with all seven let-7 binding sites disrupted through point 
mutations, allowed us to account for ELV-induced unspecific effects [31]. Nonetheless, 
also when using this more controllable reporter assay, once more no functional miRNA 
delivery was observed with the melanoma ELVs. Finally, this was also confirmed in a 
transwell® set-up, more closely resembling the in vivo intercellular ELV transfer, through 
which we could verify that the multi-step ELV purification protocol was likely not 
responsible for the inability of the ELV to functionally deliver their miRNA cargo. 
Given the absence of a miRNA/siRNA induced knockdown effect despite efficient ELV 
cellular uptake, it is reasonable to speculate that under the given experimental 
conditions the ELV content remains trapped in the endolysosomal degradation pathway. 
In addition, a too stable anchoring of the chol-siRNA into the ELV membrane might 
hamper activation of the RNAi machinery. Efficient escape from the endosome is a major 
barrier for cellular delivery of macromolecular therapeutics in general [61]. Importantly, 
when adding a lysosomotropic agent (i.e. chloroquine) that induces endolysosomal 
membrane perturbation [41] to H1299_eGFP cells, previously transfected with chol-
siRNA loaded ELVs, a marked eGFP knockdown could be observed. This result supports 
the hypothesis that endolysosomal entrapment is the predominant barrier that limits 
ELV-mediated small RNA delivery. To date it still remains an open question why under 
some conditions ELVs are very efficient in delivering their cargo [51] while in other 
circumstances they appear dysfunctional. Yet it is conceivable that, due to the vast 
complexity of these vesicles, their functionality is restricted to a particular cell type or 
even cell status. The latter has already been demonstrated for viral particles, with which 
ELVs share many features [62, 63]. Therefore, the observations reported here cannot 
simply be extrapolated to other ELVs or ELV-cell interactions. Nonetheless, our results 
question the therapeutic value of ELVs as a universal siRNA delivery vehicle. 
 
5. Conclusion 
Overall, we could show that purified ELVs can be loaded with cholesterol-modified 
siRNA. The association of the siRNA on the surface of the vesicles did not interfere with 
their uptake by recipient cells. However, using distinct experimental set-ups and 
carefully selected controls, we were able to unambiguously conclude that the ELVs used 
in this study did not allow functional delivery of small RNAs, neither the exogenously 
added siRNA nor the endogenously encapsulated miRNAs. In contrast and surprisingly, 
simple anionic fusogenic liposomes were able to induce a marked siRNA-mediated target 
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gene knockdown under the same experimental conditions. Safe and efficient cellular 
delivery of macromolecular therapeutics requires innovative delivery technologies. ELVs 
have been proposed as a bio-inspired alternative for state-of-the-art synthetic 
nanomedicines. Despite the available reports in the literature that support this claim, 
the results obtained for the ELV producer-recipient cell pairs tested here imply that 
synthetic liposomes are still preferred [64]. Future research on ELVs should focus more 
on elucidating the cellular mechanisms behind successful ELV-mediated transfection 
before generic adoption of natural ELVs or synthetic ELV mimicking nanomedicines as a 
competing drug delivery tool can be considered. 
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Supporting information 
Supporting experimental section 
Cryo-TEM imaging 
The ELV sample (3.5 µl) was applied to 300 mesh quantifoil grids and incubated for 30 
to 60 seconds. Next, excess buffer was removed by blotting the grids for 3 seconds 
using a Whatmann no.1 filter paper and the sample was snap frozen by plunging in 
liquid ethane at a temperature of -180°C and stored in liquid nitrogen until visualization. 
Next, the samples were transferred to a Gatan 914 cryoholder and imaged at low dose 
conditions at -177°C, using a JEOL JEM1400 TEM equipped with a 11 Mpxl Olympus SIS 
Quemesa camera. 
CD63-GFP transfection in B16F10 melanoma cells 
pCT-CD63-GFP (pCMV, exosome CD63 tetraspanin Tag, Virus) was purchased from SBI 
system biosciences. B16F10 melanoma cells were plated in a 24-well plate (2.8 x 104 
cells/cm²). After 24h, cell culture medium was replaced by TransDux™ (SBI System 
biosciences) supplemented cell medium and cells were incubated with viral particles at a 
multiplicity of infection (MOI) of 20. Seventy-two hours post transfection, cells were 
washed with PBS and cultured in medium supplemented with 2 µg/ml puromycin 
(Invitrogen) during one week to select transduced cells. These cells were termed 
B16F10_CD63-GFP cells throughout this chapter.  
To confirm (CD63-GFP positive) ELV transport through the transwell® permeable support 
and subsequent cellular internalization, B16F10_CD63-GFP cells were seeded in a 6-well 
plate insert (24 mm – pore size 3 µm). Recipient cells (JAWSII) were seeded in the 
bottom compartment of the 6-well plate. After 3 days of co-culture the bottom cells 
were washed 3x with PBS, detached using 0.05 % trypsin-EDTA (Gibco) and analyzed 
for GFP fluorescence using a flow cytometer (CytoFLEX, Beckman Coulter). 
miRNA profiling of B16F10-derived ELVs 
Three independent isolates of B16F10-derived ELVs were pooled and analyzed in 
duplicate. nCounter™ assays were carried out according to the manufacturer’s protocol 
v.20090807 (Nanostring Technologies). In brief, in a first annealing and ligation step, a 
unique miRNA specific miRtag was ligated to the miRNA molecules in the total RNA 
sample. Subsequently, a mastermix containing Reporter CodeSet and hybridization 
buffer was prepared. An aliquot of 5 µl from the miRNA sample preparation in the first 
step was added to 20 µl mastermix. Just before hybridization, 5 µl of Capture CodeSet 
was added and hybridization was carried out in a PCR machine for 23h at 65°C. 
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Immediately after hybridization, the post-hybridization process was started in the 
nCounter™ Prep-Station according to the manufacturer’s protocol v.20081003 
(Nanostring Technologies) using the High Sensitivity Protocol (software version 4.0.9), 
and excess probes were washed away using a two-step magnetic bead-based 
purification. Finally, the purified target/probe complexes were eluted and immobilized in 
the cartridge for data collection. Data were collected in the nCounter™ Digital Analyzer. 
Each flow cell (sample) was scanned at the highest resolution of 1150 fields of view 
using a microscope objective and a CCD camera yielding hundreds of thousands of 
target molecule counts. After processing the digital images on the nCounter™ Digital 
Analyzer, the barcode counts were tabulated in a comma separated value format. 
RT-qPCR 
JAWSII cells were plated in a 24-well plate (4.5 x 104 cells per cm2) and allowed to 
attach overnight. The next day, the indicated concentration of B16F10-derived ELVs 
(without chol-siRNA loading) were incubated with the cells for 24h after which the cells 
were washed with PBS and total RNA was purified using a RNeasy Mini Kit (Qiagen) 
according to the manufacturer’s instructions. cDNA was made using the iScript™ cDNA 
Synthesis Kit (Bio-Rad) with 1000 ng starting material. qPCR was done using the 
SensiFAST™ SYBR No-ROX kit (Bioline) on the Light Cycler 480 system (Roche). 
Expression levels were normalized to the expression of the two most stable genes β-
actin and GAPDH, which were determined using the geNorm Software [65]. Primer 
sequences can be found in table S2. 
 
Supporting figures 
 
 
Figure S1. Comparing siRNA and chol-siRNA association to B16F10-derived ELV. Increasing 
amounts of B16F10-derived ELVs incubated with 10 pmol chemically stabilized siRNA and chol-siRNA for 
1h at 37°C. 
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Figure S2. Chol-siRNA flotation on an iodixanol density gradient after overnight UC. Relative 
Cy5 fluorescence in the different density fractions when layering chol-siRNA (black) and ELV-associated 
chol-siRNA (gray), respectively on top of an iodixanol density gradient after overnight UC.  
 
 
 
Figure S3. JAWSII-derived ELV characterization and chol-siRNA loading. [A] Representative size 
distribution of JAWSII-derived ELVs, determined by scattering-based single particle tracking. [B] 
Polyacrylamide gel retention assay of chol-siRNA mixed with JAWSII-derived ELVs and chol-siRNA 
without ELVs, respectively, after 1h incubation at 37°C. [C] Relative fluorescence intensity distribution 
of Cy5-labeled chol-siRNA following incubation with JAWSII-derived ELVs when placed on top of an 
iodixanol density gradient after overnight UC. The results are represented as mean ± SD (n=3). 
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Figure S4. Cellular uptake of B16F10-derived ELVs and CHEMS:DOPE liposomes. [A] 
Representative confocal images of the internalization of chol-siRNA loaded CHEMS:DOPE liposomes and 
B16F10-derived ELVs (3.3 x 1011 particles/ml, vesicles are PKH26 labeled and depicted in yellow, nuclei 
are Hoechst 33342 labeled and depicted in blue)) into recipient cells after 24h incubation in vesicle-
depleted cell medium. The scale bar indicates 10 µm. Confirmation of B16F10-derived ELVs uptake by 
JAWSII cells using different ELV labeling strategies: [B] PKH26-labeled ELVs and [C] ELVs derived from 
B16F10_CD63-GFP cells. MFI represents the mean fluorescence intensity per cell determined by flow 
cytometry and expressed in arbitrary units (mean ± SD; n=3). 
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Figure S5. Quantification by flow cytometry of B16F10-derived ELV (Syto RNASelect-labeled) 
uptake by JAWSII cells, comparing chol-siRNA loaded and unloaded ELVs after 24h incubation. MFI 
represents the mean fluorescence intensity. The data are represented as mean ± SD (n=3). 
 
 
Figure S6. Chol-siRNA mediated gene silencing in JAWSII cells. CD45 expression in JAWSII cells 
after treatment with chol-siRNA, chol-siRNA associated to CHEMS:DOPE liposomes, chol-siRNA 
associated to JAWSII-derived ELVs and chol-siRNA associated to lipofectamine RNAiMAX. The 
expression of the target protein CD45 following chol-siCD45 transfection is represented relatively to 
identical treatment with a chol-siCTRL sequence. Chol-siRNA (50 nM) with, if applicable, ~3.3 x 1011 
liposomes or ELVs per ml were incubated with the cells for 24h in vesicle-depleted medium. In case of 
the lipofectamine RNAiMAX treatment, the concentration advised by the manufacturer was used (i.e. 10 
nM chol-siRNA; 4h incubation time). 
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Figure S7. miRNAs present in B16F10-derived ELVs determined by the nCounter miRNA expression assay. miRNAs are included if the expression is higher 
than the average plus 2x SD of the signal generated by different negative controls. Error bars indicate the SD of 2 technical replicates of 3 pooled biological 
replicates.   
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Figure S8. Alterations in gene expression profile in JAWSII cells after treatment with 
B16F10-derived EVs. mRNA expression profile of validated gene targets of some of the most 
abundant miRNAs present in B16F10-derived ELVs (cfr. table 2). JAWSII cells were incubated with 
mounting concentrations of purified B16F10-derived ELVs for 24h. The next day, expression levels of 
the indicated transcripts were determined using RT-qPCR. The data are represented as mean ± SD 
(n=4).
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Figure S9. Validation of ELV transport through a transwell® insert. Uptake of CD63-GFP positive 
vesicles released by B16F10_CD63-GFP cells (seeded in a transwell® insert) by recipient cells (JAWSII 
seeded at the bottom) after 72h co-culture, as determined by flow cytometry (CytoFLEX; Beckman 
Coulter). The data are represented as mean ± SD (n=3). 
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Table S1. Modifications and sequences of siRNAs used in this chapter 
Target Abbreviation Modification Manufacturer Sequence  
    Sense strand (5’-3’) Antisense strand (5’-3’) 
Negative control Chol-siCTRL  Cholesteryl 1 / stabilized 2 GE DharmaconTM Not available Not available 
Pan-leukocyte marker CD45 Chol-siCD45 Cholesteryl 1 / stabilized 2 GE DharmaconTM GAAGAAUGCUCACAGAUAAUU UUAUCUGUGAGCAUUCUUCUU 
eGFP 3 Chol-siGFP Cholesteryl 1 / stabilized 2 GE DharmaconTM CAAGCUGACCCUGAAGUUCUU GAACUUCAGGGUCAGCUUGUU 
eGFP 3 siGFP stabilized 2 GE DharmaconTM CAAGCUGACCCUGAAGUUCUU GAACUUCAGGGUCAGCUUGUU 
1cholesteryl-tetraethyleneglycol linker modification at the 5’ end of the sense strand, purchased from GE Dharmacon; 2RNA strand modified for the use 
in nuclease-rich environments (siSTABLE modification; GE Dharmacon); 3enhanced green fluorescent protein 
 
 
 
 
 
 
 
 Chapter 4│ 164 
 
Table S2. Primers used throughout the qPCR experiments. 
Gene name Forward primer Reversed primer 
β-actin GCTTCTAGGCGGACTGTTACTGA GCCATGCCAATGTTGTCTCTTAT 
GAPDH TGAAGCAGGCATCTGAGGG CGAAGGTGGAAGAGTGGGAG 
HMGA2 GAGCCCTCTCCTAAGAGACCC TTGGCCGTTTTTCTCCAATGG 
MTPN CCCTGAAAAACGGAGACTTGG GAAACATGACCCTCATAGACAGC 
Ywhaz GAAAAGTTCTTGATCCCCAATGC TGTGACTGGTCCACAATTCCTT 
Bcl2 ATGCCTTTGTGGAACTATATGGC GGTATGCACCCAGAGTGATGC 
CDC25c ATGTCTACAGGACCTATCCCAC ACCTAAAACTGGGTGCTGAAAC 
ARL2 GCACTGTCCTGTAATGCTATTCA GCAGTAAAGACACGACTGGAAAT 
MAPK14 GGCTCGGCACACTGATGAT TGGGGTTCCAACGAGTCTTAAA 
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Abstract 
Exosome-like vesicles (ELVs) are a novel class of biomarkers that are receiving a lot of 
attention for the early stage detection and monitoring of cancer. In this study the 
feasibility of using a Surface Enhanced Raman Spectroscopy (SERS) based method to 
distinguish between ELVs derived from different cellular origins is evaluated. A gold 
nanoparticle based shell is deposited on the surface of ELVs derived from cancerous and 
healthy cells which enhances the Raman signal while maintaining a colloidal suspension 
of individual vesicles. This nano-coating allows the recording of SERS spectra from 
single vesicles. By using Partial Least Square Discriminative Analysis (PLS-DA) on the 
obtained spectra, vesicles from different origin can be distinguished, even when present 
in the same mixture.  
 
 
 
Schematic representation of the gold nanoparticle (AuNP) coating and subsequent 
surface-enhanced Raman spectroscopy measurements of purified exosome-like 
vesicles (ELV). 
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1. Introduction 
To maximize the impact of current cancer treatments it is essential to detect 
carcinogenic cells in an early stage. To this end, the discovery of sufficiently sensitive 
and specific biomarkers is of foremost importance. Recently, circulating extracellular 
vesicles (EVs), especially exosomes, have emerged as a potential new class of 
biomarkers for early detection and treatment monitoring in cancer and other diseases 
[1, 2]. As contextualized in chapter 1, exosomes are of interest for diagnostic and 
prognostic applications as they contain molecules derived directly from the parent cell 
[3]. In addition, they are fairly easily accessible as they are found in various body fluids 
(e.g. blood, salvia, urine, breast milk, ascites, etc.) [4-6]. Currently, most exosome-
based diagnostic approaches focus on identifying specific molecular components by 
elaborate ‘omics’ studies [7]. Examples are elevated levels of miR-21 in exosomes of 
hepatocellular cancer patients [8] and the presence of EGFRvIII mutant proteins on 
exosomes derived from a specific glioblastoma subtype [9]. Despite the fact that these 
techniques provide detailed information on the molecular composition of exosomes, they 
rely on complicated and time-consuming protocols. Moreover, these analyses are 
performed on the overall EV population level which makes it less likely to find low 
abundant subpopulations. Indeed, considering that most cells secrete EVs as part of 
their normal function, it is to be expected that the amount of vesicles derived from 
diseased cells is comparatively low. Accordingly, the detection of altered levels of low 
abundant components in a bulk analysis is quite challenging. Furthermore, it is 
becoming apparent that one cell type may release multiple subtypes of EVs (chapter 1) 
due to which bulk analysis is prone to missing specific subtypes or subtype ratios of 
vesicles [10-12]. Therefore, techniques capable of identifying individual exosomes could 
prove very valuable, but are currently lacking. 
In this chapter, a new approach is explored for single vesicle identification based on 
surface enhanced Raman spectroscopy (SERS) for diagnostic applications. Raman 
spectroscopy is a label-free technique based on inelastic scattering of laser light due to 
the interaction of photons with molecular vibrations. As such, the Raman spectrum of 
inelastic scattered photons contains information on the molecular composition of the 
sample. Raman spectroscopy has been used before to characterize EVs [13, 14]. 
However, as it is a very inefficient process (only 1 in 106-8 photons is scattered 
inelastically), a high sample concentration is required in combination with high laser 
power and long signal integration times [15]. High throughput screening of single 
vesicles by Raman spectroscopy is therefore not feasible. 
Fortunately, the Raman signal can be strongly enhanced (up to 1014-15 times) by using 
surface enhanced Raman spectroscopy (SERS) [16]. SERS is based on the enhancement 
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of the incident and scattered electromagnetic field by plasmon excitation on irregular 
(metal) surfaces, typically composed of Au or Ag [17-19]. As it has single molecule 
sensitivity, SERS is increasingly applied for the characterization of biological samples 
[20, 21]. In this respect, different types of SERS-substrates have been developed to 
obtain plasmon enhancement and record Raman spectra from (sub)cellular components 
down to the single biomolecule level [22]. These can be, but are not limited to, well 
defined nanostructured surfaces of gold [23] or silver [24], (intracellular) aggregated 
Ag- [25] or Au nanoparticles (AuNP) [26]. Both Ag-nanograin coated chips and 
precipitated AuNP clusters were previously applied for bulk EV measurements [27, 28]. 
These few reports show the feasibility of obtaining SERS spectra from an EV sample and 
the capability to differentiate between EVs from different origin [27, 28]. However, it is 
important to note that these previous analyses were still performed on bulk vesicles 
from a single cell type. Yet, clinical samples contain EVs from different origin in a 
mixture, hampering the further implementation of bulk Raman measurements for 
diagnostic applications. 
To enable true single vesicle SERS identification, here we demonstrate to the best of our 
knowledge for the first time that EVs can be functionalized with AuNP on their surface, 
forming an irregularly shaped nanoshell that enables the generation of an enhanced 
Raman signal while maintaining a colloidal suspension of individual vesicles. As proof-of-
concept of the discriminative potential of this approach, we show that vesicles derived 
from B16F10 melanoma cells can be successfully identified and quantified in a mixture 
with red blood cell (RBC)-derived vesicles.  
 
2. Experimental section 
2.1. Cell culturing and ELV purification 
B16F10 melanoma cells (ATCC® CRL-6475™) were cultured in Dulbecco's Modified Eagle 
Medium (Invitrogen), supplemented with glutamine (2 mM), 10 % fetal bovine serum 
(HycloneTM), sodium pyruvate (1 mM), penicillin (100 U/mL) and streptomycin (100 
µg/ml) (Invitrogen) at 37 °C in a humidified atmosphere containing 5 % CO2. For the 
purification of ELVs, cells were first washed with phosphate buffered saline (PBS, 
Invitrogen) and the cell medium was replaced with vesicle-depleted medium. The latter 
was prepared by ultrafiltration of complete cell culture medium through a 300 kDa filter 
(Millipore) using an Amicon stirred cell set-up (Millipore) under three bar nitrogen 
pressure to remove bovine EVs. Cells were incubated for 24 hours after which the 
conditioned cell medium was harvested for vesicle isolation.  
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RBC were isolated out of blood from a healthy volunteer as described previously [29] 
with minor modifications. Briefly, blood was collected in K2EDTA coated tubes 
(Venosafe) and spun at 1 500g for 15 minutes (Heraeus Multifuge 1S-R) within 15 
minutes after blood collection. RBC were retained, washed twice and suspended in 
Ringer buffer (NaCl (150 mM), KCl (5 mM), CaCl2 (2 mM), MgCl2 (1mM), NaH2PO4 (2 
mM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (10 mM), 
Glucose (10 mM), pH=7.2) for 2 days at 37°C while shaking. 
Vesicles derived from B16F10 melanoma cells and RBC were purified from conditioned 
cell medium or Ringer buffer, respectively by differential centrifugation followed by 
density gradient ultracentrifugation (UC) (figure S1). First, conditioned cell 
medium/Ringer buffer was centrifuged for 10 minutes at 300 g and 10 minutes at 3 000 
g. Next, the supernatant was concentrated by ultrafiltration using a 30 kDa filter 
(Millipore) in a Amicon stirred cell set-up (Millipore) under nitrogen pressure. The 
concentrated sample was centrifuged (Beckman® L8-70M ultracentrifuge) at 10 000 g 
for 10 minutes using a SW55ti rotor (Beckman instruments) and the supernatant was 
placed on top of an iodixanol (OptiprepTM, Axis-Shield) based density gradient. The 
gradient was produced according to the manufacturer’s instruction. Briefly, 1 ml of 
different iodixanol dilutions (12.5 %, 25 %, 37.5 % and 50 % in sucrose (250 mM), 
EDTA (1 mM), Tris-HCl (10 mM) buffer; pH = 7.4) were carefully laid underneath one 
another using a 21G needle. The samples were then centrifuged at 150 000 g for 15 
hours. Next, the gradient was fractionated per 0.5 ml, diluted 10x in ultrapure water 
and centrifuged at 150 000 g for 150 minutes. Finally, the pellet was washed one more 
time and suspended in ultrapure water. The fraction containing the highest exosome 
associated proteins was used for further characterization and Raman spectroscopy 
experiments and the respective vesicles are referred to as ELVs. 
2.2. Immunoblotting 
In order to determine the density fraction containing the exosomes, pelleted vesicles 
from each fraction were resuspended in ice cold RIPA buffer (Sigma-Aldrich) mixed with 
MS-SAFE protease and phosphatase inhibitor cocktail (Sigma-Aldrich) and vortexed. 
Next, the samples were sonicated for 10 minutes and centrifuged at 13 000 g for 5 
minutes. For protein separation, samples were diluted in 2x laemmli buffer (Bio-Rad) 
with or without 5 % 2-mercaptoethanol (Sigma-Aldrich), heated at 95°C for 5 minutes 
and loaded on a 10 % mini-protean TGX precasted gel (Bio-Rad). The polyacrylamide 
gel was ran at 100 V for 60 minutes in running buffer (Tris (25 mM) – Glycine (200 mM) 
– 0.1 % SDS). The blotting was done on an immunoblot PVDF 0.2 µm membrane (Bio-
Rad) at 100 V for 90 minutes in blotting buffer (Tris (25 mM) – Glycine (200 mM) – 
20 % Methanol – 0.05 % SDS). The blot was blocked for 1 hour using 3 % BSA, 0.1 % 
Tween20 (Sigma-Aldrich) in PBS buffer (Invitrogen). Next, primary antibodies were 
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incubated overnight at 4°C on a shaker. After washing the blots with blocking buffer 
they were incubated with a secondary antibody conjugated to horseradish peroxidase 
(HRP) for 1 hour at room temperature (table S1). Visualization was done using the 
SuperSignal West Dura chemiluminscent kit (Thermo-Scientific) in combination with a 
VersaDocTM imaging system (Bio-Rad). All density fractions were loaded on one gel 
using equal volumes for objective comparison and the respective protein bands were 
cropped using ImageJ and aligned underneath one another for clarity. 
2.3. DMAP coated AuNP 
AuNP coated with 4-dimethylaminopyridine (DMAP) were prepared as described by 
Gittins and Caruso [30]. Briefly, a HAuCl4 aqueous solution was added to a 
tetraoctylammonium bromide in toluene solution under gentle stirring. Next, NaBH4 was 
added to the mixture. After 30 minutes the toluene phase was separated from the 
aqueous phase and washed 3 times using H2SO4, NaOH and ultrapure water. Equal 
volumes of the AuNP in toluene solution and an aqueous DMAP solution were mixed and 
left to equilibrate for 1 hour. During this period the AuNP transfer from the organic 
toluene phase to the aqueous phase concomitantly exchanging the tetraoctylammonium 
bromide coat for a DMAP coating (figure S2). Finally the aqueous phase, containing the 
AuNP coated with DMAP, is separated from the toluene phase. The final AuNP 
concentration was estimated by UV/VIS spectroscopy based on the optical density of the 
surface plasmon resonance peak (SPR)-peak (Nanodrop 2000c; ThermoFisher 
Scientific), assuming that the AuNP are spherical with a molar extinction coefficient of 
1.03 x 108  M-1 cm-1 as calculated from equation 1 reported by Liu et al. [31]. 
ln(𝜀) = 3.3211 × ln(𝑑) + 10.80505                                                                          (eq.1) 
In which  represents the molar extinction coefficient and d the diameter of the AuNP 
(10 nm). 
 
2.4. AuNP coating of ELVs 
ELVs were mixed with DMAP-coated AuNP at different AuNP:vesicle ratios by mixing 
equal volumes using a pipette. After 10 minutes incubation at room temperature, the 
samples were diluted in ultrapure water/buffer and analyzed by different techniques (i.e. 
dynamic light scattering and cryo-transmission electron microscopy (cryo-TEM)). 
2.5. Concentration, size and zeta potential measurements 
The concentration and size distribution of purified ELVs was determined by scattering-
based single particle tracking using a NanoSight LM10 instrument (Malvern instruments 
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Ltd.) equipped with a 405 nm laser. Prior to analysis, the concentrated vesicles were 
diluted in HEPES buffer (pH 7.4; 20 mM) to obtain a concentration in the range of 1.0 to 
9.0 x 108 particles/ml to guarantee reliable measurements. Movies of 60 seconds were 
recorded and analyzed with the NTA Analytical Software version 2.3 (Malvern 
instruments Ltd.). 
The size and zeta potential of ELVs and ELVs coated with AuNP (after dilution in HEPES-
buffer) were measured by dynamic light scattering using a Zetasizer Nano ZS (Malvern 
instruments Ltd.), equipped with Dispersion Technology Software.   
2.6. Cryo-TEM 
Each ELV (with our without AuNP) sample (3.5 µL) was applied to a 300 mesh quantifoil 
grid and incubated for 30 - 60 seconds. Next, excess buffer was removed by blotting the 
grids for 3 seconds using a Whatmann 1 filter paper and the sample was snap frozen by 
plunging in liquid ethane at a temperature of -180°C and stored in liquid nitrogen until 
visualization. Next, the samples were transferred to a Gatan 914 cryoholder and imaged 
at low dose conditions at -177°C, using a JEOL JEM1400 TEM equipped with a 11 Mpxl 
Olympus SIS Quemesa camera. 
2.7. Fluorescent labeling and confocal microscopy of ELVs 
Purified B16F10- and RBC-derived vesicles were incubated for 15 minutes at 37°C with 
Vibrant DiD (Invitrogen) or PKH67 (Sigma-Aldrich), respectively (final dye concentration 
is 5 µM; in Diluent C (Sigma-Aldrich)). Next, non-incorporated dye and diluent C was 
removed using exosome spin columns (MWCO 3 000) pre-incubated with ultrapure 
water according to the manufacturer’s instructions (Invitrogen).  
The labeled ELVs were mixed with AuNP in the indicated ratios (cfr. SERS 
measurements) and visualized using a swept field confocal microscope (LiveScan SFC, 
Nikon Belux) equipped with a 60x oil immersion lens (NA = 1.4, Nikon). The ELVs were 
alternately irradiated with 488 nm and 647 nm laser light and images were recorded 
with an iXon Ultra EMCCD camera (Andor). Particle detection was done with in-house 
developed software in Matlab as previously described by Deschout et al. [32]. The ratio 
of B16F10 to RBC vesicles (B16F10:RBC ratio) was determined for each mixture by 
particle counting in at least 20 individual frames at different spatial locations. 
2.8. SERS measurements 
ELVs (unlabeled) were mixed with DMAP coated AuNP at a fixed AuNP:vesicle ratio (i.e. 
~800 for B16F10-derived ELVs and ~1200 for RBC-derived ELVs). Next, samples were 
diluted in ultrapure water to ≤ 5 x 107 vesicles per µl to minimize the possibility that 
more than one vesicle is present in the focal detection volume. A droplet (60 µl) of the 
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diluted sample was placed on a quartz substrate and SERS spectra were recorded using 
an inVia confocal Raman microscope (Renishaw, UK) equipped with a 60x WI lens (NA = 
1, Nikon) and a 785 nm laser using a 10 second integration time and 15 mW power. 
Alternatively, a Raman microscope (Zeiss) equipped with a piezo-scanner (P500, 
physick instrumente) and a 785 nm laser focused through a 60x WI lens (NA = 1, 
Nikon) was used. The spectra were acquired with a Spectra Pro500i (Acton Research) 
monochromator/spectrograph (integration time 500 ms). The 785 nm laser was chosen 
to limit photodegradation and autofluorescence [33, 34]. All spectra were recorded at 
different locations in the sample. The presence of a gold coated ELV in the focal volume 
was confirmed by Rayleigh scattering (figure 4A).  
2.9. Analysis of SERS spectra 
The statistical modeling in this chapter was done by Dr. Monica Marro at the ICFO-
institute for photonical sciences. Briefly, the obtained spectra were pre-processed as 
described previously [35]. To assess the ability of Raman spectroscopy to discriminate 
RBC- and B16F10 melanoma-derived ELVs, PLS-DA was performed using the PLS 
toolbox from Eigenvector Research in MatLab. Cross-validation analysis was computed 
by venetian blinds (10 splits and one sample per split). The number of retained latent 
variables was chosen to minimize the root mean square error of cross validation curves. 
Additionally, a Multivariate Curve Resolution Alternating Least Squares (MCR-ALS) 
algorithm was used to analyze the spectra. 
 
3. Results 
3.1. ELV purification and characterization 
The potential of SERS to distinguish between vesicles released by two distinct cell types 
was explored using ELVs from RBC and B16F10 melanoma cancer cells. B16F10 cells 
were cultured in vitro and after 24h incubation, the conditioned cell medium was 
harvested and used for ELV purification. An iodixanol density gradient based UC protocol 
was used (figure S1) to obtain ELVs with a high purity with minimal protein 
contamination (chapter 3) [36] or residuals of commercial precipitation kit reagents 
[37]. After density gradient UC the fraction containing the ELVs was determined by 
immunoblotting against typical exosome-associated protein markers (Hsp70, β-actin, 
CD63, CD81) on each fraction of the density gradient [38]. In this respect, fraction 5 
contained the highest amount of exosomal markers. Moreover, the average density of 
this fraction was ~1.14 g/ml, which corresponds with earlier reports on the typical 
buoyant density of exosomes [39] (figure 1A). This fraction was used further for 
characterization and Raman spectroscopy experiments. As a ‘healthy‘ vesicle source, 
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RBC were used as they are abundantly present in patient-derived blood samples. The 
same ELV purification protocol was used as described for the B16F10 melanoma cell-
derived vesicles (figure S1). 
After two additional washing steps by UC, the ELV pellet was suspended in ultrapure 
water (Millipore) and analyzed for size and zeta potential by scattering-based single 
particle tracking analysis and dynamic light scattering, respectively. The majority of the 
B16F10 melanoma-derived ELVs had a hydrodynamic diameter of approximately 0.12 
µm. RBC-derived vesicles were slightly larger with a size of approximately 0.17 µm. 
Both types of vesicles had a negative surface charge (figure 1B). Finally, cryo-TEM was 
used as an additional confirmation of the presence of membranous structures in the 
purified samples (figure 1C). 
 
Figure 1. Characterization of purified B16F10 melanoma- and RBC-derived ELVs. [A] 
Immunoblotting against exosomal markers Hsp70, β-actin, CD63 and CD81 on the different density 
fractions after overnight density gradient UC of B16F10 melanoma-derived conditioned medium. For 
each fraction the average density is reported [g/ml]. [B] Representative size (upper) and zeta potential 
(lower) of B16F10 melanoma- (black) and RBC- (gray) derived ELVs determined by single particle 
tracking analysis and dynamic light scattering, respectively. [C] Cryo-TEM images of B16F10 melanoma 
(left) and RBC-derived (right) ELVs. The scale bar indicates 100 nm. 
 
3.2. Gold nanoparticle coating of ELVs 
As a next step, we investigated if it would be possible to coat ELVs with AuNP while 
maintaining a colloidal single vesicle suspension. Specifically, we explored a coating 
strategy that is based on the electrostatic adsorption of cationic (due to a DMAP 
coating), 10 nm AuNP (figure 2A and 2B) onto the anionic surface of ELVs. AuNP were 
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mixed with vesicles at increasing particle over vesicle ratios. It was observed that 
increasing the ratio of AuNP:vesicles causes an initial increase in size due to the zeta 
potential becoming more neutral (i.e. agglomeration). When increasing the ratio of 
AuNP:vesicles further, the zeta potential became strongly positive, resulting in a 
dispersion of individual AuNP coated ELVs, as confirmed by dynamic light scattering size 
measurements (figure 3A and 3B) and cryo-TEM imaging (figure 3C and 3D). The 
latter also confirms the association between the negatively charged ELVs and the 
positively charged AuNP. Around 600 AuNP per B16F10 vesicle (figure 3A) and 1200 
AuNP per RBC vesicle (figure 3B) were required to obtain a colloidal stable suspension. 
The fact that more AuNP per vesicles were needed to coat the RBC compared to the 
B16F10 melanoma vesicles is in accordance with the larger surface area of a RBC-
derived vesicles. Moreover, these numbers approach the average theoretical amount of 
AuNP (i.e. 912 AuNP per B16F10- and 1291 AuNP per RBC-derived vesicle) needed to 
coat an entire vesicle in a monolayer as can be calculated from equation 2. To obtain a 
SERS signal, AuNP need to be in close proximity to one another [19]. In this respect, 
high amounts of AuNP to vesicles were mixed (i.e. ~800 for B16F10 and ~1200 for 
RBC) for the SERS measurements. Indeed, for these higher ratios, cryo-TEM imaging 
showed nearly complete coating of both vesicle types with AuNP (figure 3C and 3D). 
 
 
Figure 2. Characterization of DMAP coated AuNP. [A] Zeta potential and [B] hydrodynamic 
diameter of DMAP-coated gold nanoparticles, as determined by dynamic light scattering. 
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Equation 2. Equation used to calculate the theoretical average amount of AuNP needed to 
coat an entire vesicle surface in a monolayer, with n as the total amount of vesicles, SELV,i as the 
surface of a vesicle i, ɳ is the maximum packing density of a sphere which was fixed at 0.9 (hexagonal 
packing was assumed) and SSAuNP as the surface of the section occupied by one AuNP. Calculations were 
based on the size distribution for each ELV type as depicted in figure 1B. 
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Figure 3. AuNP coating of ELVs. Average size and zeta potential of AuNP coated [A] B16F10 
melanoma-derived ELVs and [B] RBC-derived ELVs, as a function of mounting AuNP:vesicle ratios. [C] 
Cryo-TEM images of AuNP coated B16F10-derived ELVs. Mounting AuNP:vesicle ratios are indicated 
underneath the respective pictures. [D] Cryo-TEM confirmation of full coating conditions for RBC-
derived ELVs. The scale bars indicate 100 nm. 
 
3.3. Recording SERS spectra of individual ELVs 
Next, we investigated if this dense packing of AuNP on the vesicular surface indeed 
allows to generate a SERS spectral fingerprint. For these experiments we worked under 
high AuNP:vesicle ratios as described above. Spectra were recorded from individual 
AuNP coated ELVs adsorbed on a quartz surface as schematically represented in figure 
4A. Peaks from (ELV) biomolecules (green arrows) could be clearly identified in the 
spectra from B16F10 melanoma-derived vesicles (figure 4B) and RBC-derived vesicles 
(figure 4C), apart from peaks arising from the DMAP coating of the AuNP (red arrows; 
cfr. figure S3). Table 1 gives an overview of the identified biomolecule peaks with their 
tentative molecular origin. Most classes of biomolecules seem to be present, i.e. lipids, 
proteins, nucleic acids and carbohydrates. It is of note that ELVs without AuNP coating 
could not generate a clear Raman signal under the same conditions, underscoring the 
importance of SERS for enhancing the signal of single vesicles. 
 Chapter 5│ 177 
 
 
Figure 4. SERS spectra of individual ELVs. [A] Schematic representation of the SERS measurements 
of AuNP coated ELVs. Each recorded spectrum is derived from another vesicle by moving the laser to a 
different spatial location (e.g. 1, 2, 3). The presence of a gold coated ELV was confirmed by a Rayleigh 
scattering signal (cfr. location 2). The scale bar indicates 10 µm. [B] Representative, unmodified SERS 
spectrum of a B16F10 melanoma-derived ELV coated with AuNP and [C] a RBC-derived ELV coated with 
AuNP. Red arrows indicate peaks arising from the DMAP AuNP coating. Green arrows indicate ELV-
related peaks. 
 
Table 1. Enumeration and tentative assignment of SERS peaks for AuNP-coated B16F10 
ELVs (B16F10_AuNP) and AuNP-coated RBC ELVs (RBC_AuNP). 
Raman 
shift [cm-1] 
RBC_AuNP 
1 
B16F10_AuNP 
1 
Previously identified 
in EV isolates 
Presumed origin [40] 2 
486 w m  polysaccharide 
521 w m  S-S stretching (e.g. protein) 
546 w m  cholesterol  
883  w [13, 37] (CH2) (e.g. protein) 
989 sh  [28]  
1032 w sh [13, 27] CH2CH3 bending (e.g. 
phospholipid); ν(C-C) (e.g. 
polysaccharide) 
1115 sh sh [37] C-O in ribose (e.g. nucleic acid) 
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Raman 
shift [cm-1] 
RBC_AuNP 
1 
B16F10_AuNP 
1 
Previously identified 
in EV isolates 
Presumed origin [40] 2 
1124 s m [13, 14] ν22 (porphyrin half ring; typical for 
RBC) / C-C stretch (e.g. lipid, 
protein) / C-N (e.g. protein) 
1134 sh m [27] ν(C-C) (e.g. lipid) 
1172 m sh [37] (C-H) (e.g. protein) 
1179  m  ν(C-C) or ν(C-O) (e.g. 
phospholipids) 
1243 sh  [13] amide III (e.g. protein) / 
asymmetric phosphate stretching 
(e.g. nucleic acid) 
1271  w [13] amide III (e.g. protein) / C=C 
(e.g. fatty acids) 
1293  m [14] cytosine (nucleic acid) / CH2 
deformation (e.g. lipids) 
1307 m sh [13, 28, 37] C-N asymmetric stretching (e.g. 
protein) / CH3CH2 twisting (e.g. 
lipid) 
1326 sh sh [37] (CH3CH2) (e.g. nucleic acid) 
1346 sh w   
1354  w  guanine (nucleic acid) 
1367 sh sh  ν(CH3) (e.g. phospholipid) 
1370 s m  carbohydrate 
1381 sh m  CH3 symmetric (e.g. lipid) 
1411  w   
1443 sh s [13, 14, 37]  (CH2/CH3) (e.g. protein, lipid) 
1465 w  [37] lipid 
1477 w w [27] DMAP + δ(C-H) (e.g. lipid, 
protein) 
1528 w sh [13] ν(-C=C-) conjugated 
1563 sh w  tryptophan 
1576 w w [14] guanine (nucleic acid) 
1608 sh sh [13] cytosine (nucleic acid) / 
phenylalanine (protein) 
1618 s s [28] DMAP/ν(C=C) (e.g. protein) 
1s: strong, m: medium, w: weak, sh: shoulder; 2ν: vibration, : deformation, : wagging, : in 
plane rocking, DMAP: 4-dimethylaminopyridine 
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3.4. Identification of individual ELVs by spectral analysis 
The obtained Raman spectra were subjected to two previously published dedicated 
statistical models: a PLS-DA and a MCR-ALS [35, 41]. Both models were trained and 
calibrated by Raman spectra obtained from pure/unmixed samples i.e. AuNP alone, 
AuNP coated B16F10-derived vesicles and AuNP coated RBC-derived vesicles. The 
potential of Raman spectroscopy to discriminate between B16F10 melanoma and RBC-
derived ELVs in an unbiased fashion was quantified by the PLS-DA model. A sensitivity 
of 95.8 %, 88.0 %, 95.1 % and specificity of 95.5 %, 95.4 % and 98.0 % for AuNP, 
B16F10 and RBC-derived ELVs, respectively was obtained (table 2). The here reported 
specificity and sensitivity of the model to discriminate among the different types of 
vesicles was assessed by cross-validation. Moreover, a parallel experiment was 
performed with a different Raman microscope allowing shorter acquisition times (500 
ms compared to 10 s for the above measurements). Analysis of the obtained data was 
again performed using the PLS-DA model. The results show that the ability to separate 
between samples based on their SERS fingerprint was maintained (table S2). 
 
Table 2. PLS-DA classification of the Raman spectra of pure/unmixed samples (i.e. AuNP, 
B16F10 ELVs coated with AuNP and RBC ELVs coated with AuNP) . 
Sample n1 PLS-DA prediction   
  Correct 
identification 
Wrong 
identification 
Sensitivity (%) Specificity (%) 
AuNP 24 24 0 1002 / 95.83 97.02 / 95.53 
B16F10_AuNP 25 23 2 92.02 / 88.03 96.92 / 95.43 
RBC_AuNP 41 39 2 95.12 / 95.13 1002 / 98.03 
1n is the amount of spectra recorded for each sample. Sensitivity and specificity were computed 
with3 and without2 cross validation. 
 
Additionally, a MCR-ALS algorithm was applied on the obtained spectra (figure S4). 
Here it is important to note that the MCR-ALS model requires minimal constraints and 
prior information about the sample and is an unsupervised methodology. Nonetheless, 
the algorithm was able to deconvolve spectra (figure S4A) which can be attributed 
(based on the score plots represented in figure S4B and spectra in figure 4) to: Quartz 
(surface), DMAP (AuNP coating), B16F10 and RBC vesicles respectively. Indeed, this 
objectively shows the spectral discrepancy between ELVs from different origin. 
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3.5. Identification and quantification of B16F10 ELVs in a mixture with RBC 
ELVs 
Finally, to provide evidence of the diagnostic potential of this approach, mixtures of 
AuNP functionalized B16F10 cancerous- and RBC-derived ELVs were prepared at two 
different ratios. This set-up is a first step towards mimicking the in vivo situation where 
cancerous vesicles need to be detected in patient samples containing a variety of vesicle 
types, especially highly abundant RBC-derived ELVs. To determine as a reference the 
exact ratio of both types of vesicles in the prepared mixtures, ELVs were fluorescently 
labeled with lipophilic dyes (RBC ELVs = green; B16F10 ELVs = red) and subsequently 
coated with AuNP. The suspension was placed on a microscopy cover slip and confocal 
microscopy images were recorded. With in-house developed particle detection software 
the number of green and red fluorescent spots were identified and counted (figure 5A). 
It was calculated that mixture 1 contained 51 ± 17 % cancerous ELVs and mixture 2 
contained 15 ± 6 % cancerous ELVs, respectively (figure 5B). From these images it 
could also be confirmed that the two types of AuNP coated vesicles did not agglomerate 
with one another as no co-localization of green and red spots could be seen.  
 
Figure 5. Mixtures of AuNP coated, fluorescently labeled RBC- (green) and B16F10 
melanoma- (red) derived ELVs. [A] A representative confocal image of mixture 1 (left) with particle 
location analysis (right). The scale bar indicates 20 µm. [B] Percentage B16F10 melanoma-derived ELVs 
of the two B16F10:RBC mixtures based on fluorescence particle counting. The data is represented as 
mean ± SD of 20 technical replicates.  
 
Identical mixtures without fluorescent labels were subsequently prepared for SERS 
measurements. For each mixture between 60 and 80 spectra were recorded of AuNP 
coated vesicles. Using the previously build PLS-DA model, each spectrum was assigned 
to one of the following groups: Unbound AuNP, RBC-derived ELVs or B1610-derived 
ELVs (figure 6A). In mixture 1 and 2, 38 % and 6.3 % cancerous vesicles were 
retrieved, respectively (figure 6B). A few of the spectra were found to originate from 
unbound AuNP clusters. These values reasonably correspond to the ratios as determined 
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by fluorescence microscopy and clearly demonstrate the potential of identifying and 
quantifying vesicles from different origins in a mixture using the developed SERS 
platform. 
 
Figure 6. PLS-DA analysis of SERS measurements executed on two B16F10:RBC ELV 
mixtures. [A] Each point represents an individual spectrum allocated to one of the three classes 
(unbound AuNP, AuNP coated B16F10 ELVs or AuNP coated RBC ELVs). n Represents the amount of 
spectra allocated to a specific class within a mixture. For the first mixture 77 spectra were recorded, for 
the second mixture 65 spectra were recorded. [B] The results, as represented in panel A, plotted as 
percentage B16F10-derived EVs to the total amount of ELVs measured (with exclusion of spectra 
allocated to AuNP only). 
 
4. Discussion 
In this chapter we investigated the possibility of identifying single ELVs by SERS. In 
contrast to previous diagnostic approaches, where the focus lies on detecting the 
presence or modified expression of a single exosomal component (i.e. a specific nucleic 
acid, lipid or protein) [42] using elaborate and time-consuming ‘omics’ studies, here the 
potential of SERS was tested to generate an optical fingerprint of individual ELVs coated 
with AuNP. If successful, such a method holds great potential for the identification of 
vesicles from different cellular origin in a quantitative manner from patient samples.  
As an initial proof-of-concept, ELV were purified from two distinct cell types. A skin-
derived, B16F10 melanoma cell line was used as a model for carcinogenic cells and 
primary RBC as a model for healthy cells that are highly abundant in blood samples. To 
obtain vesicular concentrates as pure as possible, an iodixanol density gradient based 
UC protocol was used [36]. This is essential as it was previously shown that residuals of 
commercial purification kits can interfere with the Raman fingerprint [37]. Moreover, as 
shown in chapter 3, other less stringent purification protocols (i.e. UC and commercial 
precipitation kits) suffer from limited purity due to co-purification of vesicle-independent 
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proteins and nucleic acids, which might preclude the AuNP from interacting with the 
ELVs and interfere with the Raman fingerprint [43]. 
In a next step, the purified vesicles were functionalized with ~10 nm AuNP to generate 
the SERS signal. The small diameter ensures that a large number of hot-spots are 
created in close proximity to the ELV surface. The AuNP carry a cationic surface charge 
due to the DMAP coating which allows adsorption onto the anionic ELVs surface. Likely 
this association is charge based though it is also possible that the DMAP molecules are 
exchanged for thiol-containing proteins present on the ELV surface [44]. Although 
aggregation was observed initially at low AuNP:vesicle ratios, at higher ratios a colloidal 
suspension of individual AuNP coated vesicles could be obtained. Indeed, once the 
overall surface charge of the AuNP coated ELVs became firmly positive (due to the DMAP 
coating), a mutual repulsion between the coated vesicles was created. This was 
confirmed using dynamic light scattering, cryo-electron microscopy and indirectly by 
confocal fluorescence microscopy. Additionally, as DMAP is a small molecule, the AuNP 
can reside in close contact with the ELV surface. To the best of our knowledge this is the 
first time that single ELVs were enveloped with a gold coating. On average ~800 AuNP 
were used to coat the B16F10 melanoma vesicles, while ~1200 for RBC vesicles which is 
in agreement with the fact that RBC ELVs have a larger surface area and approaches the 
theoretical amount of AuNP to create a monolayer. This nanoshell of AuNP allowed to 
generate a SERS signal emanating from the ELVs due to a strong localized surface 
plasmon between the closely packed AuNP present on the vesicular surface [45].  
The Raman peaks in the SERS spectra of single ELVs were found to arise in part from 
the DMAP and from ELV biomolecular components that are present in the vicinity of the 
AuNP. Biomolecular exosomal components were identified at 1123 cm-1 (lipids + 
proteins), 1172 cm-1 (proteins), 1307 cm-1 (proteins + lipids), 1366-1370 cm-1 
(phospholipids + carbohydrates), 1445 cm-1 (lipids + proteins) and 1572-1576 cm-1 
(nucleic acids). Interestingly, most of these pronounced peaks have previously been 
identified by others when recording Raman spectra of biological samples like 
erythrocytes [46] or even EVs (by classic Raman or SERS on bulk isolates) [13, 14, 27, 
28, 37]. 
Next, we could show that the generated spectra, in combination with a PLS-DA 
classification model, allow us to separate between vesicles derived from B16F10 
melanoma cells and RBC-derived vesicles. The fact that Raman spectroscopy is able to 
discriminate between vesicles from different cellular origin is in accordance with the very 
few reports available to date in which it was shown that classic Raman spectroscopy 
[13] and SERS [27, 28] on bulk or clusters of vesicles have discriminative power, even 
for more similar parent cells. Yet, as mentioned above, these reports are based on pure 
samples of one type of EV measured in bulk (i.e. millions of EVs are regarded and 
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analyzed as one entity). Here, instead, we tackled the pending challenge of using SERS 
for the identification and quantification of single cancerous ELVs that are present in a 
mixture with ‘healthy’ RBC-derived vesicles. While future research should focus on 
testing more complex mixtures with multiple types of vesicles, still this is a promising 
proof-of-concept study. We consider the subtle difference discriminated by SERS in 
previous work on bulk EVs as a promising indication that detecting cancerous ELVs in 
complex mixtures would be possible with our single vesicle SERS approach [28]. 
It is of note that an alternative approach with the potential of single vesicle SERS was 
very recently developed by Lee et al.. Their setup is based on Ag coated ‘nanobowls’ for 
hot-spot generation and SERS fingerprinting of EVs deposited into the nanobowls [37]. 
Though being a complex technological feat, our approach benefits from its simplicity and 
high-throughput potential. The AuNP based shell is formed by simple self-assembly and 
AuNP functionalized ELVs can be measured by standard Raman equipment. 
Furthermore, our approach can be easily combined with (standard) microfluidics and an 
optical trapping unit, allowing automated and fast SERS measurements. These 
characteristics will help to overcome the technological challenge of upscaling this 
technology for future clinical applications.  
With the most sensitive set-up tested in this chapter, we could record clear Raman 
spectra at 0.5 s integration time per ELV. This means that per day it would be possible 
to analyze about 170 000 individual ELVs. As detectors continue to become more 
sensitive, and combined with the fact that a 0.5 s integration period already gave a 
strong and clear Raman spectrum, we expect that throughput could be increased 5-10 
fold in the near future. Rapid recording of single spectra is indeed of pivotal importance 
for potential future diagnostic applications as ‘diseased’ ELVs are likely present in low 
abundance relative to the ‘healthy’ ones. 
A particular challenge with our new approach is that SERS spectra of individual ELVs 
exhibit quite some variability, even for vesicles of the same parent cell. This originates 
from variability within the ELV population secreted by one cell type as discussed in 
chapter 1 but potentially also from the (random) adsorption of AuNP on the vesicle 
surface and non-uniformity in hot spot generation [47]. In future research, therefore, it 
will be of interest to investigate other ways of functionalizing vesicles with AuNP with 
the aim to make the SERS spectra more uniform among vesicles of the same origin. This 
would allow to detect more subtle differences in molecular compositions and obtain 
more reliable molecular information from each individual vesicle. Additionally, the 
currently used AuNP coating component, DMAP, shields part of the region-of-interest in 
the obtained Raman spectra. Using an alternative molecule with a less pronounced 
fingerprint might enhance the obtained information, hence enlarge the discriminative 
power in more complex samples. In turn this will lead to even better specificity and 
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sensitivity. Apart from diagnostic applications, this method has the potential of being 
useful in an academic setting to deepen insight in molecular composition/diversity of the 
vesicles secreted by a certain cell type. 
 
5. Conclusion 
Our findings show that applying SERS technology on AuNP-coated ELVs in combination 
with PLS-DA is capable of sensing biomolecular diversity between ELVs from different 
origins. Although future research should focus on more complex ELV mixtures, we have 
clearly demonstrated the potential of single vesicle identification by SERS to obtain 
ratios of vesicles from different origins in a mixture. 
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Supporting information 
Supporting figures 
 
 
Figure S1. Schematic representation of the protocol used to purify exosome-like vesicles 
(ELVs) from conditioned cell medium of B16F10 melanoma cells and RBC.  
 
 
 
 
 
Figure S2. AuNP transfer from the toluene phase to the aqueous phase exchanging their 
tetraoctylammonium bromide coat for a DMAP coating at three different time points (t1 = ~5 minutes, 
t2 = ~20 minutes and t3 = ~60 minutes) after mixing. 
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Figure S3. Raman fingerprint of 4-dimethylaminopyridine (DMAP). Average SERS spectrum of 
twenty normalized spectra of DMAP-coated AuNP aggregates to determine the DMAP fingerprint.  
 
 
 
 
 
Figure S4. Output of the MCR-ALS algorithm. [A] Deconvolved Raman spectra. [B] Score for each 
deconvolved spectrum (y-axis) for all recorded spectra (x-axis) allowing to allocate the deconvolved 
spectra to a specific source (i.e. quartz, DMAP, B16F10 and RBC vesicles).  
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Supporting tables 
Table S1. Antibodies used for immunoblotting. 
Target Dilution Supplier Cat.# Reducing 
conditions 2 
MW (kDa) 
CD 81 1:1 000 LS biosciences Inc. LS-C108453 No ~25-30 
CD 63 1:500 Tebu-bio GTX37555 No ~40 
β-actin 1:1 000 Cell Signaling Techn. 4970 Yes ~45 
Hsp 70 1:1 000 LS biosciences Inc. LS-C24142 Yes ~70 
Rabbit IgG1  1:50 000 Millipore AP307P / / 
1The secondary antibody is linked to a HRP-enzyme;  2Reducing conditions imply heating of the 
sample to 95 °C for 5 minutes in the presence of 2-mercaptoethanol. 
 
Table S2. PLS-DA classification of the Raman spectra of unmixed samples recorded with 
an integration time of 500 ms. 
Sample n 1 PLS-DA prediction 
  Correct identification Wrong identification 
B16F10_AuNP 53 53 0 
RBC_AuNP 64 64 0 
1n is the amount of spectra recorded for each sample 
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Abstract 
The work presented in this thesis can be categorized in two distinct biomedical domains, 
namely the development of drug delivery carriers and the search for new analytical 
techniques with diagnostic potential. Both applications were founded on the concept of 
extracellular vesicles (EVs) being molecular information packages released by cells. In 
this final chapter these two fields of application are more broadly outlined. Moreover, 
the development of the EV field is reviewed from a pharmaceutical point-of-view with a 
discussion of the current status and future perspectives of each of the potential 
applications.  
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1. Extracellular vesicles as drug delivery vehicle 
Drug delivery carriers aim to counteract intrinsic unfavorable features associated with 
free therapeutics. These depend on the nature of the compound and can include poor 
stability, poor solubility, inability to cross biological barriers and off-target effects. 
Ideally, a drug carrier should prevent recognition by the immune system, both the 
innate and adaptive immune system, to allow prolonged circulation in the bloodstream 
and enable repeated administration, respectively. Moreover, drug carriers should guide 
the therapeutic to the designated target tissue and shuttle the cargo over the relevant 
biological barriers. Fuelled by advances in the nanotechnology field, carriers have been 
developed, of which polymer- and lipid-based nano- and microparticles are most 
frequently investigated. The intensive research exploring this synthetic approach has 
only partially met the expectation with market output restricted to carriers for small 
molecules (e.g. Caelyx®, doxorubicin; Genoxol-PM®, paclitaxel) and extracellular active 
proteins/aptamers (e.g. Oncaspar®, pegaspargase; Macugen®, Pegaptanib). For the 
intracellular delivery of macromolecules (e.g. siRNA, DNA) many issues remain 
insufficiently resolved despite the many years of investigation. At the cellular level, for 
example, detailed analysis revealed that only ~3.5 % of the delivered (via lipid-based 
transfection agents) siRNA is able to escape the endosomes and reach the cytoplasm 
[1]. Moreover, only a fraction of these siRNA strands are incorporated into the RISC so 
that only 0.25 – 0.1 % of the total internalized siRNA is functional [2]. At the 
extracellular level, many inventive strategies have been developed to (1) confer stealth 
properties to (nano)carriers by modifying their surface with biocompatible, flexible and 
hydrophilic polymers (e.g. polyethylene glycol, polyvinylpyrrolidone), (2) enhance 
cellular internalization by equipping the carriers with antibodies/nanobodies® 
recognizing surface receptors of the target cell of interest [3] and (3) improve tissue 
targeting by reducing the carrier size to exploit the inherent augmented vascular 
permeability in some tissues (e.g. the EPR-effect in fast growing tumor tissue) [4]. 
However, despite these advances, the carrier biodistribution, targeting of other 
(extrahepatic) tissues of interest and the avoidance of immune recognition, remains 
inadequate. 
Bearing in mind the above intra- and extracellular deficiencies of synthetic carriers, the 
drug delivery community is increasingly interested in critically examining natural carriers 
which have evolved over millions of years to accomplish certain tasks. Red blood cells 
(RBC) for example inherently have a long blood circulation time (i.e. ~120 days) making 
them ideal candidates for the delivery of long-acting drugs who have to function in the 
blood circulation (e.g. anti-coagulant agents) [5]. Another example is the exploitation of 
the inherent ability of cytotoxic CD8(+) T cells to cross the endothelial barrier and 
infiltrate tumor tissue for the delivery of hitchhiking liposome-enclosed therapeutics [6]. 
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One of the most successful applications of bio-inspired drug delivery carriers is the use 
of viruses. As viruses have naturally evolved to transfer their genes into the host as an 
essential mechanism of self-replication, their exploitation as carrier for therapeutic 
nucleic acids (e.g. siRNA, mRNA and pDNA) is a rational concept which has led to the 
first gene-therapy based medicine approved in Europe and the USA (i.e. Glybera) [7]. In 
addition, also other, less known yet inventive approaches using pathogens have been 
explored for drug delivery, including the use of anaerobic bacteria for their potential to 
migrate to hypoxic areas (e.g. tumors or infarcted myocardium) [8, 9]. Unfortunately, 
these (modified) pathogens risk recognition by the adaptive and innate immune system 
limiting repeated applications and potentially provoking an overreaction of the immune 
system with detrimental effects (e.g. the Jesse Gelsinger case) [10]. Additionally, the 
possibility of insertional mutagenesis with subsequent cancer development for certain 
virus types (i.e. retroviruses) is reported in clinical tests, which often limits their 
envisioned applications for the treatment of life-threatening diseases [11]. 
It is within this context of bio-inspired drug delivery vehicles that EVs are considered as 
an endogenous, hence safe, new type of carrier for macromolecules. In this thesis, we 
focused on the delivery potential of EVs for oligonucleotides, more specifically siRNAs. 
Although a very promising study in 2011 reported on using targeted EVs for siRNA 
delivery to the brain in an Alzheimer mouse model [12], still many ambiguities need to 
be addressed before reproducible therapeutic applications of EVs become feasible. 
A first step in this process is the development of strategies to obtain vesicle isolates 
devoid of non-EV contaminants. Different techniques have been used throughout the 
literature as comprehensively overviewed in chapter 1. Most of these techniques are 
derived from other fields of research (e.g. virology, biopharmacy, etc.) and adapted for 
EV purification. However, to date no consensus has been reached within the ISEV 
community on which methodology should be regarded as the gold standard. Recent 
studies [13-15], including the findings presented in chapter 3, have provided new 
insights in the purity of the isolates obtained by different strategies and highlight the 
impact on both loading with nucleic acids and cellular uptake of fluorescently labeled 
EVs.  
Secondly, to translate EVs to a drug delivery vehicle, efficient methods to load EVs with 
a drug of interest are needed. One often used method is loading the EV producing cell 
with the therapeutic RNA and relies on the cell’s inherent machinery to package the 
cargo into the EVs (i.e. pre-formation loading) [16, 17]. An alternative approach, 
explored throughout this thesis, is the post-formation loading of EVs isolated from 
conditioned cell culture medium or biological fluids. In this way, it can be anticipated 
that the EV loading efficiency will be independent of the RNA sequence and the cell type 
used. Moreover, if successful, such an approach would allow for a better control over the 
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loading process, enabling quantitative and homogenous loading of all EVs produced. 
Unfortunately, in order to load purified EVs with exogenous (small) RNA’s without 
compromising its functionality, few methods are available. Out of the currently used 
nucleic acid delivery vehicles, liposomes are most analogous to EVs especially from a 
physicochemical point of view. Hence, reflection on almost five decades of research on 
liposomal drug delivery systems could provide some valuable clues on how to reach this 
goal [18]. Yet it is important to note that liposomal nucleic acid delivery generally 
involves electrostatic complexation of the negatively charged siRNA via cationic lipids 
which are notorious for their in vitro and in vivo toxicity [19]. However, EVs are known 
to carry a negative surface charge, hence precluding electrostatic siRNA complexation. 
Passive loading of siRNA into (negatively charged) liposomes requires the addition of the 
nucleic acids prior to liposome formation which is not feasible for isolated EVs and as a 
rule entails low encapsulation efficiencies. In addition, the inherent complex composition 
of EVs, containing proteins next to lipids, rules out the use of organic solvent based 
methods or repeated freeze-thaw cycles because of potential interference with protein 
stability and (partial) loss of functionality [20]. Pre-complexation of siRNA via cationic 
liposomes followed by fusion with isolated EVs has been evaluated for EV loading with 
siRNA by different groups [21, 22]. However, this approach appeared to be impractical 
as the EVs could not be isolated from the remaining transfection liposomes/micelles, 
making it impossible to determine the location of the siRNA and the associated loading 
efficiency [21]. Ideally, the loaded nucleic acids are encapsulated in the core of the 
isolated EVs as this mimics their natural localization and likely leads to the most optimal 
intracellular delivery. In a first effort towards such intravesicular loading, Alvarez-Erviti 
and colleagues used electroporation of an EV/siRNA mixture to induce transient pores in 
the EV membrane, allowing the siRNA to migrate through the lipid bilayer. Using this 
approach, these authors reported siRNA encapsulation efficiencies up to 25 % [12]. This 
post-loading method was followed by many others [21, 23-27]. Importantly, as 
thoroughly investigated in chapter 2, duplication of these experiments under identical 
experimental conditions revealed that the aforementioned siRNA encapsulation was 
largely due to unspecific aggregate formation, independent of the presence of EVs. The 
latter aggregates resulted from the interaction of multivalent cations, released from the 
metal electrodes in the electroporation cuvettes, with hydroxyl anions present in the 
electroporation buffer and were shown to co-precipitate siRNA [28]. After blocking 
aggregate formation, by virtue of an acidic citrate electroporation buffer or the use of 
polymer based electroporation cuvettes, no significant encapsulation of siRNA could be 
measured [29]. Our work underscores the importance of incorporating appropriate 
control experiments that often are not considered in the literature (i.e. electroporation 
of samples without EVs) and highlights the need to carefully optimize the applied 
electroporation buffer and EV concentration. Since the publication of our observations 
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[29], several groups have tried to prevent this aggregate formation through the use of 
chelating agents (e.g. EDTA), as used in our study, [30] or membrane stabilizers (e.g. 
trehalose) [24, 31]. Nonetheless, even if transient pores would be formed in the EV 
membrane and aggregation can be prevented, given that electroporation by definition 
relies on passive loading, it can only be efficient in extremely high concentrated EV 
isolates.  
The shortcomings of electroporation and the current lack of alternatives to load 
hydrophilic macromolecules have prompted us to explore alternative approaches. In this 
respect we used cholesterol-modified siRNA (chol-siRNA) as a general, post-formation 
loading approach to associate siRNA to EVs (chapter 4). It was clearly shown that 
simple mixing of isolated EVs and chol-siRNA lead to insertion of the latter in the 
vesicular membrane. Moreover, in this chapter we postulated three complementary 
assays that consider the inherent complexity of EV samples, which can be readily used 
by other researchers to unambiguously confirm the association of a (nucleic acid) cargo 
with EVs. Of note, before application in a clinical setting (e.g. as IV injectable) can be 
contemplated, the stability of the chol-siRNA insertion in complex biological fluids (e.g. 
blood) needs to be verified. Nonetheless, this method has proven to be useful in less 
complex biological fluids and valuable for in vitro screenings as a fast and producer-cell 
independent method for loading siRNA and hence can form an interesting research tool. 
Despite our new loading approach being useful for our intended application (i.e. 
comparing EVs with synthetic nanocarriers at the cellular level), new techniques to 
obtain therapeutic cargo loading in the lumen of EVs are still highly desired, in particular 
for macromolecular drugs. 
Thirdly, to truly assess the impact EVs might have on the drug delivery field it is 
important to compare the drug delivery efficiency of this new carrier to the state-of-the-
art. Currently, the general perception in the field is that EVs are extremely efficient in 
macromolecular cargo delivery across cellular barriers [32]. However, the direct 
experimental comparison between current state-of-the-art carriers and EVs has never 
been made. In chapter 4 we aimed to address this question and could show that EVs, 
under the indicated experimental conditions, were not efficient from a drug delivery 
point of view. Also other reports that describe EVs as vesicles involved in intercellular 
communication present data in which the functionality of EVs for macromolecular 
delivery is statistically significant yet the terminology ‘efficient’ is arguable. In the 
publication by Zomer et al., which uses the extremely sensitive Cre-loxP system as a 
transfection read-out assay for mRNA delivery, a co-culture experiment shows that 
when culturing producer and accepter cells in a 1:1 ratio maximally 2 % of the recipient 
cells was functionally transfected. For a 100:1 ratio this increased to a maximum of 10 
% positive cells. Intratumoral injection of purified EVs, bearing the Cre recombinase 
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mRNA, rendered only 0.05 % positive cells (compared to 0.02 % as negative control) 
[33]. The here reported efficiencies in macromolecule delivery, although tracking a 
different type of cargo (i.e. mRNA vs miRNA/siRNA), are in line with the lack of 
significant gene target knockdown obtained with EVs in our study (Chapter 4). 
Moreover, a major part of the literature reporting successful delivery of RNAi-based 
therapeutics with EVs, are based on EVs modified with cell penetrating peptides [12, 26] 
or additional aids such as Lipofectamine LTX and the fusogenic GALA peptide [34]. 
Indeed, an increasing number of papers focuses on modifying EVs to improve the 
biodistribution, cell targeting specificity and endosomal escape efficiency. For example, 
the RVG-targeting and delivery of siRNA using EVs, by Alvarez-Erviti and colleagues, is 
one of the most cited papers and supporters of the intensifying research harnessing EVs 
as a drug delivery carrier. However, the authors show that in the absences of RVG, no 
functional delivery of siRNA by EVs was observed (also not in vitro) [12]. Additionally, a 
more recent study shows that synthetic liposomes, equipped with the RVG targeting 
ligand, can also migrate over the blood brain barrier (BBB) [35]. In this respect it is 
important to discriminate between inherent features of EVs and functionalities endowed 
by certain modifications. The observation of the limited circulation time of IV injected 
EVs has prompted the PEGylation of EVs which indeed prolongs their circulation time 
[36]. Yet, this modification will also interfere with the EV-cell interactions, which 
inevitably evokes the question of how we should appraise the added value of EVs over 
synthetic drug delivery carriers (e.g. liposomes). Indeed, a direct comparison between 
EVs and state-of-the-art delivery vehicles urges itself and, given the complexity and 
costs associate to working with EVs, only a substantial benefit could make EVs eligible 
for further therapeutic development. 
One of the initial characteristics attributed to EVs that evoked, among others, the 
interest from the drug delivery community was that EVs might have an inherent cell 
specificity [37-39]. This is of particular interest as targeting is one of the current hurdles 
in the nanomedicine research community. Such specificity could also be of value to 
mitigate off-target effects. In this regard, it would be of interest that next to databases 
as EVpedia [40], Vesiclepedia [41] and Exocarta [42], i.e. databases that collects 
published information on the molecular composition of EVs, a database for EV specificity 
would be initiated. This database could accumulate information on e.g. producer-
acceptor cell pairs for which successful biomolecule/drug delivery was demonstrated. 
Preferably this would be accompanied by an assay, by which the efficiency of the 
(macro)molecular delivery was measured. This will provide valuable information from a 
drug delivery point-of-view as this can guide the choice of producer cell, dependent on 
the envisioned therapeutic application. Moreover, this will help mapping the 
physiological EV-mediated intercellular communication networks. 
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In summary, although harnessing EVs as carriers for macromolecular therapeutics is a 
relatively new field of research, already a substantial number of valuable achievements 
have been published. However, the findings in our studies revealed important issues 
that will have to be addressed before clinical translation becomes within reach. These 
new insights can guide future research towards new loading strategies and incite the 
drug delivery field to include comparison to state-of-the-art delivery vehicles as good 
scientific practice. Such an approach will provide critical information needed to truly 
assess the value and impact EVs will have as advanced drug delivery tools. 
 
2. Characterization of extracellular vesicles for diagnostics 
As the true complexity and heterogeneity of EVs is becoming more apparent, the search 
for new techniques to characterize them is increasing. Indeed, in chapter 1 we 
contextualize the need for techniques that allow analysis of EVs at the single vesicle 
level to increase the insight in some elementary biological principles and to enhance the 
sensitivity of EV-based diagnostic tools. To date, only few techniques are available which 
are able to characterize single EVs. An overview of such techniques, with their 
respective information output, is provided in table 1. It can be appreciated that most 
techniques are limited to physicochemical characterization (i.e. size and surface charge) 
and concentration measurements. In addition, some characterization techniques provide 
a (quantitative) window on the presence of well-defined molecular components on single 
EVs. In practice this translates in techniques that allow to confirm the association 
between an EV and an antibody/lectin/aptamer that recognizes a specific (surface) 
component. This can be done by immuno-electron microscopy, high resolution flow 
cytometry, fluorescence correlation spectroscopy and fluorescence-based SPT, providing 
useful information regarding the vesicular heterogeneity [43-45]. It is important to note 
here that these approaches are restricted to a limited amount of well characterized 
(surface) markers. A broader molecular view can be obtained with Raman 
microspectroscopy in combination with optical trapping [46]. A Raman spectrum can be 
considered as a fingerprint of all molecular bonds that are present within a focal volume, 
albeit without defining specific molecules. Nonetheless, we (chapter 5) and others [47-
49] have shown that based on this fingerprint it is possible to discriminate between EVs 
from different cellular origin. Raman spectroscopy is able to operate at single EV level in 
solution and provides a large amount of information. Yet, it lacks the speed of e.g. flow 
cytometry. Indeed, recording clear Raman spectra of individual EVs required an 
integration time of 5 minutes per vesicle [46]. It is in the context of this limitation that 
in chapter 5 we developed a SERS-based platform for EV characterization. By 
decorating single EVs with self-assembling miniature SERS substrates, clear Raman 
spectra could be obtained within 500 ms. Based on these fingerprints it was possible to 
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discriminate between EVs from RBC and melanoma cells in a mixture by means of 
statistical models trained by reference libraries of the respective EV types. 
 
Table 1. Techniques with the potential of EV characterization at the single vesicle level 
Technique Type of information Background 
Scattering-based SPT 
[50] 
 Size 
 Surface charge 
 Concentration 
 Refractive index 
Size determination via Rayleigh scattering-
based tracking of the Brownian motion of EVs. 
Tunable resistive 
pulse sensing [51] 
 Size 
 Surface charge 
 Concentration 
Monitors the change in current flow through an 
(adaptable) aperture. 
Atomic force 
microscopy [52] 
 Size 
 Mechanical stiffness 
Sample information by scanning the sample 
using a mechanical probe. 
Immuno-electron 
microscopy [43] 
 Size    
 The presence of proteins via 
gold tagged antibodies 
Morphological information but time consuming 
with low throughput. 
Frequency-locked 
microtoroid optical 
resonators [53] 
 The presence of surface 
molecules via antibodies 
Measures the change in resonant frequency of a 
microtoroid upon binding of an EV to an 
antibody in close proximity to the microtoroid 
inducing a change in refractive index  
Fluorescence-based 
SPT [45] 
 Size 
 Surface charge 
 The concentration of EVs 
containing specific surface 
molecules (via fluorescently 
tagged antibodies) 
Size determination via fluorescence-based 
tracking of the Brownian motion of EVs.  
High resolution flow 
cytometry [44] 
 The presence of surface 
molecules via fluorescent 
tagged antibodies 
 Concentration 
A flow cell through which the sample is guided 
using sheath fluid with recording of Rayleigh 
scattering and fluorescence. For EVs smaller 
than 300 nm, the scattering signals are no 
longer able to differentiate between single 
events and doublets or what is called swarm 
analysis. 
Fluorescence 
correlation 
spectroscopy [54] 
 Size 
 The presence of surface 
molecules via fluorescently 
tagged antibodies 
 Concentration 
The size distribution is obtained from 
fluorescence intensity fluctuations caused by 
particles moving by Brownian motion through a 
well-characterized illuminated volume. The 
presence of specific surface markers can be 
identified by fluorescently labeled antibodies. 
Raman micro- 
spectroscopy in 
combination with 
optical trapping [46] 
 
 A spectral fingerprint 
representative for the 
molecular bounds 
Inelastic scattering of monochromatic light by 
vibrations of molecular bounds renders a 
spectrum dependent on the molecules present. 
SPT single particle tracking 
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As EVs are regarded as easy accessible biomarkers through liquid biopsy (chapter 1), 
techniques that can provide EV-related information can be valuable in a diagnostic 
context. To date, most approaches use ‘omics’ techniques to obtain in-depth molecular 
information such as proteomics, transcriptomics, miRnomics, etc. These analysis are 
very valuable as they can provide a detailed view on molecular components that differ 
between ‘healthy’ and ‘diseased’ EVs, which can subsequently be translated in a 
diagnostic assay. One of the most successful clinical examples following this workflow 
identified EV-associated glypican-1 (i.e. a surface proteoglycan) as a biomarker for 
pancreatic cancer, which was subsequently developed into an antibody-based assay. Not 
only did it show absolute specificity and sensitivity to detect pancreatic cancer in patient 
samples but it was also able to detect the presence of tumor cells before they appeared 
on magnetic resonance imaging scans in a mouse model [55]. Despite this important 
achievement, only few liquid biopsy-based assays have been successfully introduced in 
clinical practice. One of the reasons for this is the lack of adequate analytical readout 
techniques. Indeed, assays often fail in achieving adequate sensitivity and specificity 
due to the fact that proteins or metabolites are present at an extremely low level among 
thousands of other comparable components. Using EVs as a biomarker source partially 
circumvents this needle-in-a-haystack hurdle by excluding abundant biofluid 
components (e.g. albumin in blood). Nonetheless, early stage diseased patients will still 
have a low percentage of ‘diseased’ EVs compared to healthy EVs [56]. 
Whether our SERS-based platform can provide an added value over current diagnostic 
methods will depend on some key technical and conceptual uncertainties that have to be 
addressed before the implementation in the clinic can be envisioned. A fist important 
question is to which extent Raman spectroscopy is specific enough to discriminate 
between hundreds or even thousands of EVs which are inherently present in a relevant 
biological fluid (e.g. urine, plasma). Moreover, we observed variability within the spectra 
of EVs generated by the same cell. Part of this variability will undoubtedly find its origin 
in the EV heterogeneity as was also previously observed (chapter 1) [46]. Yet, SERS is 
also notorious for the variability induced by the inconsistency in hotspot generation 
[57]. This additional factor of variability might reduce our discriminative power and 
hence should be taken into consideration. Secondly, it is difficult to estimate the amount 
of EVs that have to be screened in a diagnostic test for early disease detection. This will 
certainly depend on the location and the type of disease. Although difficult to predict, 
this factor will determine whether the current integration times are sufficiently short to 
enable the implementation of our SERS-based platform for clinical samples with 
reasonable analysis times.  
If the above mentioned hurdles can be overcome, the SERS-based platform has the 
potential to be further developed in a clinical setting. It is however important to note 
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that the technology is dependent on the availability of a reference spectrum to link the 
measured Raman signature to a cellular origin with associated pathological condition. 
One possible clinical implementation of the platform would be to build a reference library 
of spectra of different ‘diseased cell’-derived EVs (e.g. cancer cells) and screen clinical 
samples for the presence of these spectra. Using this approach, the technology can be 
positioned as a tool for early disease detection. However, this methodology might not 
always be befitting as it is for example known that tumor cells, and their secretome, 
have a high inter-patient variability, urging the implementation of personalized 
medicines and diagnostics. In this context, the presented platform can be exploited as a 
post-surgery follow-up tool in which ‘tumor biopsy’-derived EVs are used to record 
reference spectra. Following this approach, the platform can detect tumor recurrence in 
an early stage after treatment/surgery via a simple ‘liquid biopsy’.  
Independent of the success of this specific diagnostic platform, it is clear that Raman 
spectroscopy is gaining popularity to address biomedical questions. The advantage of 
non-destructive label-free detection and the possibility to work in aqueous media makes 
this technique suitable for live cell characterization [58] and direct in vivo 
measurements with diagnostic potential [59]. The latter includes cancer detection in 
easy accessible organs such as the skin, cervix and the gastro-intestinal organs [60] but 
also as a real-time probe for surgical guidance [61]. It can be anticipated that in the 
field of EV characterization Raman spectroscopy in its different forms (i.e. classic 
Raman, SERS, TERS and CARS) will be increasingly used as is evident from different 
abstracts exploiting Raman spectroscopy on the latest ISEV meetings [62, 63]. 
 
3. Pharmaceutical perspectives for extracellular vesicles 
The research on EVs is exponentially growing in the last decade as is evident from the 
increasing amount of publications on the subject appearing each year (figure 1) and 
from the growth of the ISEV community. Originally, EVs were mainly positioned as a 
cellular mechanism to discard waste material. This was shown in the late 1980s for 
certain surface proteins [64], but also more recent work reports on biomolecule removal 
via EVs as a mechanism of cellular homeostasis. With regard to miRNAs, work by 
Squadrito and colleagues showed that the sorting of miRNAs in EVs is dependent on the 
intracellular miRNA concentration. Indeed, overexpression of a miRNA target sequence 
results in an enrichment of the respective miRNA in processing-bodies and the cellular 
cytoplasm and depletion from multivesicular bodies, hence EVs. Alternatively, 
overexpression of the miRNA enhances its release via EVs [65]. Also the fact that the 
majority of EV-encapsulated mRNAs are fragmented [66] and the EV-mediated release 
of drugs by chemo-resistant malignant cells [67] strengthens this hypothesis of a waste 
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removal mechanism. Nevertheless, the last decade the perception on EVs has shifted to 
mediators of a new route of intercellular communication. Most EV-orientated research to 
date focuses on elucidating new EV-mediated intercellular networks [68]. However, 
many reports on the function of EVs should be reassessed in light of the used 
purification strategy. Our own observations (chapter 3) and other reports in the 
literature [13] indeed indicate that the traditional purification strategies co-isolate many 
non-vesicular components that might contribute to the assumed EV-induced phenotype 
in recipient cells. This does not imply that purification strategies categorized as less 
stringent (e.g. precipitation) have no place in EV research. They certainly can provide a 
valuable research tool but should be considered more as a preparative concentration 
step prior to more rigorous EV isolation and purification. When using these techniques in 
a research setting it is important to incorporate adequate controls that allow to reliably 
link an observed effect to the presence of EVs (e.g. via EV depletion experiments). 
Additionally, the nature and relevance of these EV-induced effects in an in vivo situation 
are largely unknown, which remains an important topic for future investigation.  
 
Figure 1. The growth of EV research in the last 20 years. The graph depicts the amount of 
publications that appeared each year in PubMed using: ("extracellular vesicles" OR exosomes OR 
ectosomes) as search keywords. Some of the key papers that were important for the development of 
the field are indicated in the graph: (1) EVs from B-lymphocytes are shown to be able to present 
antigens to T cells [69], which provides a first indication of the communication function of EVs. (2) EVs 
derived from dendritic cells (DC) loaded with antigens are used as an anti-cancer vaccine [70], which 
exploits for the first time EVs in a therapeutic context. (3) The first clinical trial using these DC-derived 
EVs for anti-cancer vaccination [71]. (4) Report on the presence in and functional transport of RNA by 
EVs [72] further confirming the communication function of EVs and attracting the attention from the 
drug delivery community. 
 
This seemingly conflicting function of EVs in waste removal and intercellular 
communication is not necessarily incompatible. The discrepancy in observed function 
can be in agreement with the mounting evidence of intracellular EV heterogeneity in 
which it would be theoretically possible that certain EV subtypes have an important 
communication function while others are used for waste removal. Nonetheless, its 
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ambiguity again indicates the limited understanding we currently have on EV functions. 
In this context characterization approaches that allow single EV analysis can again 
provide valuable new insights. 
Currently, most research still focuses on elucidating the physiological function of EVs. In 
addition to this fundamental research, a plethora of clinical applications are starting to 
develop, trying to harness EVs to benefit the patient (chapter 1). Here, the current 
status and future perspective of the EV landscape as a pharmaceutical tool is discussed 
by scoring the different application strategies on the ‘technology readiness level’ (TRL) 
scale (figure 2). It is clear that the field of vaccination, especially against prokaryotic 
infections, is the most developed with already a product on the market based on outer 
membrane vesicles (OMVs) derived from bacteria as antigen source adsorbed to Al(OH)3 
as adjuvant [73]. Anti-cancer vaccination is also scored high on the TRL-scale with 
various completed clinical trials. This should not be a surprise as this was one of the first 
therapeutic applications of EVs reported in the scientific literature (figure 1) [70]. 
Likely, this application will further co-develop with the anti-cancer immunotherapy field 
in general, fuelled by increasing knowledge regarding adjuvants and tumor 
microenvironment immunology [74]. 
Another application ranking high on the TRL-scale is the use of EVs as a biomarker 
source for early disease detection. Recently, the ‘ExoDx Lung(ALK) test’ developed by 
Exosome Diagnostics received FDA-approval. This test relies on qPCR-based screening 
of EV-derived RNA to detect five different mutations, all of them fusions between the 
genes encoding echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic 
lymphoma kinase (ALK), each of which giving rise to a subtype of non-small-cell lung 
carcinoma (NSCLC). Besides disease detection, this test can also be used as a predictive 
marker to evaluate treatment by ALK-inhibitors (e.g. crizotinib, ceritinib) [75], hence 
acting as a companion diagnostic tool. Comparable kits are currently in the pipeline of 
the same company for the detection of other lung cancer associated mutations and for 
prostate cancer. The exploitation of EVs as a biomarker source is likely the most 
promising application of EVs in the near future. The urgent unmet need for liquid 
biopsy-based tools that allow post-treatment follow-up incites the emergence of 
different startup companies (e.g. Codiak BioSciences, ExosomeDx, Nanosomix), 
attracting substantial venture capital to EV research in this context [76]. 
Further down the TRL scale we see the exploitation of EVs as a surrogate for cell therapy 
(mainly mesenchymal stem cell (MSC)-based therapy). A clinical case report on the 
application of MSC-derived EVs for the treatment of refractory graft-versus-host disease 
(GvHD) showed a strong reduction in symptoms with stabilization of the patient for 
several months, allowing a reduction in the standard corticoid treatment scheme [77]. 
Additionally, a Phase I clinical trial has been launched to evaluate the reduction in 
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inflammatory state, and hence improvement in β-cell mass, in Type I diabetes patients 
after IV injection of MSC-derived EVs (NCT02138331). It is envisioned that this type of 
application will continue to evolve in the slipstream of the development of MSC-based 
cell therapies for which EVs can serve as a safer alternative. 
 
Figure 2. The different pharmaceutical applications of EVs scaled for their technology 
readiness level (TRL). (Status April 2016). 
 
The exploitation of EVs as a drug carrier for macromolecules is one of the least 
developed applications. This should not be a surprise given the many obstacles for 
successful drug delivery described throughout this thesis (e.g. the loading of therapeutic 
macromolecules and crossing of biological barriers). Moreover, to date, a strong 
experimentally validated advantage over current synthetic and viral delivery vehicles is 
largely lacking. Many of the theoretical advantages such as long circulation time, 
inherent targeting and efficient cargo delivery have either been disproven or await 
further biological insight. In this respect, as this knowledge remains obscure to date, we 
cannot draw final conclusions yet on the true value of EVs as a drug delivery carrier. 
Finally, a new therapeutic approach not yet discussed in this thesis, describes the 
depletion of cancer-derived EVs. Evidence is gathering that EVs derived from cancer 
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cells are important signaling factors contributing to cancer progression and metastasis. 
They are considered (partially) responsible for the tolerogenic microenvironment in 
tumor tissue [78] and appear to be a fundamental aspect in the pre-metastatic niche 
creation [79]. Hence, inhibition of the EV production by cancer cells would allow to 
disrupt a key component of the tumor cell’s communication network. This concept has 
already been launched in the literature [80, 81] and the limited experimental data on 
the use of GW4869 (a neutral sphingomyelinase (nSMase) inhibitor, hence inhibitor of 
EV formation) shows a reduction in lung cancer multiplicities [82]. Of note, this 
approach not only disrupts the EV-mediated communication network of cancer cells but 
might also be beneficial for immunotherapy and chemotherapy as tumor-derived EVs 
have also been linked to drug resistance (e.g. by captivation of tumor-targeting 
antibodies [83] and by EV-mediated expulsion of chemotherapeutics [67, 84]). 
Alternatively, hemofiltration to deplete EVs from the blood circulation [81] and blocking 
the interaction between EVs and the target cells (e.g. integrin blocking [38]) have been 
suggested. However, like for the above mentioned diagnostic approaches, also the 
hemofiltration approach suffers from the lack of tumor EV-specific surface 
(glyco)proteins for which antibodies can be developed. On the other hand, tumor-
derived EVs have also shown to be potent anticancer vaccines in animal models, hence 
making it difficult to predict the outcome of such interventions [85]. Though still in its 
infancy, depletion of cancer-derived EVs is likely to gain interest and its exploitation will 
largely depend on progress made in unraveling EV biogenesis and characterization.  
Overall the EV field is attracting many new research groups offering a growing 
interdisciplinary toolbox to elucidate the true physiological relevance and exploitation of 
these vesicles in a pharmaceutical context. Despite the fact that EV biology is still an 
immature field, much capital is already drawn into new startup companies providing a 
basis to further explore EVs both in a therapeutic and diagnostic setting. 
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SUMMARY AND CONCLUSIONS 
 
Extracellular vesicles (EVs) are membranous structures that are released by cells in the 
surrounding biofluid. EVs consist of a lipid and protein shell that encapsulates an 
aqueous core containing, among others, proteins and nucleic acids. It is believed that 
the molecular composition of EVs is in part actively regulated by the producing cell and, 
once released, it has been demonstrated that EVs are able to interact with other cells. 
As they are composed of numerous, potentially bioactive molecules, this interaction can  
induce phenotypic alternations in the recipient cell. In this respect, EVs are increasingly 
considered as important mediators of intercellular communication, enabling the 
functional transfer of (macro)molecules from one cell to another. Their inherent 
physiological effects can be exploited in a therapeutic context for which numerous 
examples are provided and discussed in chapter 1 (e.g. cell free vaccination, MSC 
surrogate therapy, etc.). Interestingly, it is believed that part of the induced alterations 
are due to the EV’s ability to fuse with the cell and/or endosomal membrane, thus 
allowing subsequent delivery of their nucleic acid cargo (e.g. miRNAs and mRNAs) to the 
receptive cell’s cytoplasm. This is a very interesting feature that attracted the attention 
of the drug delivery community, given that efficient cytoplasmic delivery of 
macromolecular biotherapeutics (including nucleic acids and proteins) is currently one of 
the major hurdles hampering clinical translation of biologics with an intracellular target. 
In this thesis the ability of EVs to functionally deliver small interfering RNA (siRNA) was 
explored. Despite some interesting earlier reports in the literature on the value of EVs as 
bio-inspired drug carriers, many fundamental biological questions, pertaining to the EV 
biodistribution, cell uptake specificity and cargo release, remain largely unanswered to 
date. Additionally, technical hurdles such as inadequate purification strategies and the 
lack of an efficient loading strategy for macromolecular therapeutics should be overcome 
to reliably assess the true advantage EVs might have over current state-of-the-art 
delivery strategies (e.g. liposomes and viral vectors). 
A first step in pursuit of harnessing EVs for siRNA delivery is the development of a 
method to obtain purified vesicles. It is important to realize that EVs represent only a 
fraction of the cell’s secretome. Different methods to isolate and purify EVs out of 
conditioned cell medium and biological fluids have been suggested. These approaches 
rely on the EV’s typical size, density, solubility, surface components or a combination of 
the above. Currently, no consensus on a gold standard protocol exists, which hampers 
unambiguous comparison of different studies and increases the risk of misconceptions 
due to residual impurities when using insufficiently stringent purification protocols. In 
chapter 3 a number of commonly used techniques to purify EVs from endogenous (e.g. 
 Summary and conclusions│ 214 
 
protein complexes) and exogenous (e.g. fluorescent dyes) components were compared. 
Protocols based on a density gradient and size-exclusion chromatography outperformed 
differential centrifugation- and precipitation-based approaches. In combination with a 
better understanding of the influence of the respective isolation procedures on the EV 
functionality, these observations can contribute to the implementation of a more 
standardized purification protocol. 
A second technical hurdle that was addressed in this thesis, is the loading of isolated 
EVs with exogenous siRNA. One of the strategies suggested in the literature is the 
electroporation of EVs in the presence of the siRNA of interest. Despite the fact that this 
technique has already been adopted by different groups, the underlying biophysical 
loading mechanism was never thoroughly investigated. In chapter 2 an in-depth study 
on this process revealed that electric pulses in electroporation buffers result in extensive 
precipitation of siRNA into salt aggregates. This phenomenon was a consequence of 
metal ions, released from the cuvette electrodes, forming insoluble aggregates with the 
hydroxide ions present in pH neutral buffers. During this aggregate formation process, 
siRNAs (and EVs) are co-precipitated. As a result, the encapsulation efficiency for siRNA 
is easily overestimated when commonly used electroporation conditions and 
quantification techniques are employed. When preventing aggregation, e.g. by using 
chelating acidic buffers or polymer-based cuvettes, the measured encapsulation of 
siRNA into EVs decreased to negligible amounts.  
The shortcomings of electroporation and the current lack of alternatives to load 
hydrophilic macromolecules into EVs prompted us to explore new approaches. In 
chapter 4 we developed a generally applicable method to attach siRNA to the surface of 
isolated EVs by means of a cholesterol anchor. Moreover, given the complexity and 
heterogeneity of EV isolates and the previously described loading artifacts with 
electroporation, here we used a combination of three complementary assays to confirm 
and quantify siRNA loading (i.e. a gel retention assay, an antibody capture assay and a 
density gradient co-localization assay). As this approach was also able to load pre-
formed liposomes with siRNA with comparable efficiency, a direct comparison between 
EVs and synthetic liposomes with regard to siRNA delivery could be made. To this end, 
we selected negatively charged, fusogenic liposomes with a size distribution comparable 
to EVs. Unfortunately, under the tested in vitro conditions, EVs underperformed 
compared to the liposomes for their ability to functionally deliver the siRNA therapeutic, 
which could be attributed to the lack of an intrinsic mechanism to induce endosomal 
escape prior to trafficking to lysosomes for degradation. Likewise, the endogenously 
present miRNAs were not functionally delivered to recipient cells. These observations 
question the efficiency and universal applicability of EVs as a gene therapy nanocarrier. 
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Besides therapeutic applications, EVs have also been the subject of investigation in a 
diagnostic context. The EV architecture and part of the molecular composition are 
common among EVs isolated from different cells. However, some EV-associated 
components are unique for the producing cell type and even cellular status. Moreover, 
upon in vivo release, part of the EVs end up in neighboring biological fluids making them 
available for liquid biopsies. In this respect, EVs can be considered as easy accessible 
windows on otherwise difficult to reach (diseased) cells. These features make them ideal 
biomarker candidates for early disease detection and treatment monitoring.  
Yet, as contextualized in chapter 1, to optimally exploit EVs in a diagnostic setting, 
there is a need for new characterization techniques which can attain high sensitivity on 
a single vesicle level. In an attempt to address this need, in chapter 5 a 
nanotechnological platform relying on enhanced Raman spectroscopy for individual EV 
characterization, was developed. The signal enhancement was evoked by decorating the 
surface of each individual vesicle with a gold nanoparticle-based plasmonic substrate, 
which allowed to obtain a Raman spectrum with acceptable acquisition speed. 
Subsequently, the acquired spectra could be subjected to downstream analysis using 
dedicated multivariate statistical models allowing to discriminate between EVs derived 
from red blood cells and EVs derived from melanoma cells. Furthermore, due to the 
single vesicle approach, this technique was able to quantify the relative abundance of 
each EV type in a mixture.  
Conclusions 
In conclusion, in a first part of this dissertation the potential of EVs as a drug delivery 
carrier for siRNA was assessed. We could obtain pure EVs by means of a density 
gradient purification protocol and load them by exploiting the hydrophobic interaction 
between the EV membrane and a cholesterol tag covalently attached to one of the siRNA 
strands. However, under the experimental conditions EVs were unable to bypass the 
endolysosomal degradation pathway and hence were unable to functionally deliver 
siRNA upon cellular internalization. To a certain extent, our observations temper the 
high expectations linked to exploiting EVs as a drug delivery carrier and call for a more 
in-depth biological understanding of the EV’s cellular delivery mechanism and related 
cell type specificity. Nonetheless, other therapeutic applications of EVs, as discussed in 
chapter 6, are very promising and are already developed up to market level (e.g. EV-
based immunotherapy). In the second part of this dissertation, we developed a new 
nanotechnological platform that allows the fast characterization of individual EVs via  
surface enhanced Raman spectroscopy. As EVs are very promising biomarkers, the high 
sensitivity inherent to the developed technology makes this an attractive platform to 
explore further in a diagnostic setting. 
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SAMENVATTING EN CONCLUSIES 
 
Extracellulaire vesikels (EVs) zijn membranaire structuren die door cellen vrijgesteld 
worden in het omliggende medium. Ze zijn opgebouwd uit een schil van lipiden en 
proteïnen die een waterige kern omhult. Deze laatste bevat onder meer proteïnen en 
nucleïnezuren. De moleculaire samenstelling is actief gereguleerd door de producerende 
cel en, eens vrijgesteld, zijn EVs in staat te interageren met andere cellen. Aangezien ze 
samengesteld zijn uit potentieel bioactieve moleculen, hoeft het niet te verbazen deze 
interactie fenotypische veranderingen induceren in de ontvangende cel. Door deze 
mogelijkheid om (macro)moleculen functioneel te transfereren van de ene naar de 
andere cel, worden EVs steeds meer aanzien als een nieuw type mediator van 
intercellulaire communicatie. Deze intrinsieke fysiologische effecten benut worden in een 
therapeutische context waarvan enkele voorbeelden worden besproken in hoofdstuk 1 
(vb. EVs afkomstig van tumorcellen in immunotherapie en EVs afkomstig van MSC in 
regeneratieve geneeskunde). Er wordt aangenomen dat een deel van deze geïnduceerde 
veranderingen een gevolg is van de mogelijkheid van EVs om te fuseren met het cel- 
en/of endosomale membraan. Op deze manier kunnen ze hun nucleïnezuurlading (o.a. 
miRNA en mRNA) functioneel afleveren in het cytoplasma van de ontvangende cel. Deze 
eigenschap heeft de aandacht getrokken van verschillende onderzoeksgroepen in het 
veld van de gentherapie aangezien efficiënte afgifte van macromoleculaire 
biotherapeutica in het cytoplasma nog steeds één van de grote struikelblokken vormt 
die de klinische vertaling van biofarmaceutica met een intracellulair target bemoeilijkt. 
In deze thesis wordt de capaciteit van EVs om siRNA functioneel af te leveren 
onderzocht. Ondanks enkele interessante bevindingen die eerder werden gepubliceerd 
over deze nieuwe carriers, blijven vele fundamentele biologische vragen rond de EV 
distributie, cel opname specificiteit en interactiemechanismen grotendeels 
onbeantwoord. Daarenboven zijn er nog enkele technische obstakels zoals een gebrek 
aan adequate opzuiverings- en opladingsmethoden voor macromoleculaire therapeutica. 
Verder onderzoek is daarom noodzakelijk om de ware voordelen van EVs ten opzichte 
van de huidige afleveringsmethoden (vb. liposomen en virale vectoren) te kunnen 
inschatten. 
Een eerste stap om gebruik te kunnen maken van EVs voor het afleveren van siRNA, is 
de ontwikkeling van een opzuiveringsmethode. Dit is noodzakelijk aangezien EVs slechts 
een klein deel vormen van wat de cel vrijstelt. Verschillende werkwijzen om ze te 
isoleren uit geconditioneerd cel medium of uit biologische vloeistoffen zijn reeds 
ontwikkeld. Ze zijn voornamelijk gebaseerd op de typerende EV grootte, densiteit, 
oplosbaarheid, oppervlakte merkers of een combinatie hiervan. Momenteel is er nog 
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geen consensus over een ‘gouden’ standaard protocol. Dit bemoeilijkt een directe 
vergelijking tussen verschillende studies en vergroot bovendien de kans op 
misinterpretaties als gevolg van achtergebleven onzuiverheden. In hoofdstuk 3 werden 
een aantal courant gebruikte technieken om EVs te isoleren van endogene (vb. proteïne 
complexen) en exogene (vb. fluorescente labels) componenten met elkaar vergeleken. 
Strategieën gebaseerd op een densiteit gradiënt en SEC blijken superieur aan methoden 
gebaseerd op differentiële centrifugatie en precipitatie. Deze observaties kunnen, samen 
met inzichten over de invloed van de isolatieprocedures op de functionaliteit van EVs, 
verder bijdragen aan de realisatie van een meer gestandaardiseerd 
opzuiveringsprotocol. 
Een tweede technisch struikelblok dat werd aangepakt in deze thesis, is het opladen van 
geïsoleerde EVs met exogeen siRNA. Eén van de technieken voorgesteld in de literatuur 
maakt gebruik van elektroporatie van EVs in aanwezigheid van het gewenst siRNA. 
Ondanks het feit dat deze techniek reeds is overgenomen door verschillende 
onderzoeksgroepen, zijn de onderliggende biofysische ladingsmechanismen nooit 
grondig onderzocht. In hoofdstuk 2 brengt een diepgaande studie aan het licht dat 
elektrische pulsen in standaard buffers resulteren in extensieve precipitatie van siRNA in 
zout aggregaten. Dit fenomeen blijkt een gevolg te zijn van metaalionen (die loskomen 
van de cuvetelektrodes) en hydroxide ionen (aanwezig in pH neutrale buffers), die 
samen onoplosbare complexen vormen. Tijdens dit proces van aggregaat vorming 
worden siRNAs en EVs samen neergeslaan. Dit leidt ertoe dat bij vaak gebruikte 
elektroporatie condities en daaropvolgende kwantificatietechnieken, de incorporatie-
efficiëntie van siRNA overschat wordt. Wanneer aggregatie werd voorkomen door 
bijvoorbeeld gebruik te maken van chelatoren of geleidende polymeer cuvetten, daalde 
de gemeten incorporatie van siRNA in EVs tot verwaarloosbare hoeveelheden. 
De tekortkomingen van elektroporatie en het gebrek aan alternatieven om hydrofiele 
macromoleculen te laden in EVs, heeft ons ertoe aangezet om nieuwe strategieën te 
verkennen. In hoofdstuk 4 hebben we een breed toepasbare methode ontwikkeld om 
siRNA te koppelen aan het oppervlak van geïsoleerde EVs via een cholesterol anker. 
Gestuurd door de complexiteit en heterogeniteit van EV isolaten en de voordien 
beschreven oplaadmoeilijkheden met elektroporatie, hebben we een combinatie van drie 
complementaire assays gebruikt om de siRNA oplading te bevestigen en te kwantificeren 
(gebaseerd op gel retentie, antilichaam captatie en dichtheidsgradiënt co-lokalisatie).  
Bovendien liet deze benadering ook toe om liposomen met vergelijkbare efficiëntie te 
laden met siRNA, zodat een directe vergelijking van siRNA aflevering mogelijk is tussen 
EVs en synthetische liposomen. Hiervoor gebruikten we negatief geladen, fusogene 
liposomen met een grootte vergelijkbaar aan die van EVs. Helaas blijken deze laatste, 
onder de geëvalueerde omstandigheden, veel minder efficiënt voor siRNA aflevering dan 
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de synthetische liposomen. De oorzaak hiervan was het ontbreken van een intrinsiek 
mechanisme dat de vrijstelling uit het endosoom induceert voordat de EVs worden 
afgevoerd naar de lysosomen voor afbraak. Het endogeen aanwezige miRNA wordt om 
dezelfde reden niet functioneel afgeleverd aan de ontvangende cel. Deze observaties 
plaatsen een vraagteken bij de efficiëntie en de universele toepasbaarheid van EVs als 
gentherapie nanocarrier. 
Naast therapeutische applicaties, worden EVs ook geëvalueerd voor diagnostische 
toepassingen. De structuur en een deel van de moleculaire samenstelling zijn dezelfde 
voor EVs afkomstig van verschillende celtypes. Doch, sommige EV-geassocieerde 
moleculen zijn uniek voor (de toestand van) het producerende celtype. Wanneer de EVs 
in vivo worden vrijgesteld, komt een deel in de nabijgelegen biologische vloeistoffen 
terecht, wat hen toegankelijk maakt voor laag invasieve, vloeibare biopsieën. In dit 
opzicht kunnen EVs beschouwd worden als een gemakkelijk bereikbare representatie 
van (zieke) cellen. Deze eigenschappen maken van hen ideale biomerker kandidaten 
voor vroege diagnostiek en opvolging van behandelingen. 
Zoals uiteengezet in hoofdstuk 1, is er vraag naar nieuwe technieken om optimaal 
gebruik te maken van deze EVs in een diagnostische context. Voornamelijk methoden 
die een hoge gevoeligheid genereren door te functioneren op het enkelvoudige vesikel 
niveau, zijn gegeerd. In een poging om hieraan tegemoet te komen, werd in hoofdstuk 
5 een nanotechnologisch platform ontwikkeld, gebaseerd op versterkte Raman 
spectroscopie voor individuele EV karakterisatie. Deze signaalversterking werd bekomen 
door het oppervlak van elk vesikel afzonderlijk te omhullen met een plasmonisch 
substraat bestaande uit goud nanopartikels. Op deze wijze werden Raman spectra 
bekomen binnen een aanvaardbare tijdspanne. De verworven spectra werden 
vervolgens onderworpen aan specifieke statistische modellen waardoor objectief een 
onderscheid kan gemaakt worden tussen EVs afkomstig van erytrocyten en EVs 
afkomstig van melanoom cellen. Doordat op individueel EV niveau gemeten wordt, is 
deze techniek daarenboven in staat de relatieve samenstelling van beide EV types in 
een mengsel te kwantificeren.  
Conclusies 
In het eerste deel van deze thesis werd het potentieel van EVs als drager van siRNA 
geëvalueerd. Zuivere EVs werden bekomen d.m.v. een densiteitsgradiënt en oplading 
met siRNA gebeurt d.m.v. hydrofobe interactie tussen het EV membraan en een 
cholesterol anker dat covalent gebonden werd aan één van de siRNA strengen. Onder de 
geëvalueerde experimentele omstandigheden ontbrak het de EVs echter aan de 
mogelijkheid om de endolysosomale degradatie te omzeilen en bleken dus ook niet in 
staat om hun siRNA lading functioneel af te leveren. Onze bevindingen temperen in 
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zekere zin de hoge verwachtingen rond het gebruik van EVs als geneesmiddel 
afleveringsmethode en vragen een meer diepgaand biologisch inzicht van de cellulaire 
afleveringsmechanismen en daaraan gelinkte celtype specificiteit. Niettegenstaande zijn 
andere therapeutische toepassingen van EVs, zoals besproken in hoofdstuk 6, 
beloftevol en sommige zijn reeds ontwikkeld tot een geregulariseerd commercieel 
product (vb. EVs voor immunotherapie). In het tweede deel van deze thesis hebben we 
een nieuw nanotechnologisch platform ontwikkeld. Dit maakt een snelle karakterisatie 
van enkelvoudige EVs via versterkte Raman spectroscopie mogelijk. Aangezien EVs 
aanzien worden als veelbelovende biomerkers, zorgt de hoge gevoeligheid, inherent aan 
de ontwikkelde methode, ervoor dat dit platform aantrekkelijk is om verder te 
ontwikkelen in een diagnostisch kader. 
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